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Abstract
Raynaud's disease, first described in 1862, is characterised by intense vasospasm of
the extremities, particularly the digits, in response to cold exposure or marked
emotion. It is a common condition, occuring in up to 20% of the population, and more
often in females. Currently, neither the mechanism of cold-induced vasoconstriction,
nor the pathogenesis of Raynaud's disease, is fully understood. The vascular
endothelium is known to generate several potent vasoactive substances including the
vasoconstrictor endothelin (ET), and the vasodilators, nitric oxide (NO) and
prostacyclin (PGI2). A temperature-dependent disorder of the endothelium, involving
either overproduction of a vasoconstrictor or underproduction of a vasodilator, might
be a critical factor underlying the pathogenesis of Raynaud's disease. The aim of this
thesis was to investigate the role of the vascular endothelium in the development of
cold-induced vasoconstriction, and in the pathophysiology of vasospasm in
Raynaud's disease.
Experiments were performed on resistance arteries in vitro and in vivo. The small
vessel arteriograph (perfusion myograph) was used to study isolated arteries in vitro.
Cooling rat mesenteric resistance arteries from 37°C to 24°C was found to increase the
senstivity to ET-1 and the a 1-adrenoceptor agonist, phenylephrine (PE). The
endothelium was partly responsible for mediating the cold-induced potentiation of the
contractile response to these agents. Maximal contraction to KC1 was reduced during
cooling, but was restored after removal of the endothelium, indicating that
endothelium-dependent dilators inhibit the contractile response to KC1 at 24°C.
Cooling did not significantly effect the sensitivity of the arteries to the endothelium-
dependent and -independent dilators, acetylcholine (ACh) and sodium nitroprusside
(SNP) respectively, although there was a tendency for the sensitivity to be reduced,
suggesting NO-synthase and vascular smooth muscle sensitivity to NO is potentially
depressed during cooling. Having determined the physiological effect of cooling on
the response to various agents, and the role of the endothelium, studies were repeated
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in resistance arteries dissected from gluteal fat biopsies taken from control subjects and
Raynaud's patients, in order to investigate the pathophysiology of cold-induced
vasospasm. The results from these studies revealed that arteries from patients with
Raynaud's disease had an enhanced sensitivity to ET-1 compared to controls at 37°C.
A possible explanation for this could be reduced dilator function in Raynaud's
patients, as suggested by the responses to ACh and SNP, which were both attenuated
in vessels from patients with Raynaud's disease compared to controls. This implied
that there was a decrease in NO-synthase activity and smooth muscle sensitivity to NO
at 31°C. Interestingly, at 24°C, the responses to ET-1, ACh and SNP were similar in
control arteries and in those from patients with Raynaud's disease. It would appear
from the ACh data that NO-synthase activity was enhanced in vessels from Raynaud's
patients during cooling, with the increase in NO production opposing the contraction
to ET-1. This may, of course, reflect only agonist-stimulated NO generation, whilst
endogenous production may be depressed.
Studies in vivo used the autoperfused hindlimb of the anaesthetised rat, in which
stepped-cooling of the blood entering the hindlimb produced a rise in hindlimb
perfusion pressure. Possible mediators of this cold-induced vasoconstriction were
identified using antagonists selective for a-adrenoceptors and ET-receptors. The
a i/a2-adrenoceptor antagonist, phentolamine, attenuated the cold-induced
vasoconstriction, and was the only agent to have an effect that was significant in this
model.
The results demonstrate that the endothelium is an important modulator of cold-
induced effects on the response to several vasoconstrictor agents, either by enhancing
contraction through the release of vasoconstrictors such as ET, or by depressing
contraction through the release of dilators, such as NO or PGI2. The results from the
gluteal biopsy studies imply that the enhanced sensitivity to ET-1 at 37°C in
Raynaud's patients is dependent on changes in dilator function, and not to altered
xi
sensitivity of the vascular smooth muscle to ET-1. Although an increase in the
response to ET-1 was not found at 24°C, the results obtained at 37°C would support
the hypothesis that the release and/or actions of NO is reduced in Raynaud's disease,
allowing enhanced constriction to ET. These results suggest that the vascular
endothelium is involved in the pathophysiology of Raynaud's disease.
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A. The Vascular Endothelium
The wall of every blood vessel, except for the capillaries, is made up of three separate
layers: the innermost tunica intima, which consists of a single continuous layer of
endothelial cells; the tunica media, made up of smooth muscle cells (absent from
capillaries); and the outer tunica adventitia, which consists of connective tissue
(collagen and elastin) and fibroblasts (Figure 1.1). The vascular endothelium, once
thought to act merely as a lining of blood vessels, is now known to play a central role
in the regulation of blood flow and vascular tone. In addition to the sympathetic
nervous system and circulating hormones, the activity of vascular smooth muscle is
controlled by several potent vasoactive substances generated by the endothelium.
These substances include the vasodilators, nitric oxide (Furchgott & Zawadzki,
1980; Palmer et al., 1987) and prostacyclin (Moncada et ai, 1976), and the
vasoconstrictors, endothelin (Yanagisawa et al., 1988), angiotensin II (Webb &
Cockcroft, 1990) and thromboxane A2 (Auch-Schwelk et al., 1990).
The following section shall focus primarily on endothelin and nitric oxide, but
angiotensin II, thromboxane A2, superoxide anions, prostacyclin and endothelium-
derived hyperpolarising factor will be discussed briefly, since they are also potential
pathophysiological candidates for Raynaud's disease, as will be addressed later.
A.l. Endothelium-Derived Vasoconstrictors
A.1.1. Endothelin
A.1.1.1 The discovery of endothelin
The first definitive evidence of an endothelium-derived vasoconstrictor factor came
from Hickey and co-workers who, in 1985, demonstrated that the supernatant of
cultured bovine endothelial cells possessed sustained vasoconstrictor activity, a finding
which was confirmed by others in subsequent studies (Gillespie et al., 1986; O'Brien
et al., 1987). In 1988, this factor was isolated and sequenced from cultured porcine
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peptide, which they named endothelin (Yanagisawa et al., 1988). Endothelin (ET) is
the most potent vasoconstrictor agent identified to date, and has a characteristically
prolonged effect: Yanagisawa and colleagues (1988) showed that intravenous
administration of ET caused a long-lasting pressor response in chemically denervated
rats, the increase in arterial pressure being sustained for more than 60 minutes, in
contrast to other vasoconstrictor hormones.
ET exists as a family of isopeptides; ET-1, the isoform originally identified by
Yanagisawa et al. (1988), and ET-2 and ET-3, which are structurally and
pharmacologically distinct (Inoue et al., 1989) (Figure 1.2). The sarafotoxins
(SRTX's), four peptides isolated from the venom of the Israeli burrowing asp,
Atractaspis engaddensis, have a remarkable structural similarity with the ET's (Figure
1.2), and indeed share their potent effects (Kloog et al., 1988). As can be seen from
Figure 1.2, the structures of all three human ET isoforms and the four SRTX's (S6a,
b, c and d; only S6c isoform shown) are identical at 10 of the 21 amino acids; ET-2 is
the most similar to ET-1, differing by only 2 amino acids, whilst ET-3 differs by 6.
All ET and SRTX isoforms have two intrachain disulphide bonds which link cysteine
residues at positions 1, 15, 3 and 11. It is now recognised that these disulphide
bridges are important in predicting receptor binding affinities (Nakajima et al., 1989).
A.1.1.2. Generation and metabolism of endothelin
ET-1 is the major form produced by vascular endothelial cells in humans, and is
generated in response to hypoxia, vascular shear stress, and a range of other
vasoactive mediators, including adrenaline (Yanagisawa et al., 1988). The primary
translation product of the human ET-1 gene is a 212 amino acid prepropeptide,
containing a 17 amino acid signal sequence which is cleaved once the peptide is
secreted from the nucleus (Inoue et al., 1989a; 1989b). The synthesis of mature ET-1
from prepro ET-1 requires two enzymatic steps: firstly, dibasic amino acid






Figure 1.2. Amino acid sequences of the three human endothelin isoforms, and one
of the sarafotoxin family (four highly homologous peptides isolated from snake
venom). Amino acids differing from endothelin-1 are shaded, and the lines represent
disulphide bridges linking cysteine residues.
to form the 38 amino acid pro ET-1, or 'big ET-1', then cleavage at Trp21-Val22 by
endothelin-converting enzyme (ECE), yields the 21 amino acid ET-1 (Figure 1.3).
Several candidates have been proposed for the activity of ECE; based on their
sensitivity to metal ion chelators, pepstatin A and pH optima, the aspartyl and/or
metalloprotease family were thought to be responsible for ECE activity (Ikegawa et al.,
1990; Lees et al., 1990; Sawamura et al., 1990). However, the aspartyl proteases
were subsequently shown to be unlikely candidates, owing to the inability of aspartyl
protease inhibitors to attenuate ET-1 secretion from cultured endothelial cells (Ikegawa
et al., 1990; Shields et al., 1991). Neutral endopeptidase 24.11 may play a role in the
conversion of big ET to the mature peptide, but it appears that it has a greater catalytic
efficiency in degrading ET-1 (Abassi et al., 1993) (see below). The most likely
enzyme displaying ECE activity is the neutral, membrane-bound metalloprotease
which is senstive to the inhibitor phosphoramidon (Matsumura et al., 1990a; Okada et
al., 1990). Phosphoramidon has been shown to inhibit the pressor response to
exogenous big ET-1 (Fukuroda et al., 1990; Matsumura et al., 1990b; McMahon et
al., 1991), and also big ET-2 and big ET-3 (Gardiner et al., 1992b; Pollock et al.,
1993), inferring that the enzyme(s) which converts the other isoforms of big ET is
likely to be similar to that involved in ET-1 formation. ECE is now thought to exist as
a family of isoenzymes, with different selectivities for the big ET isoforms. ECE-1 and
ECE-2 from animal and human sources have recently been cloned (Xu et al., 1994;
Emoto & Yanagisawa, 1995), and both are found to convert big ET-1 more efficiently
than big ET-2 and big ET-3. Unlike ECE-1, which has optimum activity at the neutral
pH of 6.8, ECE-2 has an acidic pH optimum of 5.5, and has a 200-fold greater
affinity to phosphoramidon compared to ECE-1 (Emoto & Yanagisawa, 1995).
The metabolism of ET appears to occur by three different routes: enzymatic
degradation, receptor-mediated clearance, and urinary excretion. Membrane bound














Figure 1.3. Proposed pathway for generation of endothelin-1. Cleavage of the
signal peptide sequence (amino acids 1-17, shaded) occurs during the secretion of big
endothelin-1 from the nucleus. Enzymatic conversion of big endothelin-1 to the mature
peptide involves a dibasic amino acid peptidase(s) and endothelin converting enzyme
(ECE).
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(Sokolovsky et al., 1990; Vijaraghavan et al., 1990; Fagny et al., 1991). NEP is also
responsible for the metabolism of other peptides, including bradykinin, atrial
natriuretic peptide and substance P (Erdos & Skidgel, 1989). Although NEP-
inhibition did not potentiate the response to exogenous ET-1 in rats (Pollock et al.,
1993), its physiological role in the metabolism of ET is supported by the results of
human studies using inhibitors of NEP. Increased urinary excretion and plasma levels
of ET-1 were found after inhibition of NEP by SQ-29,072 (Abbassi et al., 1992), and
brachial artery infusion of the NEP inhibitor, thiorphan, has been shown to cause
vasoconstriction of the forearm vasculature (Haynes & Webb, 1994). When
[125I]-labelled ET is injected intravenously (Shiba et al., 1989) or into the left ventricle
(Anggard et al., 1989) of anaesthetised rats, over 60% of ET-1 is removed during the
first minute, the majority of which binds to the lung, followed by the kidney and liver.
The authors suggest ET-1 binds to its receptors and is then internalised (Anggard et
al., 1989; Shiba et al., 1989). It has been reported that intracellular proteases, such as
deamidase, then degrade the internalised ET (Jackman et al., 1992; 1993). Low
affinity ETb receptors may be clearance receptors for high concentrations of ET
(Clozel et al., 1993). As mentioned, urinary excretion accounts for part of the
clearance of ET; bilateral nephrectomy of rats has been shown to significantly reduce
the disappearance of [125I]-labelled ET-1 (Kohno et al., 1989).
A.1.1.3 Endothelin receptors and signal transduction mechanisms of
endothelin
To date, two distinct ET receptor subtypes have been cloned from human cDNA: the
ETa receptor, initially cloned by Arai et al. (1990) from bovine cDNA, is selective for
ET-1, with binding affinity: ET-l>ET-2»ET-3 (Adachi et al., 1991; Hosodaeta/.,
1991), and the ETg receptor, originally cloned from rat cDNA by Sakurai et al.
(1990), which is non-selective, with binding affinity: ET-l=ET-2=ET-3 (Ogawa et
al., 1991). A third receptor subtype, ETc, which is ET-3 selective (binding affinity:
ET-3>ET-2=ET-1), has been cloned in the amphibian Xenopus laevis (Karne et al.,
1993), but has yet to be identified in the mammalian genome. The ETa and ETg
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receptor subtypes are structurally similar, having seven transmembrane domains
characteristic of the G-protein-coupled receptor superfamily (Hosoda et al., 1992; Arai
etal., 1993).
The short term actions of ET are thought to be mediated by several signal transduction
mechanisms, involving G-protein-mediated activation of phospholipase C (PLC),
which catalyses the formation of inositol trisphosphate (IP3) and diacylglycerol (DAG)
(Pang et al., 1989; Griendling et al., 1989). IP3 induces the release of intracellular
calcium (Ca2+) from the sarcoplasmic reticulum, whilst DAG activates protein kinase
C (PKC), which may sensitise contractile proteins to Ca2+ via phosphorylation
(Sunako et al., 1989; Abe et al., 1991). PKC may also stimulate sodium-hydrogen ion
(Na+-H+) exchange by increasing the intracellular H+ affinity for the Na+-H+-
antiporter (Lonchampt et al., 1991), which leads to alkalinisation and enhanced
contractility of vascular smooth muscle cells, again, through sensitisation of contractile
proteins to Ca2+. Voltage-operated Ca2+ channels are also involved in the sustained
vasoconstrictor response to ET (Inoue et al., 1990). In addition, there is evidence that
ET-1 can stimulate arachidonic acid metabolism via activation of phospholipase A2
(PLA2) (De Nucci et al., 1988; Reynolds et al., 1989), resulting in the release of
prostacyclin, prostaglandin E2 and thromboxane A2.
The wide use of selective agonists and antagonists in vivo confirm that ETa receptors,
present on vascular smooth muscle cells, mediate vasoconstriction, whilst the ETg
receptors on endothelial cells, cause vasodilatation. In addition, selective ETb receptor
agonists, SRTX S6C and [Ala E3,i 1,15] ET-1, have been shown to increase blood
pressure in vivo, which suggests that vasoconstrictor ETb receptors exist (Williams et
al., 1991; Douglas & Hiley, 1991;Clozel etal., 1992; Gardiner et al., 1992a). Further
evidence for a constrictor ETb receptor comes from antagonist studies, where the ETa
receptor antagonists, BQ-123 or FR 139317, are unable to fully block the pressor
response to ET-1 (Ihara etal., 1992; Bigaud & Pelton 1992; McMurdo et al., 1993;
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Warner et al., 1994; Gardiner et al., 1994a). These results demonstrate that both ETa
and ETg receptors mediate the pressor effects of ET. The physiological contribution of
constrictor ETb receptors is presently uncertain, and it appears to vary depending on
the size and type of vessel under study. In the pulmonary vasculature of the rat, ETb
receptor agonists were able to induce a far greater contraction in resistance arteries
compared to the larger pulmonary arteries (MacLean et al., 1994), and their role
appears to be more important in pulmonary resistance arteries compared to mesenteric
resistance arteries in the rat (Deng et al., 1995). Non-ETA, non-ETs receptors may
also be involved, although studies in conscious rats using the non-selective ETa/ETb
receptor antagonist, bosentan, find the major haemodynamic effects of ET-1, ET-2 and
ET-3, and all those of big ET-1, are effectively antagonized (Gardiner et al., 1994b),
which is consistent with ETa and ETb receptors mediating the majority of the
haemodynamic responses to the ETs.
ET receptors can be downregulated in response to increased levels of ET. Hirata and
co-workers (1988) were first to demonstrate a reduction in [125I]-ET-1 binding sites,
and a reduced ability of ET-1 to induce a rise in intracellular Ca2+, after pretreatment
with ET-1 in cultured vascular smooth muscle cells.
A.1.1.4. Cardiovascular effects
ET has a wide range of actions throughout the body, including effects on the function
of the kidney, lung, gut, central nervous system and neuroendocrine system. The
focus of this section will be on the cardiovascular physiology of ET.
A.1.1.4.1. Pressor responses of endothelin
In addition to the prolonged pressor response to ET-1, originally demonstrated by
Yanagisawa et al. in 1988, ET-2 and ET-3 also increase blood pressure in the rat
(Inoue et al., 1989a), although ET-3 evokes the least response and has the shortest
duration of action. Similar pressor responses to the ETs have been demonstrated in
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many species, including the guinea pig (Whittle et al., 1989a; Braquet et al., 1989),
rabbit (Miyamori et al., 1990), dog (Clarke et al., 1989), pig (Pernow et al., 1989),
goat (Dieguez et al., 1992), trout (Olson et al., 1991) and man (Vierhapper et al.,
1990).
Studies using [125I]-labelled ET-1 in the anaesthetised rat show that the sustained
increase in arterial pressure occurs despite a rapid clearance of ET-1 from the
circulation (Anggard et al., 1989; Shiba et al., 1989), inferring that the long lasting
pressor response is due to an extremely slow dissociation of ET-1 from its receptors
on vascular smooth muscle, as has been reported in vitro (Hirata et al., 1988).
Big ET-1 causes a pressor effect of similar magnitude to that of ET-1 in the conscious
rat (Gardiner et al., 1991; McMahon et al., 1991), and in anaesthetised rats
(Matsumura et al., 1990a), guinea pigs (Fukuroda et al., 1990), and rabbits
(D'Orleans-Juste et al., 1991). In the anaesthetised pig, however, porcine big ET-1
shows a poor vasopressor activity compared to ET-1 (Hemsen et al., 1991); this result
may be due to the mode of administration of big ET-1, because the other studies cited
used bolus injections, whilst Hemsen et al. gave infusions, or, it could also be due to
species differences. The pressor activity of big ET-1 is dependent on its metabolism to
mature ET-1 by ECE, because big ET-1 is 100 times less potent in vitro than ET-1
(Kashiwabara et al., 1989). As described earlier, ECE has been identified as a
phosphoramidon-sensitive metalloprotease (Matsumura et al., 1990a); studies in vivo
show phosphoramidon potently inhibits the pressor response of big ET-1 without
affecting ET-1 induced hypertension (Fukuroda et al., 1990; Matsumura et al., 1990b;
McMahon et al., 1991). Vasoconstriction induced by big ET-1 in the mesenteric
vascular bed is less sensitive to phosphoramidon than its vasoconstriction in renal and
hindquarters vascular beds (Gardiner et al., 1991). This suggests that conversion of
big ET occurs locally rather than in the systemic circulation, with different vascular
beds possessing varying degrees of enzyme activity. The precursors of ET-2 and ET-3
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also result in vasoconstrictor actions similar to their mature forms when administered
in vivo to conscious rats (Gardiner et al., 1992b) and anaesthetised rats (Pollock et al.,
1993; Matsumura et al., 1993), although the magnitude of the response is smaller than
that of ET-2 and ET-3. Unlike studies in the rat, D'Orleans-Juste and colleagues
(1991) found big ET-3 had no pressor response in the anaesthetised guinea pig. The
contrasting findings in vivo may reflect species variation in the expressions of different
ECE isoforms.
A.1.1.4.2. Depressor responses of endothelin
ET elicits a transient depressor response, lasting only a few minutes, which precedes
the pressor effect and is most marked for ET-3 (Inoue et al., 1989a). From studies
using analogs of SRTX in rats, it appears to be the N-terminal amino group that
determines the vasodilator activity of the peptide (Kitazumi et al., 1990). When big
ET-1 is given to conscious rats, the depressor response observed with the mature
peptide is absent. The same is true when ET-1 is administered as an infusion rather
than as a bolus dose (Gardiner et al., 1989; Mortensen & Fink, 1990). The absence of
the hypotensive effect is most likely to reflect the physiological response to
endogenously generated ET, where plasma concentrations are much lower.
The transient depressor response to bolus administration of ET is thought to be
mediated by endothelial generation of nitric oxide and prostacyclin from endothelial
cells, after stimulation of the endothelial ETb receptor. Some studies using inhibitors
of nitric oxide synthase (Whittle et al., 1989b; Auberson et al., 1991; Fozard & Part,
1992; Lerman et al., 1992; Rogerson et al., 1993; Filep et al., 1993; Granstam et al.,
1993) and cyclo-oxygenase (De Nucci et al., 1988; Filep et al., 1991b; Rogerson et
al., 1993; Granstam et al., 1993) have shown a significant reduction in the dilator
effect, and sometimes a potentiation of the pressor effect of ET-1, indicating the
constrictor action of ET is limited by the stimulated release of vasodilators (see below).
Furthermore, the ability of ETa receptor antagonists to enhance the vasodilator activity
12
of ET again suggests a functional antagonism exists between constrictor and dilator
actions. Others have found no major role for nitric oxide or prostacyclin in mediating
the vasodilator response to ET in vivo (Gardiner et al., 1989; 1990; Ohlstein et al.,
1990), suggesting that other endothelial mediators may be involved in some vascular
beds. Plasma levels of the cardiac-derived vasodilator, atrial natriuretic peptide, are
increased following intravenous injection of ET-1 in conscious rats (Stasch et al.,
1989), although this dilator is not thought to play a major role in the depressor action
of ET-1 (Fozard & Part, 1990). It would seem unlikely that the endothelium-derived
vasodilator, platelet-activating factor (PAF), mediates the initial hypotensive response
to ET-1, since Filep et al. (1991a) have shown that pretreatment of conscious rats with
selective PAF-receptor antagonists fails to affect the haemodynamic response to ET-1.
Endothelium-dependent hyperpolarising factor (EDHF) has been proposed as another
mediator of ET-induced dilatation, although few studies in vivo have been done. One
such study demonstrated that glibenclamide, an inhibitor of ATP-dependent potassium
channel activation, failed to block the depressor response to ET-1 (Lippton et al.,
1991), suggesting EDHF may not play a major role in this response, since EDHF has
been reported to induce hyperpolarisation via the opening of ATP-dependent
potassium channels (see review by Garland et al., 1995). Glibenclamide does,
however, inhibit the dilator response to ET-1 in the pulmonary circulation (Lippton et
al., 1991; Wong et al., 1993), suggesting a role for EDHF in this vascular bed.
A.1.1.4.3. Endothelin and the maintenance of blood pressure
ET may play a role in maintaining normal resting blood pressure, since administration
of phosphoraxiiidon alone results in a significant fall in mean arterial pressure both in
normotensive and in hypertensive rats (McMahon et al., 1991). Similarly, intravenous
infusion of the ETa receptor antagonist, BQ-123, decreases mean arterial pressure in
normotensive (Pollock & Opgenorth, 1993) and hypertensive rats (Bazil et al., 1992;
Nishikibe et al., 1993), and guinea pigs (Veniant et al., 1994). ET has been shown to
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contribute to basal vascular tone in the forearm of humans, after an increase in forearm
blood flow was found following intra-arterial infusion of phosphoramidon or BQ-123
(Haynes & Webb, 1994). More recently, studies using systemic doses of the ETa/b
receptor antagonist, TAK-044, reveal that mean arterial pressure is reduced in a dose-
dependent manner after intravenous administration of this antagonist to healthy
subjects (Haynes et al., 1995). Thus, endogenous generation of ET-1 appears to
contribute to the maintenance of blood pressure, implying a fundamental physiological
role for this peptide in cardiovascular control.
A.1.1.4.4. Cardiac effects of endothelin
The coronary resistance bed is more sensitive to the effects of ET than other resistance
beds, except for the kidney (Clozel & Clozel, 1989). ET-1 has been shown to be a
potent and long-lasting constrictor of coronary arteries in vivo in animals, including
the dog (Kurihara et al., 1989a; Miller et al., 1989; Wang et al., 1991), rabbit (Hirata
et al., 1990), monkey (Clozel & Clozel, 1989), goat (Dieguez et al., 1992) and pig
(Pernow et al., 1989; Ezra et al., 1989), resulting in a marked fall in coronary blood
flow and myocardial ischaemia. Coronary angiograms reveal these effects are
primarily due to the contraction of small coronary arteries (Kurihara et al., 1989a;
Hirata et al., 1990). ET has also been reported to lead to fatal ventricular arrhythmias
(Ezra et al., 1989), possibly via a distinct proarrhythmic effect separate from
myocardial ischaemia.
Positive chronotropic and inotropic effects of ET have been found in vitro, but reports
in vivo have been conflicting. Several studies find the intial hypotension produced by
ET is associated with an increase in heart rate and cardiac output, whilst the pressor
response causes bradycardia and a fall in cardiac output, which is probably due to a
combination of systemic vasoconstriction, increasing afterload, and coronary
vasoconstriction, causing myocardial ischaemia (Miller et al., 1989; Yang et al.,
1991). In contrast, Garcia and collegues (1990) report positive inotropic actions of
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ET-1, despite a rise in mean arterial pressure in conscious rats. The early inotropic
effects most likely reflect a direct cardiac action of ET-1 (Gardiner et al., 1990c).
Ricou et al. (1992) found no effect of ET-1 on myocardial contractile function in pigs.
Chronotropic effects of ET-1 in vivo appear to be reflex in origin, since heart rate does
not change after blockade of cardiac efferent neural mechanisms (Gardiner et al.,
1990c).
A.1.2. Angiotensin II
Angiotensin II (ANG II) is a potent vasoconstrictor peptide generated by a two-step
enzymatic reaction. Renin, which is secreted into the blood from the juxtaglomerular
cells of the afferent arteriole in the kidney, catalyses the formation of the decapeptide,
angiotensin I (ANG I), from the plasma substrate, angiotensinogen. The membrane-
bound enzyme, angiotensin converting enzyme (ACE), found in high concentrations in
the lung, then cleaves two amino acids from ANG I to form the octapeptide, ANG II.
The known actions of ANG II, including vasoconstriction, result from the activation
of AT] receptors (see review by Cockcroft et al., 1995). The presence of renin,
angiotensinogen, and ACE in the blood vessel wall suggests that, in addition to the
circulating renin-angiotensin system, ANG II may be released locally from the
vasculature and contribute to the maintenance of vascular tone (Caldwell et al., 1976;
Campbell & Habener, 1986; Samani et al., 1987). Direct evidence of vascular
production of ANG II comes from studies of isolated vessels in rats (Nakamaru et al.,
1986) and humans (Mizuno et al., 1991), which reveal ANG II is generated despite
the absence of circulating blood. It is unclear to what extent the vascular renin-
angiotensin system contributes to the maintenance of vascular tone, because
administration of locally acting doses of ACE inhibitors (Webb et al., 1988) and renin
inhibitors (Haynes et al., 1993) have little effect on local blood flow or vascular tone.
An important action of ANG II generated within the vasculature is the potentiation of
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sympathetically mediated vasoconstriction (Zimmerman et al., 1981; Cockcroft et al.,
1995).
A.1.3. Vasoconstrictor cyclooxygenase products
Cyclooxygenase inhibitors, such as indomethacin, have been shown to prevent
endothelium-dependent contractions induced by several mediators (Katusic et al.,
1988), suggesting metabolites of arachidonic acid are capable of eliciting contraction,
either directly or indirectly. Some of these vasoconstrictor metabolites are discussed
below.
A.1.3.1. Thromboxane A2/Prostaglandin H2
Thromboxane A2 (TXA2), which is generated predominantly in platelets, can also be
synthesised in endothelial cells, through the action of two enzymes: cyclooxygenase,
which catalyses the formation of the endoperoxides, prostaglandin G2 (PGG2) and
prostaglandin H2 (PGH2), from arachidonic acid, and thromboxane synthetase, which
converts PGH2 into TXA2 (see review by Schror, 1993). However, in blood vessels
prostacyclin synthetase is more commonly found than thromboxane synthetase, thus
favouring prostacyclin formation over that of TXA2 (see below). Once bound to its
TXA2/PGH2 (TP) receptor (see review by Pierce et al., 1995), the vasoconstrictor and
platelet aggregatory effects of TXA2 are mediated through activation of PLC to elevate
intracellular Ca2+ through increased phosphoinositide turnover, membrane DAG and
PKC (Seiss et al., 1985; Brass et al., 1987).
Several substances, including acetylcholine, 5-hydroxytryptamine (5-HT), and
adenosine diphosphate (ADP), cause endothelium-dependent contractions which are
inhibited by TP receptor antagonists or cyclooxygenase inhibitors (Auch-Schwelk et
al., 1990; Kato et al., 1990), indicating the involvement of
endoperoxides/thromboxanes in the contractile response. It remains unclear whether
the endoperoxides/thromboxanes are released directly from the endothelium, or
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alternatively, if an endothelium-derived signal is responsible for initiating their
production in vascular smooth muscle cells.
A.1.3.2. Superoxide anions
Superoxide anions, or oxygen-derived free radicals (O2"), have been shown to be
released from cultured endothelial cells (Rosen & Fremann, 1984). PGH2 synthetase
may be a source for these anions, since the conversion of PGG2 to PGH2 has been
shown to generate oxygen-derived free radicals (Kukreja et al., 1986). Endothelium-
dependent contraction of the canine basilar artery is inhibited by superoxide dismutase,
an O2" scavenger, supporting a role for superoxide anions in mediating contraction of
this vessel (Katusic & Vanhoutte, 1989). It would appear that superoxide anions cause
contraction of vascular smooth muscle indirectly, either by stimulating the release of
PGH2 which then acts on TP receptors (Auch-Schwelk et al., 1989; 1990), or through
inactivation of the endothelium-derived dilator, nitric oxide (NO), since superoxide
anions are avid scavengers of NO (Rubanyi et al., 1986; Gryglewski et al., 1986).
A.2. Endothelium-Derived Vasodilators
A.2.1. Endothelium-derived relaxing factor
A.2.1.1 The discovery of endothelium-derived relaxing factor
In 1980, Furchgott & Zawadzki demonstrated in vitro that acetylcholine (ACh) caused
relaxation in arteries with an intact endothelium, but was unable to elicit relaxation in
those which were denuded of their endothelium, and in fact caused contraction in these
vessels due to a direct action on vascular smooth muscle (Furchgott & Zawadzki,
1980). These findings led them to believe that there existed either an electrical or
humoral signal that could pass from the endothelium to the underlying smooth muscle,
to cause dilatation in response to ACh. In order to determine the nature of this signal,
Furchgott and colleagues (1984) set up a sandwich preparation of rabbit aorta, which
comprised strips of endothelium-denuded vessels in very close contact with strips of
intact vessels. Upon addition of ACh, both strips relaxed, showing that the factor
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responsible for this relaxation could be transferred from one strip to another, i.e. was a
diffusable humoral signal. This signal was named endothelium-derived relaxing factor
(EDRF).
EDRF has a very short half-life, in the order of a few seconds, which made it very
difficult to identify. Endothelium-dependent relaxation was shown to be inhibited by
haemoglobin (Martin et al., 1985). Gryglewski and co-workers (1986) demonstrated
superoxide anions (O2O inactivate EDRF, whilst the O2- scavenger, superoxide
dismutase, stabilises EDRF. The nitrovasodilators, such as glyceryl trinitrate (GTN)
and sodium nitroprusside (SNP), activate soluble guanylate cyclase in vascular smooth
muscle cells via the production of nitric oxide (NO) (Feelisch & Noack, 1987). EDRF
was also shown to stimulate soluble guanylate cyclase (Forstermann et al., 1986;
Ignarro et al., 1986). These observations led to the belief that EDRF could itself be
NO. The identity of EDRF as NO would explain its short half-life (rapidly decays to
nitrate and nitrite), its destruction by O2- and enhancement by superoxide dismutase,
the actions of the nitrovasodilators, and its inhibition by haemoglobin, since NO fits
into the haem ring in exactly the same place as oxygen (O2). Further evidence for NO
being the EDRF came from superfusion cascade experiments by Palmer et al. (1987)
who added bradykinin, a known releaser of EDRF, to strips of rabbit aortae. Their
findings showed that the amount of NO released, measured by chemiluminescence,
quantitatively accounted for the relaxation of the aortic strips produced by bradykinin-
induced release of EDRF. Similar findings were reported by others in the same year
(Hutchison et al., 1987; Ignarro et al., 1987; Khan & Furchgott, 1987). In addition,
the rate of loss of relaxing activity with increasing time was similar for NO and EDRF
(Palmer et al., 1987). Similarities between the inhibitory effect of EDRF and NO on
platelet aggregation were also demonstrated (Radomski et al., 1987). The above
observations provide good evidence that EDRF is NO. Several other candidates, such
as S-nitroso-L-cysteine (Myers et al., 1990), have been proposed to be the EDRF, but
the results of a recent study comparing the properties of several of these other
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candidates with those of NO, further support the identity of EDRF as NO (Feelisch et
al., 1994) (Figure 1.4).
A.2.1.2. Generation and metabolism of endothelium-derived relaxing
factor
NO is synthesised within the vascular endothelium by nitric oxide synthase (NOS)
acting on the amino acid substrate, L-arginine (Palmer et al., 1988a; 1988b). Three
distinct NOS enzymes have been identified to date: two constitutive, Ca2+-calmodulin-
dependent types present in the endothelium (and platelets) and neuronal tissue (Mayer
et al., 1989; Bredt et al., 1991), and an inducible Ca2+-independent type found in
immune cells, vascular smooth muscle cells, endothelial cells and myocytes, which is
expressed during immunological and inflammatory reactions (Kilbourn & Belloni,
1990). The three isoforms of NOS (endothelial, neuronal, and cytokine-inducible) are
derived from three separate genes (for review see Sessa, 1994). NADPH, FAD and
FMN are required as cofactors for each isoform, and tetrahydrobiopterin potentiates
their activity (Mayer et al., 1991; Yui et al., 1991; Schmidt et al., 1992). Endothelial
NOS is activated by a rise in the endothelial intracellular calcium concentration (Mulsch
et al., 1989; Mayer et al., 1989), which explains the endothelium-dependent relaxing
effect of the Ca2+-ionophore, A23187 (Ignarro et al., 1987), and the various mediators
of relaxation, including bradykinin and ADP, which release Ca2+ from the
sarcoplasmic reticulum via stimulation of the IP3 pathway (Fambert et al., 1986;
Pirotton et al., 1987). NO has been shown to inhibit its own synthesis through a
negative feedback mechanism on NOS (Assreuy et al., 1993). Griscavage and
colleagues (19941 suggest that NO interacts with NOS-bound haem iron in the ferric
state to inhibit the enzyme.
NO degrades within seconds to form nitrite (NO2") and nitrate (NO3"):
2 N02 + H20 > N02" + NO3- + 2H+
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Wennmalm and co-workers (1993) report that one of the major metabolic pathways for
NO is uptake into the red blood cells, where it is converted into nitrate and
methaemoglobin. Nitrate then enters the plasma and is excreted via the kidney.
NO can also act as a free radical scavenger, neutralising superoxide anions to form
nitrate:
NO + O2" > NO3"
However, the reaction between NO and superoxide anions can result in the formation
of highly toxic peroxynitrite anions (ONOO"), which are cytotoxic and can cause
considerable tissue damage (Beckman et al., 1990).
A.2.1.3. Nitric oxide receptors and signal transduction mechanisms of
nitric oxide
Once NO has been formed it diffuses to the underlying smooth muscle, where it binds
to the haem moiety associated with soluble guanylate cyclase and causes a
conformational change, which activates the enzyme, leading to production of cGMP
(Ignarro et al., 1986) (Figure 1.4). The cGMP in turn activates cGMP-dependent
protein kinases (Fiscus et al., 1984; Popescu et al., 1985) which can then cause
vasodilatation by several methods: for example, by inhibiting sarcolemmal calcium
channels (Collins et al., 1986; Ratz et al., 1987) or activating sarcolemmal calcium
extrusion pumps (Popescu et al., 1985), to result in a net reduction of Ca2+ influx; or
by affecting the phosphorylation/dephosphorylation of myosin light chain contractile
protein (Rapoport et al., 1983). Recently, Bolotina and co-workers (1994)
demonstrated that NO can cause smooth muscle relaxation independently of cGMP,
through the direct activation of Ca2+-dependent potassium channels. NO has also been
shown to stimulate ADP-ribosylation of G-proteins, which enhances the activation of
adenylate cyclase whilst inhibiting the activation of PLC, thus resulting in
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Figure 1.4. Schematic pathway for the generation of nitric oxide (NO). NO is
producedfrom the enzymatic conversion of L-arginine to L-citrulline by NO synthase
(NOS). After diffusing to the underlying smooth muscle, NO activates soluble
guanylate cyclase (sGC), leading to the accumulation of cyclic guanosine
monophosphate (cGMP). cGMP-dependent protein kinases then mediate smooth
muscle relaxation. Inhibitors of the pathway are shown in grey: NG-monomethyl
L-arginine (L-NMMA) and NG-nitro-L-arginine methyl ester (L-NAME) inhibit NOS;




A.2.1.4. Vasodilator effects of nitric oxide
NO is released in response to hypoxia, pulsatile flow and shear stress (Pohl et al.,
1986; Rubanyi et al., 1986), and is the final common pathway for the action of many
vasodilator substances. Increases in blood flow have been shown to potentiate the
endothelium-dependent dilator response to ACh in the dog hindlimb (Miller &
Vanhoutte, 1988) and the rabbit ear (Griffith et al., 1987). Griffith & Edwards (1990)
have reported that the greatest release of NO is in the large arterioles, which experience
the highest levels of shear stress. NO is also released by endogenous vasoconstrictors,
including ET (Warner et al., 1989), and serves to modulate their actions (see below).
Analogues of L-arginine, such as L-NMMA, act as antagonists of NOS, and have
been found to cause vasoconstriction in resistance vessels (Vallance et al., 1989),
indicating that nitric oxide exerts a tonic dilator action opposing constrictor influences
in the arterial circulation. Most veins produce little, if any, NO under resting
conditions and are very sensitive to exogenous NO in the form of nitrovasodilators
(Vallance et al., 1989). This supersensitivity to NO could result from an increased
amount of soluble guanylate cyclase in vascular smooth muscle cells, or an enhanced
sensitivity of the enzyme, in the venous circulation.
A.2.2. Prostacyclin
Prostacyclin, or prostaglandin I2 (PGI2), was discovered in 1976 by Moncada and
colleagues (Moncada et al., 1976). It is mainly generated in endothelial cells, although
some can be formed in the smooth muscle, from arachidonic acid, through the action
of cyclooxygenase and prostacyclin synthetase. Once bound to its IP receptor (see
review by Pierce et al., 1995), the vasodilatory and anti-aggregatory effects of
prostacyclin are mediated through a rise in intracellular cyclic AMP concentrations in
smooth muscle cells and platelets (Tateson et al., 1977). Because many investigators
have used cyclooxygenase inhibitors as part of a standard protocol, the contribution of
PGI2 endothelium-dependent dilatation has not been well documented. Pulsatile flow
and vasoactive mediators such as bradykinin and thrombin stimulate PGI2 synthesis
(Piper & Vane, 1977). It appears that arteries can synthesise three to ten times more
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PGI2 than veins (Skidgel & Printz, 1978), and larger vessels produce more PGI2 than
the microvasculature (Maclntyre et al., 1978).
A.2.3. Endothelium-derived hyperpolarising factor
Bolton and colleagues (1984) first described an endothelium-dependent, carbachol-
induced hyperpolarisation in the guinea pig mesenteric artery. The finding that NO was
unable to change the membrane potential of vascular smooth muscle cells (Komori et
al., 1988), indicated that the endothelium probably releases a hyperpolarising factor
which is distinct from NO (reviewed by Garland et al., 1995). Direct evidence for the
existence of a separate endothelium derived hyperpolarising factor (EDHF) comes
from studies showing that inhibitors of EDRF, such as haemoglobin and methylene
blue, inhibit vasorelaxation induced by acetylcholine, but do not alter endothelium-
dependent smooth muscle hyperpolarisation (Chen et al., 1988; Komori et al., 1988;
Chen & Suzuki, 1989). The fact that exogenous nitro-vasodilators produce relaxation
with little or no change in smooth muscle membrane potential further supports this
theory (Komori et al., 1988). Studies using selective agonists and antagonists for the
different subtypes of muscarinic receptor, have revealed that endothelial Ml receptors
mediate transient relaxation by EDHF release, whilst endothelial M2 (now M3)
receptors are responsible for relaxation via EDRF (Komori & Suzuki, 1987). As artery
size decreases, it appears that EDHF accounts for a greater proportion of the relaxation
than NO (Nagao & Vanhoutte, 1993).
A.3. Interactions between endothelium-derived relaxing and
contracting factors
A.3.1.Endothelin and nitric oxide
Experiments have shown that removal of the endothelium, or addition of inhibitors of
NO, potentiates the contractile response to ET-1 and ET-3, indicating that ET
stimulates the release of EDRF/NO (Warner et al., 1989; Whittle et al., 1989b;
Auberson et al., 1991; Fozard & Part, 1992, Lerman et al., 1992). This effect is most
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marked for ET-3, and is mediated through endothelial cell ETb receptors (Warner et
al., 1989; 1992; Hirata et al., 1993). ET production is inhibited by NO via a cGMP-
dependent mechanism (Boulanger & Luscher, 1990; Warner et al., 1992). When the
NO-synthase inhibitor, NG-nitro-L-arginine methyl ester (L-NAME), is administered
to anaesthetised rats, it produces a rise in mean arterial pressure (Richard et al., 1995).
This is not solely due to removal of basal dilator tone, because prior administration of
the ET-receptor antagonists, BQ-123 or bosentan, resulted in a 50% reduction of the
L-NAME-induced pressor response, implying that basal NO-mediated inhibition of ET
release occurs (Richard et al., 1995).
A.3.2. Endothelin and prostacyclin
Indomethacin, but not L-NMMA, was able to prevent the ET-1-induced endothelium-
dependent relaxtion in the isolated perfused rat mesentery, suggesting prostacyclin or
PGE2 is released in response to ET-1 (Dohi & Luscher, 1991). Similarly, ET-1
stimulates the release of dilator prostaglandins in vivo, as demonstrated by the
potentiation of the pressor reponse to ET-1 in the presence of indomethacin (De Nucci
et al., 1988; Filep et al., 1991b; Rogerson et al., 1993; Granstam et al., 1993). ET-3
has been shown to stimulate the synthesis and release of prostacyclin in cultured
endothelial cells (Emori et al., 1991b). Yokokawa and co-workers (1991) have found
ET-3 -induced formation of ET-1 in cultured human endothelial cells is augmented by
indomethacin. Similarly to NO, it would therefore appear that prostacyclin can inhibit
ET release and/or synthesis.
A.3.3. Nitric oxide and prostacyclin
Relaxations produced by exogenous prostacyclin are potentiated in the presence of the
endothelium (Shimokawa et al., 1988). Furthermore, this potentiation is inhibited by
haemoglobin, implying prostacyclin induces the release of NO. It is, of course,
possible that synergistic mechanisms are responsible for the enhanced relaxation.
Prostacyclin production, however, has been shown to be inhibited by NO in cultured
bovine endothelial cells (Doni et al., 1988).
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A.3.4. Endothelin and angiotensin II
The contractile response to ANG II is augmented through an endothelium-dependent
mechanism, which is most likely to be the release of ET, because phosphoramidon,
BQ-123 or an ET antibody, prevents this augmentation (Dohi et al., 1992; Webb et al.,
1992). The fact that ANG II and ET increase blood pressure in a synergistic manner,
suggests a common pathway exists in the pressor mechanism of the two peptides
(Yoshida et al., 1991; 1992); common signalling mechanisms appear to exist for the
delayed mitogenic action of ANG II and ET (Weber et al., 1994). In vitro, ANG II has
been shown to stimulate ET production in cultured endothelial cells (Dohi et al., 1992;
Chua et al., 1993), smooth muscle cells (Scott-Burden et al., 1991), cardiomyocytes
(Ito et al., 1993), and mesangial cells (Kohno et al., 1992). Emori and co-workers
(1991a) propose ANG II-induced stimulation of ET release is mediated by
mobilisation of intracellular Ca2+ and activation of PKC. The results of subsequent
studies provide further evidence for this mechanism (Kohno et al., 1992). The positive
interaction between ANG II and ET occurs both ways; in cultured endothelial cells, ET
enhances the conversion of ANG I to ANG II (Kawaguchi et al., 1990). Interestingly,
ANG II has been shown to downregulate ET-1 receptors in vascular smooth muscle
cells (Roubert et al., 1989) and in vivo in the pithed rat (Guillon et al., 1991),
revealing a cross-desenstisation exists between ANG II and ET-1.
B. The Vascular Endothelium In Pathophysiology
Endothelial dysfunction has been implicated in a number of vascular conditions.
However, it is difficult to predict the pathophysiological role of individual
endothelium-derived factors, given that intrinsic regulatory mechanisms exist between
dilator and constrictor substances released from the endothelium (see above), and the
fact that pressor agents, adrenaline and ANG II (Yanagisawa et al., 1988) for
example, can enhance the release of endothelium-derived vasoconstrictors, such as
ET. Discerning what is the cause, and what is an effect of the disease, is therefore
difficult; increases in levels of vasoconstrictors may be secondary to a dysfunction in
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release/action of vasodilators. Many studies have measured plasma concentrations of
vasoconstrictors as a means of identifying potential pathophysiological candidates.
Plasma levels of ET are not very informative, since experiments in cultured endothelial
cells found -80% of ET was preferentially secreted abluminally (Wagner et al., 1992),
implying ET is unlikely to be acting as a circulating hormone. Indeed, normal plasma
levels of ET, in the low picomolar range in healthy humans (Davenport et al., 1990),
are lower than concentrations required to elicit contraction in isolated vascular rings
(Yanagisawa et al., 1988).
Despite the difficulties highlighted above, there is strong evidence that certain disease
states are related to an imbalance between endothelium-derived dilator and constrictor
function. Studies using ECE-inhibitors and ET-receptor antagonists, and inhibitors of
the prostacyclin and NO pathways, have supported a role for the endothelium in
numerous pathological conditions. Some of these conditions are listed in Table 1.1. As
this thesis addresses the vasospastic disorder of Raynaud's disease, the role of the




The debate as to whether migraine headaches are primarily the result of a vascular or
neurological disturbance remains unresolved, but there clearly is a decrease in regional
blood flow preceding migraine (Skinhoj & Paulson, 1969; Skyhoj-Olsen et al., 1987).
The cause of cerebral vessel vasospasm is unknown. The role of ET in mediating
cerebral vasoconstriction has been investigated by Farkkila and colleagues (1992), and
their interesting, though limited, results show that plasma ET-1 levels are raised in
migraine patients during an attack, compared to controls. There is to date, no
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Table 1.1. Pathophysiological conditions associated with endothelial dysfunction
Myocardial infarction Miyauchi et al., 1989; Omland et
al., 1994
Chronic heart failure McMurray et al., 1992; Wei et al.,
1994
Ischaemic stroke Ziv et al., 1992
Atherosclerosis Zeiher et al., 1991
Hypercholesterolaemia Bath & Martin, 1991;
Chowienczyk et al., 1992
Subarachnoid haemorrhage Masaoka et al., 1989; Suzuki et
al., 1992
Migraine Farkkila et al., 1992; Olesen et
al., 1994
Variant angina Quyyumi et al., 1992; Matsuyama
et al., 1991
Raynaud's phenomenon Zamoraeta/., 1990;
Hypertension Panza et al., 1990; Kohno et al.,
1990
Pulmonary hypertension Stewart et al., 1991
Pre-eclampsia Dekker et al., 1991; Florijn et al.,
1991
Chronic renal failure Koyama et al., 1989
Acute renal failure Tomita et al., 1989
Diabetes mellitus Takahashi et al., 1990; Johnstone
et al., 1993
Septicaemic shock Petros et al. ,1991
Gastric ulcer Wallace et al., 1989
Bronchial asthma Mattoli et al., 1991
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information regarding basal ET levels between migraine attacks. ET is also implicated
in subarachnoid haemorrhage-induced vasospasm (Matsumura et al., 1991; Suzuki et
al., 1992; Clozel et al., 1993) favouring the possibility that ET may play a
pathogenetic role in migraine.
NO may also be involved in the pathophysiology of migraine. Subjects given
continuous intravenous infusion of the endothelium-independent vasodilator, glyceryl
trinitrate (GTN), had reproducible, dose-dependent headaches during infusion, which
rapidly disappeared after infusion stopped (Iversen et al., 1989). GTN infusions
caused more severe headaches in migraine sufferers compared to controls (Olesen et
al., 1993), and similar findings were reported in studies using histamine, an
endothelium-dependent dilator (Krabbe & Olesen, 1980). It appears therefore, the
'fault' in migraine sufferers lies downstream from NO itself, because the sensitivity to
NO is increased in migraineurs in response to both histamine and GTN, and is thus
independent of NO-synthase. A possible candidate for the 'fault' is soluble guanylate
cyclase, which may display increased activity, or another enzyme, cofactor or receptor
in the NO-mediated pathway (Olesen et al., 1994).
B.1.2. Variant angina
Variant angina, first described by Prinzmetal and co-workers in 1959, results from
transient vasospasm of the coronary arteries (Prinzmetal et al., 1959; Dhurandhar et
al., 1972). Endothelial dysfunction has been reported in patients with variant angina
who have a reduced vasodilator reserve (Quyyumi et al., 1992). Impaired NO release
probably accounts for this dysfunction because vasodilatory responses of the coronary
microvasculature to the endothelium-dependent dilator, acetylcholine, are depressed in
these patients, whilst sodium nitroprusside, an endothelium-independent dilator,
produces similar responses to those found in patients without a reduced vasodilator
reserve, indicating the smooth muscle sensitivity to NO is normal (Quyyumi et al.,
1992).
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ET has been implicated in the pathophysiology of variant angina, but there is some
controversy as to its exact role. Basal plasma ET-1 concentrations are elevated between
vasospastic attacks in patients with variant angina (Toyo-oka et al., 1991), but it is
unclear if ET is primarily involved in intiating coronary spasm, because Toyo-oka and
colleagues (1991) found there was a transient decrease in plasma ET levels from
coronary sinus blood during an attack, in contrast to Matsuyama et al. (1991), who
reported increased levels 20 to 30 seconds after arteriographic evidence of spasm.
Although ET itself may not be directly responsible for initiating the spasm, it may be
important in influencing the sensitivity of coronary arteries to other constricting agents;
subthreshold concentrations of ET-1 have been shown to potentiate the contraction of
isolated human coronary arteries to noradrenaline and 5-HT (Yang et al., 1990;
Chester et al., 1992).
B.1.3. Raynaud's disease
Raynaud's disease is characterised by intense vasospasm of the extremities,
particularly the digits, in response to cold exposure or marked emotion. Evidence
suggests a temperature-dependent disorder of the vascular endothelium, whereby
either overproduction of a vasoconstrictor factor, or underproduction of a dilator
factor, might be a critical factor underlying the pathogenesis of Raynaud's (see under
Pathophysiology: D.1.10. for a detailed discussion).
B.1.4. Generalised vasospasm
An association exists between the vasospastic conditions of migraine, variant angina,
and Raynaud's disease (Miller et al., 1981; Zahavi et al., 1984; Kaiser, 1992;
O'Keeffe et al., 1992; 1993), in that there is a significantly higher incidence of
Raynaud's in patients with migraine and/or variant angina, suggesting that there may
be a vascular defect common to these conditions. Interestingly, patients with variant
angina show an enhanced forearm vasoconstriction to the cold pressor test, further
supporting the hypothesis of a generalised vasospastic disorder in these patients
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(Nakamura et al., 1984). Incidently, in common with Raynaud's disease, migraine has
a higher incidence in women (Linet & Stewart, 1987), again supporting a generalised
disorder. As discussed for the individual conditions, the endothelium is a favoured
candidate for the pathogenesis of this generalised vasospasm.
An increased prevalence of Raynaud's disease and migraine has also been reported in
subjects with ocular vasospasm (Phelps & Corbett, 1985; Guthauser et al., 1988;
Drance et al., 1988), a condition which is thought to be an important factor in the
pathophysiology of low-tension glaucoma (Gasser, 1989). Drance and co-workers
(1988) demonstrated in finger blood flow experiments that patients with vasospastic
diseases of the eye had an abnormal response to cold. The results of a recent study
suggest that ET-1 may be associated with ocular vasospasm (Sugiyama et al., 1995).
C. The Digital Circulation
Before describing Raynaud's disease and its pathophysiology in detail, it is
worthwhile to provide an overview of the anatomy and physiology of the digital
circulation. The symptoms of Raynaud's disease occur predominantly in the fingers,
but the following information is also relevant to the other extremities which can be
affected, including the toes, ears, and nose.
C.l. The arterial circulation
The blood supply to the hands and fingers comes from the ulnar and radial arteries.
From Figure 1.5, it can be seen that each digit receives two digital arteries. The blood
supply to the thumb arises directly from the radial artery, and not the palmar arch as
for the fingers, which accounts for the fact that the thumb is often spared from
vasospastic attacks in Raynaud's patients. Not all the fingers may be involved in an
attack, which suggests that the vasospasm occurs in vessels distal to the common
palmar digital arteries, since they supply branches to two fingers (Figure 1.5).
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C.2. Arteriovenous anastomoses
The digits contain a large number of arteriovenous (A-V) anastomoses, or shunts, in
addition to the capillary circulation (Hale & Burch, 1960; Sherman, 1963). The coiled
blood vessels which form A-V anastomoses have thick muscular walls but very little
elastic tissue, and tend to be either fully open or closed. Their function is to regulate
body temperature. When body temperature rises, A-V anastomoses open to allow large
amounts of blood to flow through subcutaneous veins, from which heat can dissipate.
During exposure to cold, blood is directed through the peri-arterial venae comites,
bypassing superficial veins in the skin, as a result of the A-V anastomoses closing
(Figure 1.6). The A-V anastomoses are under the control of both central and
circulating stimuli. Closure of A-V anastomoses is brought about by sympathetic
adrenergic stimulation, in a reflex response to cold or to mental stress, acting via 0C2-
adrenoceptors, and by circulating 5-HT acting on 5-HT2 receptors, noradrenaline and
angiotensin II (Coffman & Cohen, 1988). Dilatation of A-V anastomoses results from
decreased sympathetic stimulation, histamine acting on Hj and H2 receptors, and P-
adrenoceptor stimulation (Coffman & Cohen, 1988). Interestingly, Raynaud's disease
affects only skin areas that possess A-V anastomoses.
C.3. Cold vasoconstriction
The primary mechanism controlling digital blood flow is the sympathetic nervous
system; stimulation of sympathetic nerves results in vasoconstriction via a-
adrenoceptors, and withdrawal of their activity induces vasodilatation. The degree of
sympathetic nerve activity is controlled centrally through the medulla oblongata, which
contains the pressor and depressor vasomotor centres, which are themselves
influenced by the hypothalamus and other higher centres of the cortex. Serotonergic
vasoconstrictor mechanisms also play a role. 5-HT and a-adrenoceptor function is
covered in a subsequent section and so will not be discussed in detail here (see under



























Figure 1.6. Diagram of the arteriovenous (A-V) anastomoses of the digits. When









Local cooling produces vasoconstriction of the fingertip, but at temperatures of less
than 10°C, vasoconstriction alternates with periods of vasodilatation (Grant & Bland,
1931), most likely as a means of preserving tactile sensation in the digits. This
phenonemon is largely due to local axon reflex mechanisms, whereby cold-induced
stimulation of sensory C-fibre neurons causes the release of various neurotransmitters,
including calcitonin gene-related peptide (see below), which then act on the vascular
smooth muscle of blood vessels to cause vasorelaxation. Other vasodilatory
mechanisms in response to cold may include the stimulation of P-adrenoceptors
(Cohen & Coffman, 1981), histamine receptor activation (Coffman et al., 1984) and a
cholinergic vasodilator mechanism in the capillary vascular bed of the digits (Coffman
& Cohen, 1987).
D. Primary Raynaud's Disease
Raynaud's phenomenon takes its name from the French physician, Maurice Raynaud,
who first described its symptoms in his thesis entitled 'De I'asphyxie locale et de la
gangrene symetrique des extremities' ('On local asphyxia and symmetrical gangrene of
the extremities'), which he submitted in 1862. Raynaud's phenomenon is now
recognised as a common condition, occurring in up to 20% of the population, and
more often in females, affecting eight times as many women as men (Reviewed by
Cotton & Khan, 1986; Belch, 1991; Coffman, 1991; Lally, 1992). The reported
prevalence of the phenomenon varies according to a survey's diagnostic criteria, and
the climatic conditions of where the survey is carried out; warmer climates tend to
favour a lower percentage of the population being affected. The primary condition,
where no underlying disorder is found, is known as Raynaud's disease, but it can
occur secondary to several other conditions, in which case it is referred to as
Raynaud's phenomenon or syndrome (Allen & Brown, 1932). Raynaud's disease
most commonly affects the fingers and toes, but can affect any cold-exposed
extremity, including the nose, ears and tongue (Cooke, 1991). Characteristically,
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during an attack there is a triphasic response, although some patients do not experience
all of the three phases. Initially, on exposure of the digits to cold, or in response to
emotional stimuli, there is vasoconstriction producing extreme pallor, followed by the
development of cyanosis through reduction in tissue oxygenation, and then rubor on
return of the circulation. This last phase is often accompanied by intense local
discomfort or pain. Vasoconstriction in response to cold exposure is a physiological
response, which is exaggerated in subjects with Raynaud's disease. Currently, neither
the mechanism of cold-induced vasoconstriction, nor of Raynaud's, is fully
understood and, although many treatments are available for patients with Raynaud's
and may be useful in individual subjects, none are effective in the majority of patients
(Cooke & Nicolaides, 1990) (see later).
D.l. Pathophysiology
At present, the pathophysiology of primary Raynaud's disease remains unresolved,
despite its first description over 130 years ago (Raynaud, 1862). Outlined below are
some of the possible candidates that may be responsible for the condition.
D.l.l. Sympathetic nervous system
Raynaud's disease was originally attributed to overactivity of the sympathetic nervous
system (Raynaud, 1862). Evidence to support this theory comes from work by
Peacock (1959), who reported elevated catecholamine levels in wrist venous blood
taken from patients with Raynaud's disease. Excess sympathetic activity is also
implied from the fact that postural changes produce an exaggerated vasoconstrictor
response in patients with Raynaud's (Olsen et al., 1987), and sympathectomy,
surgical cutting of the sympathetic nerves, can often prevent attacks, although usually
it is only the toes which benefit from this treatment (Janoff et al., 1985).
There are, however, a number of studies which dispute the role of the sympathetic
nervous system in the pathogenesis of Raynaud's disease. Among them is work
35
carried out by Sir Thomas Lewis (1929) who demonstrated the nerves could not be
solely responsible for vasospastic attacks (see below). In contrast to the findings of
Peacock (1959), Kontos and Wasserman (1969) did not find an increase in plasma or
urinary catecholamine levels in primary Raynaud's patients. Perhaps the strongest
evidence against sympathetic vasoconstrictor overactivity comes from a study in
Raynaud's patients, where microelectrodes were used to record sympathetic nerve
activity in one hand, whilst the other was cooled by ice water immersion (Fagius &
Blumberg, 1985). The authors were unable to find an abnormal increase in
sympathetic outflow. Although sympathetic activity per se may not be increased in
Raynaud's, receptors on the vascular smooth muscle may be abnormally sensitive to
the neurotransmitters released from the sympathetic nerve terminals (see section
D. 1.3.).
Despite the conflicting results regarding the role of the sympathetic nervous system in
Raynaud's, the fact remains that emotional stress can induce vasospastic attacks in
some people, indicating that there is some neuronal basis for the initiation of an attack.
D.1.2. Local fault
In 1929, Lewis' studies indicated that the theory of sympathetic overactivity, first
proposed by Raynaud in the 1800's, could not be the full explanation for the cause of
the disease. He effectively denervated the hand using a local anaesthetic at the ulnar
nerve, and was still able to produce vasospastic attacks in Raynaud's patients (Lewis,
1929), a finding which has since been reproduced by Freedman et al. (1989). Lewis
concluded that the 'fault' in patients with Raynaud's lay in the digital arteries
themselves, which exhibit abnormal sensitivity to cold. Potential candidates for this
'local fault' are introduced in some of the sections below.
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D.1.3. Alpha-adrenoceptors
a-Adrenoceptors were originally subdivided on an anatomical basis: ai-adrenoceptors
were found postjunctionally, with (^-adrenoceptors located prejunctionally. The
postjunctional vascular ai-adrenoceptor was thought to be solely responsible for
vasoconstriction. However, it is now evident that, in addition to inhibiting further
release of noradrenaline from nerve terminals by a negative feedback mechanism, the
a2-adrenoceptor is also present postjunctionally, where it can mediate vasoconstriction
(Stevens & Moulds, 1981; McGrath, 1982; Flavahan et al., 1984). Among the many
different vessels studied, the human digital artery has been shown to possess
vasoconstrictor oq - and (^-adrenoceptors postjunctionally (Stevens & Moulds, 1986).
Flavahan and colleagues (1987) have demonstrated that a greater proportion of
vasoconstriction is mediated by 0(2-adrenoceptors as blood vessels become more
distal, a finding that has been confirmed by others (Hughes et al., 1987; Nielsen et al.,
1989).
Increased a2-adrenergic function has been implicated in the pathophysiology of
Raynaud's disease. In 1978, Janssens & Vanhoutte reported that cooling potentiated
contractions to noradrenaline in cutaneous veins from dogs, and suggested an
increased affinity of postjunctional a-adrenoceptors may have been responsible for
this effect (Janssens & Vanhoutte, 1978). Subsequent in vitro studies, using selective
agonists and antagonists of aj- and (^-adrenoceptors in canine (Flavahan et al., 1985;
Flavahan & Vanhoutte, 1986) and human veins (Bodelsson et al., 1990; Harker et al.,
1990), indicate that it is the a2-subtype which is augmented by cooling. Similar
findings have been reported from in vitro arterial studies (Ekenvall et al., 1988; Harker
et al., 1991). Interestingly, the results from one group suggest that the sensitivity of
both receptor subtypes is increased at 24°C in human skin arteries (Gomez et al.,
1991), but this potentiation was only seen when using low concentrations of
phenylephrine, an ai-adrenoceptor agonist, and clonidine, an (^-adrenoceptor
agonist. At higher doses, the contractile responses were reduced during cooling,
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which led Gomez and co-workers to conclude that cooling depresses the maximum
contractility of human skin arteries to a-adrenergic stimulation. The same group have
carried out studies in rabbit ear and femoral arteries (Garcia-Villalon et al., 1992), and
find that cooling inhibits the contraction to a-adrenoceptor agonists (through increased
availability of NO in the ear arteries, and depressed sensitivity of a-adrenoceptors in
the femoral artery). However, it has previously been demonstrated that 0C2-
adrenoceptors make little contribution to the contraction of rabbit ear arteries (Harker &
Vanhoutte, 1988) or deep, non-cutaneous vessels like the femoral artery (Vanhoutte &
Flavahan, 1986), which would explain the lack of a potentiating effect of cooling on
the responses to a-adrenergic agonists in these preparations.
Several clinical studies have investigated the effect of temperature on a-adrenergic
vasoconstriction, and the role of a-adrenoceptors in Raynaud's disease. Reflex
sympathetic vasoconstriction to body cooling has been demonstrated to be primarily
mediated by a2-adrenoceptors in healthy subjects (Coffman & Cohen, 1988).
Freedman and colleagues (1992) infused phenylephrine and clonidine into the brachial
artery of healthy male volunteers, and found cooling abolished the vasoconstriction to
phenylephrine, but potentiated that induced by clonidine, this effect being inhibited by
the a2-adrenoceptor antagonist, yohimbine. In similar studies, brachial artery
infusions of phenylephrine and clonidine produced a greater decrease of finger blood
flow in Raynaud's patients compared to controls, suggesting that the sensitivity and/or
number of a-adrenoceptors is increased in patients with Raynaud's disease (Freedman
et al., 1989; Coffman & Cohen, 1990). This is supported by studies showing platelets
from Raynaud's patients have an increased number of a2-adrenoceptors (Keenan &
Porter, 1983; Edward et al., 1987). In a recent study, Freedman and co-workers
(1995) assessed the effectiveness of prazosin and yohimbine in attenuating cold-
induced vasospastic attacks in Raynaud's patients, and found that aj-adrenoceptor
activation is not required for inducing vasospasm, which further supports the findings
outlined above.
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The sensitivity and/or density of peripheral vascular aj- and ot2-adrenoceptors have
been shown to be lower in women compared to men (Freedman et al., 1987), a
finding which does not correlate with the higher incidence of Raynaud's disease in
women, if the (^-adrenoceptor is to be considered as a primary pathophysiological
candidate. Although there is strong evidence to support a pathogenetic role for 0C2-
adrenoceptors in Raynaud's disease, it is possible that another factor(s) may be
simultaneously involved, with vasospastic attacks resulting from the combination of
oc2-adrenoceptors and other factor(s). An example of such a factor is an abnormality of
endothelium-dependent dilator function (see below), which would lead to a reduced
ability of the endothelium to oppose vasoconstriction mediated by oc-adrenoceptors.
D.1.4. 5-Hydroxytryptamine
5-hydroxytryptamine (5-HT, serotonin) receptors are present in the finger vascular bed
(Coffman & Cohen, 1988; Blauw et al., 1991). The 5-HT2 subtype is responsible for
mediating vasoconstriction and platelet aggregation. Cooling has been found to
enhance the contraction induced by 5-HT in canine cutaneous veins (Vanhoutte &
Shepherd, 1970), and patients with Raynaud's disease have an increased finger
vasoconstrictor response to 5-HT compared to controls (Coffman & Cohen, 1990).
Biondi and colleagues (1988) found increased levels of plasma 5-HT in Raynaud's
patients compared to controls, the highest being in those with the secondary form, but
other workers have failed to detect such an increase (Coffman & Cohen, 1994).
Ketanserin, a selective 5-HT2 antagonist with weak ai-adrenergic antagonistic actions,
relieves cold-induced vasoconstriction in Raynaud's patients, but does not alter the
frequency of occurrence of the vasoconstriction (Seibold, 1985). This suggests that
although 5-HT may be involved in the maintenance of digital artery vasospasm,
perhaps released on platelet activation, other factors are probably responsible for the
initiation of an attack.
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D.1.5. Platelets
Platelets are essential for haemostasis and are involved in the repair of damaged blood
vessels, through a process involving their adhesion, activation and aggregation, which
results in the formation of a haemostatic plug. When platelets are activated they release
a number of vasoactive and trophic factors, including 5-HT, thromboxane A2 (TXA2)
and platelet activating factor (PAF). An increased level of TXB2, the stable metabolite
of TXA2, and an increased sensitivity of platelets to ADP and collagen, has been
reported in patients with Raynaud's disease, although both effects are more marked in
patients with secondary Raynaud's phenomenon (Wilkinson et al., 1989). In contrast,
others have reported no increase in the activation of platelets in Raynaud's disease
(Seibold & Harris, 1985). It is difficult to determine whether raised TXA2 and
increased activity of platelets are causes, or merely effects of Raynaud's, because
platelets both release, and are in turn regulated, by eicosanoids. Aggregated platelets
have been shown to contract human digital artery strips (Moulds et al., 1984), and
platelet-induced contraction of canine arteries is potentiated by cooling (Lindbland et
al., 1984), indicating a potential involvement of platelets in cold-induced vasospasm.
However, it would appear from the results of Seibold & Harris (1985) and Wilkinson
et al. (1989) that platelets are unlikely to have a pathogenetic role in Raynaud's
disease. The fact that ticlopidine, a drug which inhibits platelet aggregation, had no
effect on the frequency or duration of vasospastic attacks in Raynaud's patients
provides further evidence against a primary involvement of platelets in this condition
(Destors et al., 1986). Platelets probably have a greater role in secondary Raynaud's
phenomenon, where endothelial damage promotes their adhesion and subsequent
aggregation.
D.1.6. Calcitonin gene-related peptide
Peptidergic nerves are known to innervate the skin microvasculature and appear to be
involved in cold vasodilatation. Vasodilatation occurs through a local axon reflex
mechanism, whereby stimulation of cold receptors on the terminals of cutaneous
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sensory neurons triggers the release of neurotransmitter peptides, which then act on
the adjacent cutaneous microvessels. Calcitonin gene-related peptide (CGRP) is a
potent vasodilator released from such nerves (O'Halloran & Bloom, 1991). By acting
on endothelial receptors linked to adenylate cyclase, CGRP increases cAMP levels,
which in turn stimulate the synthesis of NO, inducing relaxation in the vascular
smooth muscle through cGMP production (Marshall, 1992).
The digital skin of patients with Raynaud's disease has been shown to have a
deficiency in CGRP-containing neurons (Bunker et al., 1990; Terenghi et al, 1991),
but the ability of these nerves to mediate an axon reflex response to histamine is not
diminished in Raynaud's patients (Brain et al., 1990). Furthermore, the
responsiveness of the vasculature to CGRP does not appear to be reduced in
Raynaud's disease since Brain and co-workers (1990) found in forearm blood flow
studies, comparable vasodilator respsonses to exogenous CGRP in patients with
Raynaud's disease and in control subjects, whilst Shawket et al. (1989) demonstrated
a hypersensitivity to CGRP in Raynaud's patients, which perhaps reflects depressed
endogenous generation of CGRP These results suggest that the coupling mechanism
between cold-stimulation and the axon reflex response may be dysfunctional in these
patients. A fault in the CGRP cold-induced vasodilatory mechanism would reduce the
counterbalancing effect on vasoconstriction, and could therefore result in the
vasospasm found in Raynaud's disease.
D.1.7. Blood viscosity
Blood viscosity is determined by haematocrit, plasma viscosity and red cell
deformability. Several investigators have found increases in whole blood viscosity in
patients with Raynaud's disease (Tietjen et al., 1975; Goyle & Dormandy, 1976; Blunt
et al., 1980), but haematocrit and red cell deformability do not appear to be altered
(Rustin et al., 1985; Challenor et al., 1987). Plasma viscosity is raised in Raynaud's
patients, which correlates with elevated plasma levels of fibrinogen (Tietjen et al.,
41
1975). The contraceptive pill, which is associated with a higher incidence of
Raynaud's phenomenon (see below), increases blood viscosity through increasing
fibrinogen levels. Jarret (1976) found that fibrinogen levels decreased and symptoms
improved, when patients stopped taking the pill.
It should be noted that an increase in whole blood viscosity at low temperatures is a
physiological phenomenon, and patients with Raynaud's disease do not appear to have
any hyperviscosity during cooling. It is therefore unlikely that blood viscosity is of
pathogenetic importance in Raynaud's, but merely exacerbates the condition by further
reducing the blood flow through constricted arteries during vasospasm.
D.1.8. Sex hormones
Raynaud's disease is more prevalent in women, suggesting hormonal influences are
involved. Anecdotal evidence supports this: often a remission of symptoms is found
during pregnancy; vasospastic attacks are exacerbated at different times during the
menstrual cycle in some patients; the menopause is sometimes linked with the
development of Raynaud's or, alternatively, the disappearance of symptoms in women
whose Raynaud's disease began at puberty; and females taking the contraceptive pill
have been reported to have a higher incidence of Raynaud's disease.
Oestrogen is known to enhance the sensitivity of small arteries to noradrenaline and
adrenaline (Altura, 1975), by affecting the synthesis, uptake and release of
catecholamines in the neurovascular junction (Vanhoutte et al., 1981). Progesterone
has the opposite effect, inhibiting smooth muscle contraction by promoting the uptake
of calcium into the sarcoplasmic reticulum of smooth muscle cells (Carsten, 1979).
Receptor density is also changed by the sex hormones: in rabbit uterus oestrogen
increases the number of a-adrenoceptors, favouring vasoconstriction, whilst
progesterone decreases a-adrenoceptors and increases the number of p-adrenoceptors,
thus favouring vasodilatation (Roberts et al., 1977). Recent evidence supports an
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interaction between female sex hormones and the endothelium. In 1988, Williams et
al. reported that treatment of female spontaneously hypertensive rats (SHR) with 17(3-
oestradiol significantly enhanced endothelium-dependent relaxation. Later studies in
SHR found that pregnancy restored endothelium-dependent relaxation, compared to
the diminished responses in nonpregnant animals (Ahokas et al, 1991). Oestrogen has
been shown to potentiate endothelium-dependent and -independent relaxation in the
forearm vasculature of postmenopausal women (Gilligan et al., 1994). Sex hormones
appear to alter the expression of ET receptors: studies in human endometrial tissue
have shown changes in the ratio of ETa and ETb receptors occur during the menstrual
cycle (O'Reilly et al., 1992).
In addition to their indirect effects on vascular tone, sex hormones may also have a
direct effect: specific oestrogen- and progesterone-receptors have been identified on
animal (Nakao et al., 1981; Horwitz & Horwitz, 1982) and human vascular smooth
muscle cells (Campisi et al., 1987; Ingegno et al., 1988). These receptors have been
shown to mediate changes in the electrical properties, and contractility, of coronary
vascular smooth muscle cells (Harder & Coulson, 1979).
Thermal entrainment studies, where one hand is alternately warmed and cooled whilst
blood flow in the other hand is monitored, show the reactivity of peripheral blood
vessels is influenced by the menstrual cycle (Lafferty et al., 1985), with the maximum
entrainment occuring when oestrogen levels are at their highest. During the peri-
ovulatory period, normal woman displayed Raynaud's-like responses to thermal
entrainment, in that the rapid post-sympathetic vasodilatation was delayed or absent
(De Trafford et al., 1984). However, Bartelink et al. (1994) examined the effects of
single oral doses of oestrogen and progesterone on finger skin circulation, and found
the female sex hormones had minor effects on finger blood flow, in both female
controls and Raynaud's patients.
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It would certainly appear that sex hormones do have a role in Raynaud's disease, but
another factor must be responsible for causing the condition, since not all females
suffer from vasospasm, and some men do, albeit in a smaller proportion. Lafferty et
al. (1985) suggest that the women who do suffer from Raynaud's may have an
exaggerated vascular response to the fluctuations in female sex hormones and, indeed,
the fluctuations themselves may be abnormal. A plausible candidate(s) for this
exaggerated vascular response may be one of the other factors outlined in this section.
D.1.9. Hereditary or familial factor
There is no conclusive evidence that there is a hereditary factor in primary Raynaud's
disease since few studies have addressed this issue. Greenwood (1976) reported a
case study of three generations of a family, in which the inheritance of Raynaud's
disease was compatible with an autosomal dominant transmission. It should be
remembered that familial occurences can be due to the Raynaud's phenomenon being
secondary to another disorder, such as connective tissue disease (see later) which can
be hereditary, or indeed, the Raynaud's may be secondary to different etiologies in the
same family.
D.1.10. The vascular endothelium
Endothelial involvement in Raynaud's disease was first implicated after Zamora and
colleagues (1990) performed cold provocation studies in patients with Raynaud's, and
found an exaggerated increase in ET-1 concentrations in venous blood draining the
cold-challenged arm when compared to the control arm, and with responses from
healthy control subjects. Basal ET-1 levels were also elevated in Raynaud's patients, a
finding which has been supported by others (Biondi et al., 1991). In addition, a rapid
increase in plasma ET-1 during the cold-pressor test in healthy subjects has been
reported (Fyhrquist et al., 1990). These results are consistent with a role for ET-1 in
mediating the prolonged cold-induced vasospasm of Raynaud's disease. The rapid
increase of ET-1, within minutes during cold exposure (Fyhrquist et al., 1990),
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implies ET is released from a pre-formed pool. Evidence to support the presence of
such ET-secretory stores is limited at present, though their existence has been reported
in rabbit (Milner et al., 1990) and bovine (Harrison et al., 1993) aortic endothelial
cells. Measurements of big ET-l/C-terminal fragment concentrations in plasma would
help to confirm the source of ET-1 produced during cooling; an increase in big ET-
l/C-terminal fragment levels would imply de novo synthesis of ET-1, making ET
release from secretory granules seem unlikely. Such studies have yet to be carried out.
Several groups did not find such an increase in ET-1 concentrations during cold
exposure, thus forming some controversy as to whether ET is primarily involved in
the pathogenesis of Raynaud's disease. Bottomley & Goodfield (1994) found no
significant difference in basal or cold-challenged plasma ET-1 levels in Raynaud's
patients when compared to controls. Smits and colleagues (1991), who also found
basal ET-1 levels to be the same in control versus Raynaud's subjects, argue that
Zamora et al.'s (1990) findings of increased venous ET-1 concentrations in blood
draining the cold-challenged arm, can be explained by a decrease in forearm blood
flow, resulting in decreased dilution, rather than an actual rise in ET-1 production.
However, Zamora and co-workers (1990) accounted for this by demonstrating
Raynaud's subjects consistently had a higher rise in ET-1 concentrations compared to
controls, despite similar falls in pulsatility in both groups. Another study which
disputes the involvement of ET in mediating cold-induced vasoconstriction, found no
change in circulating ET-1 levels in healthy subjects, during a 2-hour stay in a room
cooled to 10°C (Hassi et al., 1991). The authors suggest that to see a rise in ET-1, the
cold stimulus might have to be more intense than that experienced with whole-body
cold exposure; cold-induced release of ET-1 is perhaps mediated through nociceptors,
which are stimulated during cold-pressor tests (Klement & Arndt, 1992). An important
finding of this study, was that circulating atrial natriuretic peptide (ANP) was
increased during cold-exposure (Hassi et al., 1991). ET-1 is known to stimulate the
release of ANP in vitro and in vivo (Stasch et al., 1989; Ohman et al., 1990). Cold-
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induced release of ET-1 may be responsible for the rise in ANP, with the changes in
ET-1 being too low to detect because, as explained in a previous section, measuring
plasma levels of ET is not a good predictor of its pathogenetic role in disease, since ET
is preferentially secreted abluminally (Wagner et al., 1992), and is therefore unlikely to
be acting as a circulating hormone, with raised levels merely reflecting over-spill from
its release in the vasculature. Cimminiello et al. (1991) dismiss their findings of higher
ET baseline levels in Raynaud's patients as a result of endothelial damage, stating the
concentrations found are too low to elicit vasoconstriction. However, the concentration
of ET at the endothelium-smooth muscle interface is probably a lot higher than plasma
levels of ET (low picomolar range in healthy humans; Davenport et al., 1990), which
are indeed lower than concentrations required to elicit contraction of vascular smooth
muscle in vitro and in vivo (Yanagisawa et al., 1988). Furthermore, it should be
remembered that subpressor doses of ET can potentiate vasoconstriction to other
factors, such as noradrenaline and 5-HT (Yang et al., 1990).
Further support for the involvement of ET in Raynaud's disease comes from
experiments showing that ET-1 causes vasoconstriction of isolated perfused simian
digital arteries (Haniuda et al., 1991). Since the simian digital artery forms branches to
the skin, the authors propose that its vascular reactivity is an important determinant of
skin circulation. When ET-1 was injected intradermally into rabbit (Brain et al., 1988)
and human skin (Hughes et al., 1989), it caused vasconstriction, as observed from the
pronounced blanching at the site of injection. Autoradiographic experiments have
demonstrated the presence of both ETa and ETb receptors in the microvessels of
human skin (Knock et al., 1993), and in vivo studies, using selective ET-receptor
antagonists, have revealed that it is the ETa receptor whicn is primarily involved in the
regulation of vascular tone in human skin microvasculature (Wenzel et al., 1994).
Interestingly, the ET-receptor density was found not to differ between patients with
Raynaud's disease and controls, but was increased in patients with Raynaud's
secondary to systemic sclerosis (Knock et al., 1993). Given the reports of elevated
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plasma levels of ET in Raynaud's disease, one could reasonably have predicted to find
receptor down-regulation. Since the ET-receptors are not reduced in number, Knock
and colleagues (1993) suggest that increased concentrations of plasma ET will result in
enhanced contraction, and may therefore contribute to the vasospasm found in
Raynaud's disease.
More direct evidence of a role for the endothelium in cold-induced vasoconstriction is
provided by studies of cutaneous blood vessels, using the rabbit ear artery (Monge et
al., 1991). Here, the responses to ET-1 are temperature dependent, and under
physiological conditions the vasoconstriction to ET-1 is attenuated by an increase in
NO production during cooling. If blood vessels in patients with Raynaud's disease
lack this NO-mediated inhibitory function of the endothelium during cooling, increased
production and exaggerated vasoconstriction to ET-1 might lead to prolonged
vasospasm. From the above observations, it appears that overproduction of ET-1,
reduced production of NO, or a combination of these effects, might account for the
vasospasm seen in Raynaud's disease.
As already mentioned, there is a higher incidence of migraine, variant angina and
ocular vasospasm in patients with Raynaud's disease, suggesting that there may be a
common vascular defect in these conditions (see above). Thus, the experimental
evidence implicating the involvement of endothelial dysfunction in these related
vasospastic conditions (e.g. Nakamura et al., 1984; Toyo-oka et al., 1991; Farkkila et
al., 1992), supports its role in the pathogenesis of Raynaud's disease.
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E. Secondary Causes of Raynaud's Phenomenon
When Raynaud's disease is known to be caused by an underlying disorder, it is
referred to as Raynaud's phenomenon (Allen & Brown, 1932). There are numerous
disorders associated with secondary Raynaud's phenomenon (Table 1.2), the most
common of which are discussed below.
Table 1.2. Some secondary causes of Raynaud's phenomenon
Connective tissue diseases
Systemic sclerosis, systemic lupus erythematosus, CREST syndrome, mixed
connective tissue disease, rheumatoid arthritis, Sjogren's syndrome,
dermatomyositis, polymyositis
Drugs or chemicals
^-adrenoceptor antagonists, ergotamines, bleomycin, cisplatin, vinblastine,
oral contraceptives, vinyl chloride
Occupational
Vibration white finger or hand-arm vibration syndrome
Occlusive arterial disorders
Thrombosis, atherosclerosis, carpal tunnel syndrome, thoracic outlet
syndrome
Blood abnormalities
Cryoglobulinaemia, cold agglutinins, polycythaemia
Miscellaneous
Hypothyroidism, tumours, diabetes mellitus, chronic renal failure
E.l. Connective tissue diseases
The most frequent conditions underlying the cause of Raynaud's phenomenon are
those with immunological abnormalities, in particular the connective tissue diseases,
the commonest of which is systemic sclerosis, or scleroderma. Ninety percent of
patients with scleroderma have vasospastic attacks typical of Raynaud's phenomenon
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(Tuffaneilli & Winkelmann, 1961), which are usually associated with CREST
syndrome (subcutaneous calcification, Raynaud's phenomenon, esophageal
dysfunction, sclerodermatous skin thickening, and telangiectasia). Other connective
tissue disorders asociated with Raynaud's phenomenon include systemic lupus
erythematosus, rheumatoid arthritis and Sjogren's syndrome. Unlike primary
Raynaud's disease, where there is no conclusive evidence that structural changes exist,
the digital arteries in patients with connective tissue disorders are prone to intimal
thickening and medial hypertrophy, sometimes resulting in occlusion of one or more
digital arteries (Scott et al., 1961; Laws et al, 1963; Norton & Nardo, 1970).
E.2. Drugs
The P-adrenoceptor antagonists, commonly used in hypertension, are the most
common group of drugs known to induce Raynaud's phenomenon (Marshall et al.,
1976), possibly through an enhanced sensitivity of a-adenoceptors in peripheral
vessels (White & Udwadia, 1975; Cohen & Coffman, 1980), or a reflex peripheral
vasoconstriction induced by the decrease in cardiac output following P-adrenoceptor
blockade. Drugs used in chemotherapy, such as bleomycin, cisplatin, and vinblastine,
can induce secondary Raynaud's phenomenon, perhaps via induced hyperreactivity of
the sympathetic nervous system (Hansen et al., 1990). Ergotamine, which is effective
against migraine headaches, causes vasospasm by acting on a-adenoceptors, although
the attacks are likely to be more prolonged than those associated with Raynaud's
disease, and can lead to digital gangrene (Cameron & French, 1960).
E.3. Vibration white finger
Raynaud's phenomenon resulting from work involving the repeated use of vibrating
instruments and tools, such as pneumatic drills, is termed vibration white finger
(VWF) (or sometimes hand-arm vibration syndrome, HAVS). VWF was first
described in Italian miners by Loriga (1911). Since then, a large proportion of workers
using vibratory tools have been reported to develop vasospastic symptoms
49
characteristic of Raynaud's phenomenon (Cherniack, 1990). Lloyd Davies and
colleagues believed that vibration only induces Raynaud's phenomenon when
experienced in conjunction with cold exposure; body cooling and cold pressor tests did
not produce symptoms of Raynaud's phenomenon in workers using vibratory tools in
hot climates, such as Singapore (Lloyd Davies et al., 1957). This theory is supported
by Hellstrom and Anderson (1972), who report the highest incidence of VWF occurs
in outdoor workers. Prolonged use of vibratory tools has been associated with
peripheral neuropathy and neuromuscular dysfunction, particularly in the dominant
hand (Marshall et al., 1954). The pathogenesis of VWF is unknown, though reflex
sympathetic hyperactivity and release of local hormones have been suggested (Olson et
al., 1975; Gemne, 1982).
F. Treatment
F.l. General measures
For the majority of patients with Raynaud's disease, where there is no obvious
underlying disorder, preventative measures, such as avoiding the cold and other
provocative stimuli, are more important than drug therapy. Although sufferers are
advised to keep their whole body warm, electrically heated gloves and socks are found
by many to be particularly helpful in preventing vasospastic attacks. Avoidance of
tobacco smoking is also advised because it constricts digital blood vessels through
sympathetic stimulation and reflexly via chemoreceptor stimulation. Smokers with
Raynaud's phenomenon have been reported to have a greater smoking-induced
decrease in digital blood flow, compared to non-smoking Raynaud's patients
(Goodfield et al., 1990). Interestingly, a recent study has found plasma ET-1 levels
are increased within 10 minutes of cigarette smoking in healthy male subjects, together
with a rise in systolic blood pressure (Flaak et al., 1994), whilst a study by Bodis &
Haregewoin (1994) shows salivary NO production is reduced in smokers. Thus,
smoking-induced vasoconstriction may be mediated through a change in ET and NO
production, in addition to stimulation of the sympathetic nervous system.
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F.2. Drug therapy
Pharmacological intervention is usually reserved for Raynaud's patients who find their
attacks are severe or are an intolerable inconvenience to their daily lives. The
assessment of treatment in Raynaud's is made difficult due to the strong influence of
factors such as the possibility of an underlying disorder, weather conditions,
psychological stimuli, hormonal status in females, and smoking status. Although
measures can be taken to standardise conditions within an individual study, this is
difficult to ensure for trials carried out in different centres, and is a possible reason for
the reported differences in effectiveness of therapies between individual research
groups. A further confounding factor is the difficulty in provoking reproducible
vasospastic attacks which correlate with those experienced by patients outside the
laboratory. The effectiveness of the treatment on these vasospastic attacks then has to
be objectively assessed by choosing a suitable means of measurement, which may not
always be in agreement with the subjective report given by the patients themselves.
Some of the common pharmacological treatments presently used in Raynaud's disease
are briefly reviewed below. Potential therapeutic approaches for the future are also
addressed.
F.2.1. Calcium channel antagonists
The calcium-channel antagonists are currently the first line of drug treatment for
patients with Raynaud's disease, but are only effective in approximately 50% of
patients. Nifedipine in the slow-release form is the most commonly used, owing to its
preferential peripheral (over cardiac) vasodilator action (Smith & Rodeheffer, 1985;
Finch et al., 1988). Prophylactic sublingual nifedipine is an effective alternative in
patients with predictable attacks or who are intolerant of long-term nifedipine treatment
(Wollersheim et al., 1987). Although the calcium-channel blockers' primary mode of
action is to reduce the amount of calcium entering the smooth muscle cell, and thereby
decrease contractility, they have been reported to have additional effects:
a-adrenoceptor antagonist activity, antiaggregatory action on platelets, and a beneficial
effect on red blood cell deformability (Dale et al., 1983; Timmermans et al., 1983;
Malamet et al., 1985). Unfortunately, the side effects from calcium-channel blockers
are considerable, including headaches and dizziness, flushing, palpitations and fluid
retention, and may prevent their use in some patients.
F.2.2. 5-HT2 receptor antagonists
5-HT receptor antagonists prevent the vasoconstriction and platelet aggregation
induced by 5-HT. Ketanserin has been the most widely investigated selective 5-HT2
antagonist in Raynaud's disease, but naftidrofuryl, another 5-HT2 blocker has also
been examined (Haavik Nilsen, 1979; Gaylarde et al., 1980). Ketanserin has been
found to be beneficial in Raynaud's disease (Stranden et al., 1982; Meloni et al., 1987;
Brouwer et al., 1987; 1990), although at doses used clinically it may also be blocking
aj-adrenoceptors and histamine H, receptors (Trenk et al., 1983). However, Coffman
and colleagues (1989) report in their large, international randomized trial, that the
magnitude of the improvements by ketanserin in Raynaud's patients were small, and
indeed, Longstaff et al. (1985) found the drug did not have any beneficial effects in
their study. Seibold and co-workers have shown ketanserin reduces the severity but
not the frequency of vasospastic attacks in patients with Raynaud's disease,
suggesting 5-HT is involved in the maintenance of vasospasm, but other factors are
important in the initiation of an attack (Seibold & Jageneau, 1984; Seibold &
Terregino, 1986). The opposite was found in the trial by Coffman and colleagues
(1989); the frequency of attacks was reduced, with no difference to the severity or
duration. However, in thermometry studies carried out by Arosio et al. (1991), in
addition to an increase in skin temperature, a decrease in the duration and the number
of vasospastic attacks in patients was found, with no effect on their severity. Thus, the
exact role of 5-HT in Raynaud's disease remains obscure. Side effects of ketanserin,
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though less common than with nifedipine, include dizziness, sedation, dry mouth or
eyes, fluid retention and anxiety.
F.2.3. Prostaglandins
The prostaglandins, PGE2 and PGI2 (prostacyclin), have powerful vasodilatory and
antiaggregatory effects. Prostacyclin and its stable analogue, iloprost, have proved
successful in reducing the frequency and duration of vasospastic attacks in Raynaud's
patients (Belch et al., 1983; Yardumian et al., 1988), and have been found to be
effective in patients with secondary Raynaud's phenomenon who failed to respond to
other forms of treatment (Watson & Belcher, 1991). Results from a study using PGE2
are less convincing (Mohrland et al., 1985). The mechanism of the prolonged
improvement (several months) found in most studies after brief prostacyclin infusion
is not understood; the vasodilatory and antiaggregatory effect declines shortly after
treatment (Dowd et al., 1982). Prostaglandin therapy can cause side effects such as
headaches, flushing, diarrhoea, and postural hypotension, but a more serious criticism
of this treatment has been raised by Kovacs and colleagues (1991), who report that
patients receiving such therapy have a potential risk of thromboembolism. However,
the methodology used by Kovacs et al. to measure coagulability has been questioned
(Belch et al., 1991). Until recently, this vasodilatory form of treatment had the
disadvantage that it could only be given by intravenous infusion, as prostacyclin is
easily destroyed in the gut. Although objective assessment of the effectiveness of oral
iloprost failed to reach significance, a recent study has shown that Raynaud's patients
found an subjective improvement in their symptoms (Belch et al., 1995) which may
make this therapy more readily available in the future, although at present it is usually
confined to patients with severe secondary Raynaud's phenomenon due to the high
incidence of side effects mentioned above. A transdermal PGE2 preparation has also
been developed, although it has since been withdrawn, despite promising effects in
clinical trials (Belch et al., 1985; Cooke et al., 1985; Dunger et al., 1985).
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F.2.4. Dietary fish oil & evening primrose oil
An alternative approach to prostacyclin therapy is to administer essential fatty acids,
precursors of prostaglandins, in the form of dietary fish oil (DiGiacomo et al., 1989)
and evening primrose oil (Belch et al., 1985), in order to stimulate the synthesis of
endogenous prostaglandins. In addition to the resulting vasodilatation and inhibition of
platelet aggregation, the fatty acids are thought to increase red blood cell deformability
after becoming incorporated into their membrane (Green et al., 1990). Interestingly,
fish oil supplements were found to improve digital artery flow in primary, but not
secondary Raynaud's patients (DiGiacomo et al., 1989), although there is currently no
evidence to confirm these early findings.
F.2.5. ACE inhibitors
Inhibitors of the angiotensin converting enzyme (ACE)/kininase II inhibit the
production of the vasoconstrictor, ANG II (All) from ANG I, and the breakdown of
the vasodilator, bradykinin. Their use in Raynaud's disease remains controversial.
Uncontrolled studies, using captopril without a placebo, demonstated beneficial effects
(Trubestein et al., 1984; Tosi et al., 1987) but, whilst the results of several controlled
studies looked promising, they were inconclusive because statistical significance was
not achieved (Miyazaki et al., 1982; Janini et al., 1988). Rustin and colleagues (1987)
found no improvement of symptoms with captopril in patients with Raynaud's
disease, and similar findings have been obtained with enalapril (Challenor et al.,
1991). Captopril may even induce digital vasospasm in patients being treated for
hypertension (Havalka et al., 1982), and in the study of Challenor and co-workers
(1991), a substantial number of patients experienced more attacks during enalapril
treatment.
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F.2.6. Miscellaneous drug treatments
F.2.6.1. ai-adrenoceptor antagonists
The use of selective ai-adrenergic antagonists, such as prazosin (Wollersheim et al.,
1986) and thymoxamine (Grigg et al., 1989), can reduce vasospasm in some patients
with Raynaud's disease but are associated with considerable side effects, including
headaches, dizziness and palpitations - especially during exercise - though these effects
are usually less severe with thymoxamine (Aylward et al., 1982). Although it is the
(^-adrenoceptors that have been implicated in the pathogenesis of Raynaud's disease
(see above), selective a [-adrenoceptor antagonists are preferable to nonspecific
a-adrenoceptor blockers like phentolamine, since vasodilatation mediated by
endothelial (^-adrenoceptors is not prevented, and the amount of noradrenaline
released from nerve terminals is still regulated by the pre-synaptic negative-feedback
(X2-adrenoceptor.
F.2.6.2. Thromboxane synthetase inhibitors
Antiaggregatory drugs, such as dazoxiben, act by inhibiting thromboxane synthetase
to prevent the production of TXA2, a potent platelet aggregant and vasoconstrictor. In
addition they increase prostacyclin formation by diverting the metabolism of PGH2
exclusively down the prostacyclin synthetase pathway. Their vasodilatory action
therefore prompted several investigators to study their effectiveness in Raynaud's
disease (Jones & Hawkey, 1983; Coffman & Rasmussen, 1984; Luderer et al., 1984).
The results of these studies were disappointing; only small reductions in the frequency
of attacks were observed, suggesting platelets are probably not playing a
pathophysiological role in primary Raynaud's disease (see above).
F.2.6.3. Nitrovasodilators
The effects of topical glyceryl trinitrate (GTN) in Raynaud's disease are conflicting.
Some trials have shown improvement (Nahir et al., 1986), whilst others have not,
despite subjective efficacy (Sovijarvi et al., 1984; Teh et al., 1995). Headaches and
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dizziness, which are common complaints, are a major deterrent for its use. GTN has a
greater vasodilator action on veins than on arteries; because the vasospasm in
Raynaud's disease affects primarily the arterial circulation, higher doses of GTN are
required to induce arterial vasodilatation, thus increasing the likelihood and severity of
headaches.
F.2.6.4. Fibrinolytics
Patients with primary and secondary Raynaud's phenomenon have been shown to
have a decreased blood fibrinolytic activity, increased blood viscosity and increased
plasma fibrinogen levels (Jarrett et al., 1978). The fibrinolytic drug stanozolol, an
anabolic steroid, has been examined in Raynaud's patients. In one study, 80% of
patients reported a reduction in the frequency, severity and duration of their
vasospastic attacks (Jarrett et al., 1978). Jayson and colleagues (1991), however,
failed to show any beneficial effects with stanozolol. Given that anabolic steroids can
cause amenorrhoea and hirsutism, in addition to other side effects including oedema,
acne, and potential liver damage, it is not wise to use these drugs in Raynaud's
patients, the majority of whom are female.
F.2.7. Behavioural treatment
Behavioural treatment in Raynaud's disease aims to give patients self-control of their
peripheral blood flow. Temperature biofeedback, conditioning or relaxation techniques
(autogenic training) are the commonest behavioral approaches used (Freedman, 1989).
Although positive results have been shown by some investigators (Freedman et al.,
1981; Jobe et al., 1982; Yocum et al., 1985), behavioral treatments require a lot of
time, effort and motovation from the patient and their physician, and few studies have
examined the long term success of this form of therapy.
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F.2.8. Sympathectomy
Cervical sympathectomy has not been found to prevent Raynaud's disease affecting
the hands; any reported improvements often disappear shortly after the operation, with
vasospastic attacks recurring within 6 months to 2 years (Johnston et al., 1965). In
Raynaud's disease which affects the toes, however, lumbar sympathectomy has
proved more successful in preventing vasospasm, and the results are often permanent
(Janoff et al., 1985).
F.2.9. Plasmapheresis
Plasmapheresis, or plasma exchange, is an expensive procedure which has been
shown to reduce blood viscosity (Talpos et al., 1978), and is reserved for patients
with severe Raynaud's phenomenon with digital ulcers, who are unresponsive to other
forms of treatment.
F.2.10. Future developments
It has been shown that the digital skin of patients with Raynaud's disease has a
deficiency in calcitonin gene-related peptide (CGRP)-containing neurons (see above).
The use of CGRP in the treatment of Raynaud's disease looks promising: in one
study, intravenous infusion of CGRP into Raynaud's patients increased hand-skin
blood flow throughout the infusion period, in contrast to prostacyclin, and its effects
persisted for 3 days after the infusion (Shawket et al., 1991). Similarly, Bunker and
colleagues (1993) found intravenous CGRP to be an effective peripheral cutaneous
vasodilator in patients with severe Raynaud's phenomenon. However, because
intravenous CGRP treatment can only be administered in hospital, it is likely to be
reserved for those patients suffering from severe Raynaud's phenomenon. The
development of non-peptidergic CGRP agonists would enable wider use of this form
of treatment.
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Flavonoids and ginkgolides extracted from the leaves of the Ginkgo biloba tree have a
potential role in the treatment of Raynaud's disease. Among its known effects, ginkgo
extract has been shown to cause an increase in blood flow and a decrease in blood
viscosity (Kleijnen & Knipschild, 1992). This may be due to its antagonistic effects on
platelet activating factor (PAF) or its ability to act as a superoxide anion scavenger,
thereby increasing the half-life of NO (Robak & Gryglewski, 1988).
Whilst the therapies described above can be useful in some patients with Raynaud's,
none are effective in all cases. Clearly there is a need to develop specific and effective
treatments for Raynaud's disease, but until the exact cause of the disorder is identified,
therapy has to remain on a 'trial and error' basis. A clearer understanding of the
mechanisms underlying vasospasm may also indicate new directions for the treatment
of migraine, variant angina and ocular vasospasm, three vasospastic conditions with
which Raynaud's disease is associated.
G. Aims
The object of this thesis was to examine the role of the vascular endothelium in the
development of cold-induced vasoconstriction, and in the pathophysiology of
vasospasm in Raynaud's disease. From a review of the literature at the outset of this
thesis it was hypothesised that, firstly, in healthy subjects during cold exposure,
vasoconstriction to ET is opposed by increased NO production, the balance favouring
vasoconstriction but not of sufficient severity or duration to cause vasospasm.
Secondly, the 'local fault' in Raynaud's disease is within the vascular endothelium,
and is associated with an imbalance between the production of ET and NO, favouring
prolonged vasospasm, probably through a mechanism involving impaired NO
synthesis.
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The specific aims arising from the above hypotheses were:
1. To investigate the effect of cooling on the contractile response to ET-1 in
resistance arteries obtained from rat and human tissue.
2. To determine whether cooling exerts a general effect on the contractile
response of the vascular smooth muscle by studying its effects on the ai-
adrenoceptor agonist, phenylephrine, and the direct activator of smooth
muscle, potassium chloride.
3. To assess the contribution of the vascular endothelium to any cold-induced
effects on the above vasoconstrictor substances by examining the effects of
endothelial removal, inhibitors of the NO and PGI2 pathways, and of ET-
receptor antagonists.
4. To investigate the effect of cooling on vasorelaxation to the endothelium-
dependent dilator, acetylcholine (ACh), and the endothelium-independent
dilator, sodium nitroprusside (SNP), in resistance arteries obtained from rat
and human tissue.
5. To investigate potential mediators of cold-induced vasoconstriction in vivo
using the autoperfused hindlimb of the anaesthetised rat.
6. To compare the responses to ET-1, ACh and SNP in resistance arteries
obtained from subcutaneous fat biopsies from patients with Raynaud's disease
and healthy control subjects, in order to determine the potential contribution of





2.1. Small vessel arteriograph (perfusion myograph)
2.1.1. Introduction
Prior to the 1970's, experimental work on isolated vessels had been mostly confined
to large arteries, the aorta in particular. However, it was recognised that most of
peripheral vascular resistance lay in the smaller arterial vessels, the so-called
'resistance' arteries, which are chiefly responsible for regulating blood flow and
capillary pressure (Furness & Marshall, 1974). In 1976 Mulvany and Halpern
published a study of resistance arteries using the then new technique of wire
myography (Mulvany & Halpern, 1976), first proposed by Bevan & Osher (1972).
Essentially, the wire myograph involves mounting the microvessel as a ring
preparation by passing two fine wires through the lumen. Wall tension is then
measured by recording the isometric force exerted on the wires. Since its introduction,
the wire myograph has been modified and improved to produce a more physiological
method of studying microvessels. These modifications have essentially allowed a
pressure to be applied across the vessel walls (Duling et al., 1981; Sipkema &
Westerhof, 1989; Halpern & Kelley, 1991; Hoogerwerf et al., 1992). The small
vessel arteriograph, or perfusion myograph, used in the experimental procedures
during this thesis was the version developed by William Halpern and colleagues
(Halpern & Kelley, 1991), and manufactured by Living Systems Instrumentation Inc.,
Burlington, Vermont, USA.
There are several advantages in using the perfusion myograph rather than the wire
myograph; these allow the vessels under study to be closer to physiological
conditions:
• the axial length can be adjusted to compensate for retraction of arteries after
dissection (but the set length can only approximate that found in vivo)
• a transmural pressure exists across the vessel wall
• because the vessel is pressurised, it assumes a more normal, cylindrical
shape than in the wire myograph, where it is pulled out flat
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• the endothelium is untouched along the area under study, whereas wires
impinge, and cause local damage to the endothelium in the wire myograph
• the diameter is allowed to change when the vessel contracts and relaxes
• drugs can be independently administered both intra- and extra-lumenally
Buus and co-workers (1994) have demonstrated significant differences in the
responsiveness of small arteries between the wire and pressure myograph; the
sensitivity to a-adrenoceptor agonists was greater in arteries mounted in the pressure
myograph. The authors suggest the responses found in the pressure myograph may be
of greater relevance to the situation in vivo, compared to those found with wire
myography.
2.1.2. Isolation of microvessels
2.1.2.1. Rat mesenteric vessels
Male Wistar rats were obtained from in-house stock bred at the Biomedical Research
Facility (Western General Hospital, Edinburgh) and maintained on standard chow and
tap water ad libitum. The animals (11-16 weeks of age) were killed by cervical
dislocation and a ventral midline incision was made. Mesenteric vascular beds were
removed and pinned out in a silicone-coated (Sylgard, Dow-Corning, U.K.)
dissecting dish containing physiological salt solution (PSS) (mM: 118 NaCl, 4.7 KC1,
2.5 CaCl2, 1.2 MgS04, 1.2 KH2P04, 25.0 NaHC03, 0.026 EDTA, and
5.5 glucose) at room temperature (22 - 24°C).
For resistance arteries of ~200-300jlm in diameter, second and third order vessels, i.e
those appearing after the 2nd and 3rd branch of the superior mesenteric artery (Figure
2.1), were excised under a dissection microscope (Zeiss, U.K.) using No.5
watchmaker forceps and fine ocular scissors (Altomed Ltd, Tyne & Wear, U.K.).
Care was taken during the dissection not to touch the section of vessel to be studied.
To avoid touching the vessel, surrounding fat was gently pulled away from it to
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Figure 2.1.Photograph of an excised rat mesenteric bed pinned out on a silicone-
coated dissecting dish, showing the location of 1st (1), 2nd (2) and 3rd (3) order
mesenteric arteries. G = gut wall (x3 magnification).
expose the thin membrane running between the fat and the artery. This membrane was
cut, thus isolating the artery from the fat cells. The artery was then excised, with a
diagonal cut being made to the proximal end. It was important to be able to
differentiate the two ends of the artery in order to mount it in the correct orientation
(proximal -> distal) in the myograph, i.e. any flow introduced through the lumen
would have been in the same direction as that of blood in vivo.
2.1.2.2. Human vessels: tissue from surgery
The use of human tissue in the following studies was approved by the Lothian
Research Ethics Committee. Subcutaneous fat biopsies obtained from 15 patients (age
range 18-77; 11 males, 4 females; Table 2.1) undergoing elective gastro-intestinal
surgery at the Western General Hospital, were placed directly into PSS. Quite often,
due to the time-course, samples were kept in a refrigerator, at 4°C, overnight before
beginning the dissection procedure the following day. This does not appear to have
any adverse effects on the vessels (Laing et al., 1995). Overnight storage of vessels
may allow any depressant effects of the general anaesthetic to wear off, as volatile
anaesthetics have been shown to inhibit endothelium-dependent dilatation (Muldoon et
al., 1988; Johns, 1989; Stone & Johns, 1989); it was therefore important to
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randomise the order of experiments so that the anaesthetic did not influence one
particular group over another. Small arteries (~300|im) were dissected out from the
biopsy in a similar way to that described for rat mesenteric arteries. Unless a branch
point existed in the vasculature, it was hard to identify the direction the artery was
orientated. This meant some vessels were probably mounted in the opposite direction
from that in vivo. The danger of mounting vessels in such a way is that the
endothelium is at risk of damage or removal. This did not pose a serious problem
though, because the only vessels which were exposed to any substantial amount of
flow through their lumen, were those which were to have their endothelium removed
intentionally by air (see later).
TABLE 2.1. Patient details for vessels studied at 37°C and 24°C
37°C 24°C
Age (years) 58 ±6 57 ± 10
Sex ratio (M:F) 6 : 2 5 : 2
Operation performed:
Hemicolectomy 3 1
Inguinal hernia repair 3 2




Hartman's operation - 1
Values are mean ±SEMfor n = 8 at 37°C and n= 7 at 24°C.
2.1.2.3. Human vessels: tissue from gluteal fat biopsies
Thirty-nine volunteer control subjects and Raynaud's patients were recruited in this
study (controls: 29-64 years; 14 females and 4 males. Raynaud's patients: 28-62
years; 18 females and 3 males) (see Table 2.2). Patients with primary Raynaud's
disease were classified according to the criteria of Allen & Brown (1932): (i) colour
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changes occurring bilaterally in the hands evoked by cold or emotional stimuli; (ii)
absence of gangrene; (iii) absence of any known causative disease; and (iv) history of
symptoms for a minimum of two years. The mean duration of the Raynaud's disease
was 18 ± 3 years. One patient had Raynaud's phenomenon secondary to Sjogren's
syndrome. All subjects had an alcohol intake <14 and <21 units/week, for females and
males respectively, and were normotensive (systolic blood pressure <140 mmHg;
diastolic blood pressure <90 mmHg). Three control subjects, and one Raynaud's
patient were smokers.
The protocol of this study was approved by the Lothian Research Ethics Committee,
and written, witnessed, informed consent was obtained from each subject. All subjects
abstained from aspirin-containing drugs for one week, and from caffeine-containing
drinks or alcohol for 12 hours before the biopsy was taken. A 50ml blood sample was
taken from each subject for immunological screening and for the measurement of
haemoglobin, erythrocyte sedimentation rate, urea and electrolytes, glucose and
creatinine.
TABLE 2.2. Subject and patient details for vessels studied at 37°C and 24°C
Control subjects Raynaud's patients
37°C 24°C 37°C 24°C
Age (years) 42 ±4 37 ±3 47 + 2 * 45 ±3
Sex ratio (M:F) 1 :7 2 : 6 2 : 10 1 : 9
Values are mean ± SEM. *P<0.05 compared to control group at 24°C (unpaired
t-test). Note: the details refer only to the volunteers whose biopsies yielded arteries
which were used in the study (see below).
Skin biopsies, approximately 2 cm long, 0.75 cm wide and 0.75 cm deep, were taken
from the gluteal region under local anaesthetic (1% lignocaine, Astra Pharmaceuticals
Ltd., U.K.) (Aalkjaer et al., 1987) by Dr Charles J. Ferro at the Clinical
Pharmacology Unit and Research Centre, Western General Hospital, and were placed
directly into PSS. Small arteries (~300p.m) were dissected out from the biopsy as
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described above. From the 39 biopsies taken, a total of 34 yielded arteries, thus
making an 87% success rate of obtaining arteries from the biopsies. Usually, the
biopsy yielded more than one artery. If there were two arteries, the first was mounted
in the myograph, whilst the second was kept in a refrigerator overnight to use the
following day. The order of experiments performed on the vessels was randomised to
prevent any influence of overnight storage on the results.
2.1.3. Mounting and pressurising of vessels in myograph
Once dissected, arteries were carefully transferred on the tip of a pair of forceps to the
vessel chamber of the myograph (Living Systems Instrumentation, Burlington,
Vermont, U.S.A.), which contained 10ml of PSS. Here, the resistance arteries were
tied onto two fine glass cannulae (~150|im tip diameter) using single-fibre silk threads.
This was done by firstly gently pulling the proximal end of the vessel onto the cannula
tip until approximately 200|im of the tip was inserted into the lumen of the vessel.
Two silk threads (~20|im diameter) which had already been looped onto the cannula,
were then slid down over the vessel and secured by pulling both ends with forceps
(Figure 2.2a). To remove any blood present in the lumen of the artery, which would
obstruct measurement of the diameter, the stopcock to the proximal cannula was
opened and a slow flow of PSS was passed through the lumen, by means of a
miniature peristaltic pump (PS/200, Living Systems Instrumentation Inc., Burlington,
Vermont, USA). Care was taken not to raise the intra-luminal pressure above
3-4 mmHg at this stage, in order to avoid damage to the endothelium. Once the lumen
was cleared of blood, the stopcock was closed and the distal end of the artery was then
secured onto the distal cannula in the same way as described for the proximal end.
Each end of the vessel had two ties therefore, which helped to ensure it would
maintain a set pressure.
An intraluminal pressure of 60 mmHg for rat, and 50 mmHg for human vessels, was
achieved by slowly introducing PSS through the vessel lumen using the miniature
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peristaltic pump, which was connected to a pressure servo unit (Figure 2.2b). As the
vessels were pressurised, they usually developed a bend due to a change in axial
length. These 'buckles' were removed by gently moving back the proximal cannula
using the attached length transducer, so as to reset the vessel to its 'original' axial
length (prior to dissection), whilst being careful to avoid introducing any axial stretch.
Once the pressure had reached the desired level set on the servo unit, the artery was
checked for leaks by changing the pressure servo from automatic to manual mode
(pump no longer running). If the mounted arteries had no leaks, the pressure reading
remained at the original setting. If a fall in pressure was seen, either a further attempt
was made at securing the ties, or the artery was discarded and another one mounted.
The pressure servo unit maintained the set intraluminal pressure throughout the
experiment. Pressures of 60 mmHg for rat, and 50 mmHg for human vessels, were
chosen because arteries of the size used in these experiments have been estimated to
experience pressures approximately 50% of mean arterial pressure in vivo (Halpern &
Kelly, 1991).
The myograph was placed on an inverted stage microscope (Nikon TMS-F, Japan)
which was connected to a monochrome television camera (Burle, U.S.A.), thus
allowing the mounted arteries to be visualised on a television monitor (Burle, U.S.A.)
(Figure 2.3). The lumen diameter and wall thicknesses were measured using a video
dimension analyser (Living Systems Instrumentation, Burlington, Vermont, U.S.A.),
which had been calibrated against a stage micrometer (resolution = 1pm). The video
dimension analyser is able to detect changes in optical density along a chosen scan
line. The walls have a much higher optical density than the rest of the vessel, hence
continuous measurements of both wall thicknesses and lumen diameter can be made.
Once mounted, the arteries were continously superfused with PSS which was gassed
with 95% O2 and 5% CO2. The temperature of the fluid within the vessel chamber,
measured using a digital thermometer (TM-903, Lutron Equipment, UK) held in close
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Figure 2.2a. Photograph of the myograph vessel chamber where the proximal end
of a resistance artery (~ 250pm i.d.)hasbeen secured onto the first glass cannula
using single fibre silk thread (x5 magnification).
Figure 2.2b. After securing the distal end of the resistance artery to the second glass
cannula, an intraluminal pressure of 60mmHg has been introduced by means of a
miniature peristaltic pump and pressure servo control unit (x5 magnification).
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Figure 2.2.Photograph showing the components of the small vessel arteriograph
(perfusion myograph): vessel chamber (A); miniature peristaltic pump (B); pressure
servo unit (C); inverted stage microscope (D); television camera; (E); television
monitor (F); and video dimension analyser (G).
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proximity to the vessel, was maintained at 37°C; before entering the vessel chamber
the superfusate was passed through a glass heat-exchanger, which was warmed with
circulating water from a water bath (at 40°C), and a Peltier heat-exchange unit
(MHE-1, Moor Instruments, Millwey, Axminster, Devon, UK).
2.1.4. Cooling procedure
Cooling of the arteries to 24°C was achieved by firstly switching off the water circuit
to the glass heat-exchanger, and then re-setting the Peltier unit from 37°C to 27°C;
because of an overshoot of temperature during cooling, a temperature higher than
24°C was chosen to avoid cooling to below 24°C. Once the temperature stabilised at
around 24°C, after approximately 5 minutes, fine tuning of the Peltier unit maintained
a constant temperature of 24°C.
2.1.5. De-endothelialisation
In large arteries the most common approach for removing the endothelium is by
mechanical means, usually by rubbing the inner surface of a vessel segment with a
small stick or wire. This technique is difficult to apply to small resistance arteries
because of their fragility. A wide range of alternative chemical and enzymatic methods
have been employed to remove or inactivate the endothelium from microvessels; for
example, perfusion with detergents such as 3-[(3-cholamidopropyl)dimethyl
ammonio]-l-propane sulphonate (CHAPS) (Hiley et al., 1987) or sodium
deoxycholate (Byfield et al., 1986), dissolving the intracellular matrix with enzymes
such as collagenase (Carvalho & Furchgott, 1981) or elastase (Furchgott &
Zawadzki, 1980), rupturing endothelial cells osmotically with distilled water
(Criscione et al., 1984), or perfusion with 40mM potassium chloride (Griffith et al.,
1985). Unfortunately, chemical techniques are difficult to control precisely (e.g.
exposure time, shear rate) and carry the risk of damaging adjacent smooth muscle
cells. It then becomes difficult to know with certainty whether an observed difference
in the vessel response is due specifically to endothelial cell removal.
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Alternative ways of denuding resistance arteries mechanically are the introduction of a
single hair into the vessel lumen (Osol et al., 1989), and perfusion of the lumen with
an air bubble (Ralevic et al., 1989; Bjorling et al., 1992; Falloon et al., 1993). The 'air
bubble technique' is employed by Professor Heagerty's group in Manchester, and was
the chosen method here, as it gave consistent results during preliminary tests.
2.1.5.1. Air bubble technique
Removal of the endothelium was achieved by passing air through the lumen of the
mounted artery, similar to the method described by Falloon et al. (1993) as follows:
first, the setting on the length transducer was recorded so that the vessel could later be
reset to its original axial length. The pressure within the vessel was then slowly
reduced whilst the axial length was simultaneously re-adjusted to prevent any axial
stretch on the vessel. The stopcock at the end of the distal cannula was then opened,
and after disconnecting the luer fitting at the proximal end of the vessel chamber, an air
bubble about an inch in length was introduced into the tubing (Tygon: I.D. 1/32")
feeding the proximal cannula. This was achieved by switching to the flow mode on the
pressure-servo box whilst reconnecting the luer fitting. The air was slowly moved
down the tubing to the vessel at a flow rate which produced a pressure of 20-30
mmHg. A series of small air bubbles (usually between 10 and 15) were passed
through the lumen of the vessel. Once all of the air had passed through the vessel,
flow was maintained for a further 2-3 minutes to allow endothelial debris to be washed
away. Switching back to the pressure mode on the pressure servo unit, the stopcock
was closed again and the vessel restored to its original axial length and pressure.
Removal of the endothelium was assessed using various methods. In every vessel
studied, functional tests were made using the endolhelium-dependent vasodilator,
acetylcholine (ACh, 10"6 to 10~4M), administered during contraction to phenylephrine
(a]-adrenoceptor agonist, PE, 10"5M) (see Experimental protocol below). Some
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vessels were studied morphologically by means of scanning and transmission electron
microscopy, or by confocal microscopy.
2.1.5.2. Confocal microscopy
Four vessels (from 1 rat) were mounted in the myograph and contractility assessed
with PE. The first two arteries were gently removed from the cannulae and immersed
in the nuclear fluorescent dye, ethidium bromide (5pg/ml), for 30 minutes. The third
and fourth arteries were denuded (confirmed by loss of response to ACh) using the
'air bubble technique' before removal from the cannulae and ethidium bromide
staining. The vessels were then viewed under a confocal microscope (Odyssey XL,
Noran Instruments Inc., U.S.A) at the Department of Physiology, University of
Glasgow, with the assistance of Mr Craig Daly and Dr Silvia Arribas. Essentially, the
confocal microscope allows 3D images to be visualised by reconstructing a series of
2D confocal images. It was used here simply to scan the vessels at different depths in
order to detect the absence or presence of the endothelium. Because ethidium bromide
labels the nuclei of cells which have a permeabilised membrane, i.e. those which are
damaged, it is possible to visualise the degree of damage, if any, caused to endothelial
and smooth muscle cells after the passage of an air bubble through the lumen.
2.1.5.3. Fixation of vessels for electron microscopy
Arteries to be examined by electron microscopy were firstly fixed. Three vessels (from
2 rats) which had not been mounted on the myograph were fixed immediately after
dissection. Two vessels (from 2 rats) were mounted in the myograph and contractility
assessed with PE. After removal from the myograph they were fixed. Another three
vessels (from 2 rats) were mounted and denuded using the 'air bubble technique',
confirmed with acetylcholine, before removal and fixation. The vessels were fixed by
immersion into Karnovsky's fixative (see section 2.4.) for exactly 2 hours in a
refrigerator, and were then washed in fixative free buffer and stored in the fridge
overnight, before being sent in a vacuum flask containing ice to Dr. K. Cracknell at
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the Division of Physiology, St Thomas' Hospital in London for further processing.
The following procedures relating to electron microscopy were carried out by Dr
Cracknell and colleagues in London.
2.1.5.4. Transmission electron microscopy
Arteries were rinsed in 0.1M physiological buffer and fixed with 1% osmium
tetrooxide. The samples were dehydrated in a graduated series of ethanol solutions
followed by propylene oxide, before being embedded in Araldite Resin (Fisons,
Loughborough, U.K.). Transverse sections (~90nm thick) were cut using an LKB
ultratome III microtome. After staining with uranyl acetate and lead citrate, the vessels
were examined on a Zeiss EM 10C electron microscope.
2.1.5.5. Scanning electron microscopy
Arteries were dehydrated in ethanol as above, then dried using a critical point drier
(Fisons, Loughborough, U.K.). The samples were then mounted on a scanning
electron microscopy stub, endothelial layer uppermost, using 'sticky tabs' (Agar
scientific, Stansted, U.K.), after which they were sputter coated (Polaron SEM
coating unit E5000) with gold (Agar scientific, Stansted, U.K.) and viewed in a
Hitachi S-510 scanning electron microscope.
2.1.6. Experimental protocol
2.1.6.1. Rat Vessels
Following a 60-90 min equilibration, during which the temperature of the vessel
chamber was raised from room temperature to 37°C, three 'wake-up' doses of PE
(10'5M) were given to produce a contraction to < 35% of resting lumen diameter. ACh
(10"6M) was given during the third contraction to assess endothelial integrity.
2.1.6.2. Human Vessels
Following a 60-90 min equilibration, during which the vessel chamber was
superfused with PSS, continuously gassed with 95% 02:5% CO2, and the temperature
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raised to 37°C, the contractility of the arteries was assessed separately using PE
(10~5M, Sigma) and potassium chloride (KC1, 60mM, Sigma). KC1 was given in
addition to PE because, unlike rat vessels, human arteries did not always respond to
the ai-adrenoceptor agonist, implying there was a reduced density and/or sensitivity
of these receptors in the unresponsive human vessels, compared to arteries from the
rat. ACh (10"6M, Sigma) was given during maximum contraction to PE to assess
endothelial integrity.
Removal of the endothelium was achieved by passing air through the lumen of the
vessel (see above) and confirmed functionally by the loss of ACh-induced (up to
10"4M) relaxation during constriction to a fourth dose of PE. Cooling was achieved by
passing the superfusate through a Peltier heat-exchange unit (see above) before it
entered the arteriograph.
Cumulative concentration-response curves were generated using a reperfusion circuit.
Because drugs such as ET-1 are expensive, other users of the myograph have simply
added drugs directly into the vessel chamber, during which the superfusate is switched
off. Although this method minimises the amount of drug used, it has the disadvantage
that the temperature is not maintained at 37°C. From Figure 2.4, it can be seen that
switching off the superfusate for the approximate time required to complete a
concentration-response curve to ET-1 (-40 min.), results in a rapid and sustained
decline of the chamber temperature. Since the effects of cooling are the focus of this
thesis, this is clearly unsatisfactory.
The reperfusion circuit was set up in order to obtain cumulative concentration-
response curves whilst maintaining a constant temperature in the vessel chamber. The
total volume of the circuit was 30 mis, as opposed to just 10 ml in the vessel chamber;
thus three times as much drug had to be used with the reperfusion method. This did
not pose a serious problem however, since the maximum response to all the agonists
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Figure 2.4. The effect of switching off the superfusion circuit on vessel chamber
temperature over a 40 min period. Mean ±SEM ofn=3.
2.1.6.3. An investigation of vasoconstrictor substances
Cumulative concentration-response curves to the agonists shown in Tables 2.3 and
2.4. were obtained at 37°C or 24°C, and with endothelium either intact or removed, in
a randomised order. In further experiments, the effects of the nitric oxide synthase
inhibitor, NG-nitro-L-arginine methyl ester (L-NAME; 10~4M), the cyclooxygenase
inhibitor, indomethacin (10"5M), or the ETa/b receptor antagonist, bosentan (10~6M),
were examined (Tables 2.3 and 2.4).
2.1.6.4. An investigation of vasodilator substances
Cumulative relaxation-response curves to the endothelium-dependent dilator, ACh,
and the endothelium-independent dilator, sodium nitroprusside (SNP), were obtained
at 37°C or 24°C, and with endothelium either intact or removed (Table 2.5). The
endothelium was removed in the experiments involving SNP in an attempt to
standardise conditions, because basal production of NO can affect the responses to











Intact / / y
Denuded / / y
L-NAME / Indo. / X y
Bosentan / /
Table 2.3. Concentration-response curves to agonists generated in rat mesenteric
resistance arteries. Note: for potassium chloride (KCl), combined NG-nitro-L-arginine
methyl ester (L-NAME)/indomethacin (indo.) was used, whereas the effects of
separate L-NAME and indomethacin administration was studied for endothelin-1
(ET-1). (See text for dose of inhibitor/antagonist used).
Surgical biopsy Gluteal biopsy
ET-1 ET-1
37°C & 24°C 37°C & 24°C
Intact y y
Denuded X y
Table 2.4. Concentration-response curves to endothelin-1 (ET-1) (10'12 - 3xlO~7M)




37°C & 24°C 37°C & 24°C
Intact y X
Denuded X y
Table 2.5. Concentration-relaxation curves to vasodilators generated in rat




Responses are expressed as a percentage (%) of the contraction to PE (rat) or KC1
(human) at 37°C. EC50 values were calculated by plotting individual concentration-
response curves (Cricket-graph, Macintosh) and measuring, by hand, the
concentration of the agonist producing 50% of the maximum contraction of each
individual curve. EC50 and Emax (the maximal contraction) values are shown as
mean ± standard error of the mean (SEM), and n = the number of vessels studied. In
cases where more than one vessel was obtained from one animal/biopsy, n/n = the
number of vessels from the number of animals/patients studied (where appropriate).
Note: the same experiments were never repeated in subsequent vessels from any one
rat or biopsy tissue, i.e. subsequent vessels were placed in a different group to that of
the first studied, thus n/n is only referred to when discussing combined data. Student's
paired t test was used to compare the responses between 37°C and 24°C groups, intact
and denuded groups, or absence and presence of antagonist groups. The significance
of the data obtained from the human resistance artery studies was further analysed by
two-way analysis of variance (ANOVA). Statistical significance was accepted when
P < 0.05.
2.2. Autoperfused hindlimb of the anaesthetised rat
The rat autoperfused hindlimb preparation was set up with the aim of examining the
effects of temperature on vascular resistance in vivo, and to characterise possible
mediators of the responses using selective antagonists and inhibitors. It was
anticipated that the results obtained from the physiological responses to cooling in the
rat hindlimb would help to elucidate the mechanisms underlying the pathophysiology
of Raynaud's disease.
The rat autoperfused hindlimb preparation was set up as a modification of the method
used by Bom & Palinski (1989); instead of perfusing the right hindlimb with blood
from the carotid artery, the present technique used blood from the left femoral artery.
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Before entering the right femoral artery, the blood was cooled using a rapid heat-
exchange device, or Peltier cell, which allowed temperature changes to be made in a
matter of seconds. It can be argued that this preparation is not representative of the
conditions occuring in Raynaud's Disease, whereby it is the external surface of the
limb, and not the blood, which is cooled initially. However, it would be difficult to
measure the temperature the vasculature was subjected to if the hindlimb was cooled
externally. An advantage of cooling the blood by means of the Peltier cell, is that the
temperature of the blood going to the hindlimb can be monitored accurately, by means
of a fine thermistor probe placed at the site where blood enters the hindlimb, and is
reproducible from animal to animal.
2.2.1. General surgery
Male Wistar rats were obtained from Charles River (Kent, UK) and maintained on
standard chow and tap water ad libitum. The animals (378 ± 9g; n=64) were
anaesthetised with sodium pentobarbitone (60mg/kg i.p., Sagatal, Rhone Merieux
Ltd., UK). A tracheal cannula was inserted to allow measurement of airflow using a
pneumotachograph (CS5, Mercury Electronics, UK). Catheters filled with heparinised
saline (50 units/ml) were inserted into the right jugular vein and right carotid artery for
drug administration and blood pressure measurement by a pressure transducer
(P23Dc, Statham, UK) respectively.
The rats were then heparinised (lOOOU/kg intra-venously i.v.) prior to cannulation of
the right and left femoral arteries to prevent coagulation of blood in the perfusion
circuit. Blood from the cannulated left femoral artery was passed into the right femoral
artery using a peristaltic pump (MRHE 200, Watson Marlow, UK). A pressure
transducer (P23Dc, Statham, UK), situated between the pump and the right hindlimb,
measured hindlimb perfusion pressure (HLPP), which was used as an index of total
vascular resistance of the hindlimb (Figure 2.5). The pump was set at a constant flow
rate so that the HLPP matched the mean arterial blood pressure (MAP).
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Rectal temperature was measured using a thermistor probe and maintained at 37±1°C
by a homeothermic blanket connected to the probe (Harvard Apparatus Ltd., Kent,
UK). Blood samples were taken approximately every hour from the carotid artery to
monitor blood gas tensions and pH, using a pH/blood gas analyser (238, Ciba-
Corning, UK).
2.2.2. Cold-induced vasoconstriction
Cooling was achieved by passing blood through a rapid heat-exchange element (Peltier
cell) before it entered the right hindlimb (Figure 2.5). Initially, the effect of cooling on
perfusion pressure was examined by changing the temperature from 37°C to 21°C in
4C° steps, each held for 2 minutes, before rewarming to 37°C in 4C° steps. Random
temperature changes were also made in order to determine how reproducible the
temperature-HLPP curves were (see Chapter 3). The reduction in temperature was
associated with a rise in HLPP, implying cold-induced vasoconstriction was
occurring. Temperature-HLPP curves were obtained before and after drug
administration by cooling the blood in the 4C° steps outlined above.
In order to establish whether the rise in perfusion pressure seen during cooling was
due to vasoconstriction of the hindlimb vasculature and not merely the result of a
temperature-induced increase in blood viscosity, and hence an increase in resistance,
the hindlimb was perfused with saline by removing the cannula from the left femoral
artery and placing it into a vial containing saline (n=4). Only a single temperature-
HLPP curve was obtained in any one animal during saline-perfusion, because the
increase in blood volume following the perfusion would affect subsequent responses
(see Chapter 3).
In four experiments, the skin from the hindlimb was surgically removed and
temperature-HLPP curves carried out to determine what proportion, if any, of the rise
in HLPP with cooling was mediated by the cutaneous circulation (see Chapter 3).
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Figure 2.5. Diagram of the rat autoperfused hindlimb preparation showing
cannulation of: trachea (T) for airflow measurement; carotid artery (CA) for
measurement of mean arterial pressure; jugular vein (JV) for intravenous
administration ofdrugs; leftfemoral artery (LFA) where blood enters perfusion circuit;
and right femoral artery (RFA) where blood enters the hindlimb under observation.
The relative positions of the components of the perfusion circuit are also shown.
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2.2.3. Experimental protocol for an investigation of vasoconstrictor
substances
In order to validate the autoperfused hindlimb model, an attempt was made to
reproduce the results of vascular studies quoted in the literature. It has been
demonstrated that cooling augments noradrenaline-induced contraction in canine veins
(Janssens & Vanhoutte, 1978) and that this is mediated by an apparent increase in
responsiveness of (^-adrenoceptors (Flavahan et al., 1985; Flavahan & Vanhoutte,
1986). Experiments were carried out using several a-adrenoceptor antagonists (Table
2.6) in an effort to attenuate the cold-induced rise in perfusion pressure. In addition,
the role of endothelin was investigated using the ET receptor antagonists, bosentan
(ETa/b) and BQ-123 (ETa) (Table 2.6). All the antagonists were administered intra-





Prazosin a i-adrenoceptor antagonist 100 jig/kg
Yohimbine 0(2-adrenoceptor antagonist 300 |ig/kg
Prazosin & yohimbine ai/0(2-adrenoceptor
antagonists (combined)
as above
Bosentan ETa/b receptor antagonist 1000 pg/kg
BQ-123 ETA-receptor antagonist 1000 |ig/kg
Table 2.6. Antagonists and inhibitors used in the autoperfused rat hindlimb
preparation. Doses used were shown to be effective against the appropriate agonists
(see Chapter 3).
To prevent pressure changes caused by injection, drugs were administered so that they
passed through the peristaltic pump before reaching the hindlimb. At the start of every
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experiment 0.1ml of saline was injected intra-arterially to establish whether the vehicle
itself had any direct effects. Because drug/saline solutions are of lower viscosity than
blood, they produced a sharp fall in resistance and hence perfusion pressure when
injected. To minimise this effect and to allow greater mixing with the blood, drugs
were injected slowly (over 5-6 seconds).
2.2.4. Statistical Analysis
The results are expressed as the slope of temperature-HLPP curves which were
constructed by plotting the natural logarithm of HLPP (In HLPP) versus the inverse of
temperature (1/T), according to Arrhenius analysis (a straight line is expected from the
original Arrhenius equation, which is used as a means of expressing the temperature
dependence of a response: k = Ae-M^T, where k = rate constant; A = constant; e =
natural logarithm; p = Arrhenius energy; R = gas constant; and T = temperature).
Values are shown as mean ± standard error of the mean (SEM), and n = number of
animals studied. Student's paired t test was used to compare the curves before and
after the addition of an antagonist or inhibitor. Statistical significance was accepted
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CHAPTER 3:
VALIDATION OF TECHNIQUES USED
87
3.1. Small vessel arteriograph (perfusion myograph)
3.1.1. Reproducibilty of concentration-response curves
It was originally anticipated that the effect of cooling on the response to ET-1 would
be examined by generating concentration-response curves to ET-1 firstly at 37°C, and
then repeating in the same vessel after cooling to 24°C; the order of the temperatures
would be randomised between vessels. In order to determine whether it was feasible
to carry out more than one concentration-response curve to ET-1 in a single vessel, up
to four consecutive curves were generated in individual vessels, allowing each to
recover to its original resting lumen diameter - or the maximum diameter attainable
after a 2 hour recovery period (Table 3.1) - after the completion of each curve. It
should be noted that the maximum concentration of ET-1 attainable with the batch of
ET-1 used in this set of experiments was not sufficient to achieve maximal contraction
to ET-1. Subsequent experiments used a single batch of ET-1 that enabled a 10-fold
increase in concentration of the stock solution.
Table 3.1. Resting lumen diameter of vessels before each concentration-response
curve to ET-1 at 37°C, and the time taken to recover between curves
Curve 1st 2nd 3rd 4th
% Resting LD 100 + 0 100+ 1 97 + 2 101 ± 3
Recovery time _ 93 ±7 91 ± 10 75 ± 11
Lumen diameter (LD); recovery time in minutes. All values are mean ± SEM. n = 9-12
for 1st, 2nd and 3rd curves; n = 4 for 4th curve.
From Figure 3.1, it can be seen that there is a significant rightward-shift of second,
and subsequent concentration-response curves to ET-1 compared to the first curve
(EC50 values have not been calculated because the responses to ET-1 did not reach a
maximum). Since the responsiveness to ET-1 was found to be significantly depressed
after the first concentration-response curve, it was decided to examine the effect of
cooling on the response to ET-1 by generating single concentration-response curves in
individual vessels, either at 37°C or 24°C.
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Figure 3.1. The reproducibility of responses to ET-1 in rat mesenteric resistance
arteries: consecutive concentration-response curves to ET-1 (expressed as % response
to PE, 10'5M) at 37°C: 1st curve (O; n=12); 2nd curve (0; n=12); 3rd curve (0; n=9);
and 4th curve (A; n-4). All values are mean ± SEM. *P < 0.05; ***P < 0.001
(paired t-test; 1st vs. subsequent curves). Note: in this set ofexperiments the maximal
response to ET-1 was not attainable with the concentrations available (see text).
3.1.2. De-endothelialisation techniques
After attempts were made to de-endothelialise vessels using the air bubble technique
(see Chapter 2; under section 2.1.5.1.), the integrity of the endothelium was assessed
in four ways. The results from each of these assessments are given below.
3.1.2.1. Functional tests
The endothelium-dependent dilator ACh (10~6M) was given during contraction to the
ai-adrenoceptor agonist, PE (10~5M), in order to determine endothelial integrity
functionally. In vessels with an intact endothelium, ACh induced relaxation to, or
close to, the original resting lumen diameter of the vessel (Table 3.2). After the
passage of air through the vessel lumen, ACh was unable to induce relaxation, and
indeed quite often elicited a small contraction (Table 3.2). These effects were
independent of temperature.
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Table 3.2. The relaxant response to ACh before and after passage ofair through the
vessel lumen
Before After
37°C 88 ±4 j ***
24°C 92 + 5 _9 -)- Q ***
% Relaxation to acetylcholine, ACh (10~6M). Values are mean ±SEM. n = 6 vessels at
each temperature. ***P < 0.001 (paired t-test).
The results from these tests implied that the air bubble destroyed the endothelium;
morphological techniques were employed to investigate whether this was due to
removal of the endothelium or to its damage (see below).
3.1.2.2. Confocal microscopy
Ethidium bromide labels the nuclei of cells which have a permeabilised membrane, i.e.
those which are damaged. Figure 3.2 shows an artery with an intact endothelium,
which had been stained with ethidium bromide (5|0.g/ml) for 30 minutes after removal
from the myograph and then imaged through a confocal microscope. Only adventitial
cells from the top (a) and bottom (c) of the vessel were stained; these cells were likely
to have been damaged during the dissection procedure. No endothelial cells were seen
when the plane of focus was set away from the adventitia to the luminal surface (b),
indicating the presence of an intact endothelium. Figure 3.3 shows confocal images of
two vessels which had air infused through the lumen, before removing from the
myograph and immersing in ethidium bromide. The permeabilised endothelial cells
had lost their usual ordered orientation, and had formed clusters. Thus, it appears that
the passage of an air bubble through the vessel lumen damages the endothelial cells,
but does not completely strip them from the vessel wall. The absence of staining of
smooth muscle cells suggests this method of de-endothelialisation does not have
adverse effects on the underlying smooth muscle.
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Figure 3.2. Confocal images of an endothelium-intact rat mesenteric resistance
artery, stained with ethidium bromide after removal from the myograph. Only
adventitial cells from the top (a) and bottom (c) of the vessel are stained. When the
plane offocus is set away from the adventitia to the luminal surface (b), no endothelial
cells are seen, indicating the presence ofan intact endothelium. Scale bar= 40pm.
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3.1.2.3. Scanning electron microscopy
Examination of the luminal surface of arteries by scanning electron microscopy (SEM)
revealed the presence of an intact endothelial cell layer in all control arteries, which
was effectively removed following the passage of air through the lumen (Figure 3.4).
Substantial endothelial cell remnants were attached to the luminal surface in a clustered
formation (Figure 3.5), similar to those observed by confocal microscopy.
3.1.2.4. Transmission electron microscopy
In the intact control arteries which had been fixed after removal from the myograph,
transmission electron microscopy (TEM) showed the intima, consisting of a single
layer of endothelial cells and the inner elastic lamina, and the media, made up of
smooth muscle cells (Figure 3.6). Large vacuoles were seen under some of the
endothelial cells in these control arteries (Figure 3.6a). Because they were also present
in arteries which had been fixed immediately after dissection from the mesentery
(Figure 3.6b), vacuoles would appear to be artefacts of the fixation procedure, rather
than a result of the pressure myograph technique; indeed, others have also found
similar vacuoles in non-pressurised arteries (Greensmith et al., 1984). The number of
vacuoles has been found to increase after storage of vessels for several hours in a
refrigerator (Abebe et al., 1993; K. Cracknell, personal communication). A large
number of the experiments carried out in this thesis were done in vessels which had
been stored at 4°C for similar time periods. Relaxation to ACh was not impaired in
these arteries, however, suggesting the functional response can remain normal despite
the occurence of some morphological changes.
From Figure 3.7 it can be seen that the passage of air through the vessel lumen
effectively removed the endothelium from the inner elastic lamina, but that substantial
endothelial debris remained in the lumen, which is similar to the findings from SEM
and confocal microscopy. In several micrographs the underlying smooth muscle cells
showed some signs of damage: the presence of vacuoles (Figure 3.7b) or swollen
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Figure 3.4.Scanning electron micrographs of the luminal surface of rat mesenteric
resistance arteries, fixed by immersion after removal from the myograph. A. In
endothelium-intact vessels the folded luminal surface is covered by a continuous layer
ofendothelial cells (arrows). Scale bar = 50pm. B. Several endothelial cells (En) under
higher magnification. Scale bar = 10pm. C. In arteries which had an air bubble passed
through the lumen there are no intact endothelial cells remaining. Scale bar = 50pm. D.
Higher magnification of a de-endothelialised vessel reveals the absence of any
endothelial cells in the folds of the luminal surface. Scale bar = 10pm.
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Figure 3.5.Scanning electron micrograph showing the effect of the passage of air
through a rat mesenteric resistance artery, fixed after removal from the myograph.
Remnants ofendothelial cells (En) can be seen adhering to the luminal surface of the
vessel. Scale bar = 50pm.
97
Figure 3.6.Transmission electron micrographs of endothelium-intact rat mesenteric
resistance arteries, fixed by immersion after removal from the myograph (A) andfixed
immediately after removal from the animal This micrograph shows an intact
layer of endothelial cells (En) beneath which are the inner elastic lamina (IEL) and
smooth muscle cells (SM). In some areas vacuoles (V) have formed in the endothelial
sells and in the subendothelial space. Scale bar= 10pm. B. Similar vacuoles are
ilso present in vessels which had not been mounted on the myograph. Scale bar =
I Opm.
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Figure 3.7.Transmission electron micrographs of rat mesenteric resistance arteries
which were perfused with air, and fixed by immersion after removal from the
myograph. A. This micrograph shows remnants of endothelial cells (En) in the lumen
(L), above an intact inner elastic lamina (IEL). Swollen mitochondria are present in the
endothelial cell remnants (single arrows). The mitochondria (double arrow) in the
underlying smooth muscle cells (SM) appear normal. Scale bar = 10pm. B. A large
vacuole (V) can be seen in the smooth muscle layer (SM), directly beneath a disrupted
section of the inner elastic lamina (IEL). Scale bar= 10pm.
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7igure 3.8.High magnification transmission electron micrographs of rat mesenteric
■esistance arteries fixed by immersion after removal from the myograph. Endothelial
rells (En) in intact arteries (A) appear normal, in contrast to those found in vessels
hrough which an air bubble was passed (B), where swollen mitochondria are present
arrows). Scale bars = 5pm. Lumen (L); inner elastic lamina (IEL); smooth muscle
SM).
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mitochondria. This damage did not, however, affect functional responses to PE which
were tested in these same vessels before fixation, and in all vessels of subsequent
studies (see below). Rubbing the vessel lumen with a human hair appears to be more
effective in completely removing the endothelium than the passage of an air bubble,
but the hair technique results in more damage to the smooth muscle (K. Cracknell,
personal communication). TEM under higher magnification revealed the presence of
swollen mitochondria in the detatched endothelial cells of denuded arteries, which
were not observed in intact control vessels (Figure 3.8), indicating that the endothelial
cells which remained were damaged, and were therefore unlikely to be functional (as
was evidenced by the abolition of the relaxant response to ACh).
The air-bubble technique thus appears to be an effective way of denuding resistance
arteries, whilst causing less damage to the underlying smooth muscle than other
mechanical methods. Perhaps increasing the time of PSS perfusion through the vessel
lumen, from 2-3 min to a longer period, after the passage of air would further assist
the removal of the endothelial debris.
3.1.3. Effects of de-endothelialisation and cooling on artery diameter
Removal of the endothelium and/or cooling did not cause a significant change in
resting lumen diameter (Tables 3.3 and 3.4), or to the contractile response to the
'wake-up' dose of PE (10~5M) (Tables 3.5 and 3.6). This was obviously an
advantage, as it meant the results could be expressed as a % of the maximal response
to the 'wake-up' dose of PE regardless of the temperature or endothelial state of the
vessel. % Contraction to PE was calculated as:
LP. - LDZ x 100
LDj 1
where LDj = resting lumen diameter; LD2 = lumen diameter at maximal contraction.
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Table 3.3. The effect of de-endothelialisation on vessel diameter at 37°C and 24°C
Before After
37°C 278 + 21 277 + 21
24°C 283 ± 14 279 ± 16
Vessel diameter in flm. Values are mean ± SEM. n = 6 vessels at each temperature.
Table 3.4. The effect of cooling on diameter of intact vessels
Vessel diameter at 37°C Vessel diameter after cooling to 24°C
278 + 20 276 ± 22
Vessel diameter in pm. Values are mean ±SEM. n = 12 vessels at each temperature.
Table 3.5. The effect ofde-endothelialisation on the contractile response to PE at
37°C and 24 °C
Before After
37°C 74 ± 1 75 ± 1
24°C 75 + 1 75 ± 1
% Contraction to phenylephrine, PE (10~5M). Values are mean + SEM. n = 6 vessels
at each temperature.
Table 3.6. The effect of cooling on the contractile response to PE (10~5M)
% Contraction at 37°C % Contraction after cooling to 24° C
73 ± 1 73 ± 1
% Contraction to phenylephrine, PE (10~5M). Values are mean ±SEM. n = 12 vessels
at each temperature.
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3.1.4. Justification for using arteries obtained from gluteal fat biopsies
In order to study the pathophysiological role of the vascular endothelium in Raynaud's
disease, resistance arteries were obtained from fat biopsies taken from the gluteal region
of Raynaud's patients and healthy control subjects (see Methods 2.1.2.3). Ideally, one
would examine vessels isolated from the digits, i.e. the actual region predominantly
affected by the condition, but this approach would almost certainly be unacceptable to
volunteers. Digital biopsies could be obtained from post-mortem tissue, but such a
source raises potential problems that would need to be addressed: cause of death; length
of time taken to receive tissue after death; accumulation of toxic substances; and the
temperature at which the body was stored. Variability of these factors would affect the
viability of arteries dissected, and ultimately the responses of any arteries studied.
Although it may be interesting to study such samples, they inevitably could not be used
to conduct an age- and sex-matched, controlled study between Raynaud's patients and
control subjects.
It is likely that Raynaud's disease manifests itself in, for example, the fingers, toes,
ears, lips and nose, because these parts are extemities which are exposed to the cold.
The gluteal region is usually well protected from the elements and is, therefore, an area
which one would not normally expect to find cold-induced vasospasm. Nevertheless,
when interviewing the Raynaud's patients recruited for the studies in this thesis, it was
learned that several of them did indeed suffer from cold buttocks as a result of poor
circulation to this region. Perhaps this is not so surprising since there is a higher
incidence of Raynaud's disease in patients with migraine and/or variant angina,
suggesting that it may be part of a generalised vascular defect. If this is true, one would
expect the abnormality to be evident in vessels not generally associated with the
symptoms of Raynaud's disease. For this reason, it would seem that subcutaneous
resistance arteries isolated from gluteal biopsies are a suitable alternative to digital
vessels. In addition, the buttocks have a large proportion of subcutaneous fat, and the
scar resulting from the biopsy procedure is at an unobtrusive site.
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3.2. Autoperfused hindlimb of the anaesthetised rat
3.2.1. Reproducibility of cold-induced vasoconstriction
A series of experiments were performed in order to determine the reproducibility of the
temperature-hindlimb perfusion pressure (HLPP) curves; four consecutive curves
were generated in each animal, as described in Chapter 2. From Figure 3.9, it can be
seen that the tc mperature-HLPP curves were reproducible, when generated both by
direct cooling from 37°C to 21°C in 4C° steps (Figure 3.9a), and by random changes
to each temperature (Figure 3.9b). There was no significant difference between the
slope of the curves (Table 3.7).
When examining the effect of drugs on the cold-induced rise in HLPP, two control
temperature-HLPP curves were generated prior to drug administration into the
hindlimb. Thus, the effect of a drug was examined by comparing the second and third
temperature-HLPP curves; because there was no significant difference between these
curves in the control experiments (Figure 3.10), this was a satisfactory way to study
the effect of drugs on the increase in HLPP during cooling.
3.2.2. Influence of HLPP on systemic blood pressure
The cold-induced rise in HLPP had no effect on mean arterial blood pressure (MAP); a
representative trace of HLPP and MAP is shown in Figure 3.11. The flow rate of
blood through the hindlimb was chosen to achieve a HLPP approximately equal to that
of MAP. The flow rate required for this was 2.5 ±0.1 ml/min. One study has reported
hindlimb blood flow in rats to be 3.8 ± 0.2 ml/min (Drexler & Lu, 1992), which
suggests the flow used in the present model was low. This might have resulted in
hypoxaemia, inducing the release of substances such as ET and NO, and is something
that should be considered when evaluating the data obtained from this model.
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Figure 3.9. The effect of cooling the blood on hindlimb perfusion pressure (HLPP)
in anaesthetised rats: consecutive temperature (T)-HLPP curves from 37°C to 21 °C,
directly (Figure 3.9a): 1st (O; n=6), 2nd (•; n=6), 3rd (M; n=6), and 4th curve (A;
n-6); or at random (Figure 3.9b): 1st (O; n=3) and 2nd curve (A; n=3). All values are
mean ± SEM.
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Table 3.7. Slope of consecutive temperature-HLPP curves
Curve 1st 2nd 3rd 4th Random 1 Random 2
Slope 23.69±3.24 23.67±3.25 23.83±4.38 24.42±3.70 26.11±3.25 28.82±5.05
Slope refers to simple line ofbestfit through each curve. All values are mean ± SEM.
0.02 0.03 0.04 0.05
1/T
Figure 3.10. The effect of cooling the blood on hindlimb perfusion pressure
(HLPP) in anaesthetised rats: 2nd (%; n-6) and 3rd (M; n=6) consecutive temperature-














Figure 3.11. Representative tracing showing the effect of cooling from 37°C to 21 °C
in 4C° steps on hindlimb perfusion pressure (HLPP) and mean arterial pressure (MAP)
(mmHg).
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The doses of antagonist drugs injected i.a. into the hindlimb circulation were shown to
be effective in significantly attenuating the pressor response to the appropriate agonists
administered intra-arterially (i.a.) into the hindlimb, whilst having non-significant
effects on the pressor response to agonists injected intravenously (i.v.) into the
systemic circulation (Figures 3.12 - 3.14). This implies the doses used were small
enough to have greater local, over systemic, actions.
The effect of the ET receptor antagonists on the systemic circulation was not
investigated because ET-1 elicited a prolonged pressor response in the hindlimb, and a
similar response systemically would have led to pressure changes in the hindlimb
circulation which may have affected the degree of responsiveness shown to the
antagonists. The effectiveness of the ETa receptor antagonist BQ-123 (1000|ig/kg
i.a.), and the mixed ETa/b receptor antagonist bosentan (1000|ig/kg i.a.), in blocking
the pressor response to ET-1 (lOOng/kg i.a.) in the hindlimb are shown in Figures
3.15 and 3.16. The degree of attenuation was not significant for either drug (P=0.10
and P=0.07 for BQ-123 and bosentan respectively) because of the low number of
experiments carried out (n=2 for each drug owing to the expense and lack of


















Figure 3.12. Local vs. systemic antagonist action of phentolamine on the pressor
response to noradrenaline: the change in hindlimb perfusion pressure (A HLPP)
(mmHg) resulting from hindlimb (i.a.) or systemic (i.v.) administration of
noradrenaline (lOOng), before (unhatched columns) and after (hatched columns)
hindlimb (i.a.) administration ofphentolamine (lOpg/kg). All values are mean ± SEM
(n=4). *P < 0.05 (paired t-test).
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Figure 3.13. Local vs. systemic antagonist action of prazosin on the pressor
response to noradrenaline: the change in hindlimb perfusion pressure (A HLPP)
(mmHg) resulting from hindlimb (i.a.) or systemic (i.v.) administration of
noradrenaline (lOOng), before (unhatched columns) and after (hatched columns)
hindlimb (i.a.) administration ofprazosin (lOOpg/kg). All values are mean ± SEM
(n=5). **P < 0.01 (paired t-test).
Figure 3.14. Local vs. systemic antagonist action of yohimbine on the pressor
response to clonidine: the change in hindlimb perfusion pressure (A HLPP) (mmHg)
resulting from hindlimb (i.a.) or systemic (i.v.) administration of clonidine (lOOng),
before (unhatched columns) and after (hatched columns) hindlimb (i.a.) administration











Figure 3.15. The antagonist action of BQ-123 on the pressor response to ET-1:
hindlimb (i.a.) administration of ET-1 (lOOng) alone (unhatched column) and after













Figure 3.16. The antagonist action of bosentan on the pressor response to ET-1:
hindlimb (i.a.) administration of ET-1 (lOOng) alone (unhatched column) and after
bosentan (1000pg/kg) (hatched column). All values are mean ± SEM (n=2).
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3.2.3. Contribution of blood viscosity to cold-induced increase in
HLPP
Temperature-HLPP curves were generated during saline-perfusion of the hindlimb to
establish whether the rise in HLPP induced by cooling was due to vasoconstriction or
merely the result of an increase in blood viscosity. A cold-induced rise in HLPP was
found during saline perfusion, implying that the rise was indeed dependent on
vasoconstriction (Figure 3.17). Increased viscosity would also appear to contribute to
the rise in HLPP since the slope of the temperature-HLPP curves had a tendency to be
lower than that for the blood-perfused hindlimb, though this did not achieve statistical
significance (slope = 17.19 ± 4.40 vs. 23.83 ± 4.38 for saline- and blood-perfused
respectively; P=0.34, unpaired t-test).
Figure 3.17. Comparison of the cold-induced increase in hindlimb perfusion
pressure (HLPP) in the blood- and saline-perfused hindlimb of anaesthetised rats:
temperature (T)-HLPP curves in blood perfused (O; n=6) and saline perfused (0;
n=4). All values are mean ± SEM.
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3.2.4. Contribution of the cutaneous microcirculation to HLPP
Surgical removal of the skin from the perfused hindlimb did not cause a significant
difference in the slope of temperature-HLPP curves (slope = 20.95 ± 10.12 before vs.
20.46 ± 2.82 after removal of hindlimb skin; P=0.96, paired t-test) (Figure 3.18).
This implied that the skin microcirculation did not contribute to the cold-induced
vasoconstriction.
Figure 3.18. The effect of hindlimb skin removal on the cold-induced increase in
hindlimb perfusion pressure (HLPP) in anaesthetised rats: temperature (T)-HLPP
curves before (O; n=4) and after surgical removal of the skin (0; n-4). All values are
mean ± SEM.
The fact that the temperature-dependent changes in HLPP were the result of changes in
blood flow to skeletal muscle rather than the cutaneous circulation is a weakness when
comparing the present model to the situation that occurs in patients with RD, where the
skin microcirculation is primarily affected. Thus, although the effects of cooling in the








Cooling has been shown to potentiate contractions to noradrenaline in canine
cutaneous veins (Janssens & Vanhoutte, 1978). Subsequent studies using selective
agonists and antagonists of cq- and a2-adrenoceptors have indicated that it is the CX2-
adrenoceptor-mediated vasoconstriction which is augmented by cooling, probably
through an increase in receptor affinity (Flavahan et ai, 1985; Ekenvall et al., 1988;
Bodelsson et al., 1990; Harker et al., 1990). Contraction induced by
5-hydroxytryptamine (5-HT), acetylcholine, and adenosine phosphate (ATP) is also
enhanced by cooling in canine cutaneous veins (Vanhoutte & Shepherd, 1970).
Cooling does not uniformly augment the response to contractile agents. It would
appear to depend on the agonist used and the type of vessel under study. Garcia-
Villalon et al. (1992) demonstrated that the responses to a-adrenoceptor agonists were
inhibited during cooling in rabbit ear arteries, through increased availability of nitric
oxide (NO), and in femoral arteries, through a decrease in receptor sensitivity.
Contraction to potassium chloride (KC1), a direct activator of smooth muscle, is
depressed at 24°C in canine cutaneous veins (Vanhoutte & Shepherd, 1970), a finding
which has been attributed to a decrease in smooth muscle permeability to calcium ions
(Ca2+) during cooling (Vanhoutte, 1980). The response to the potent endothelium-
derived vasoconstrictor, endothelin-1 (ET-1), has also been shown to be inhibited by
cooling in the rabbit ear artery (Monge et al., 1991). In this study the authors suggest
that cooling enhances the release and/or activity of the opposing vasodilator NO.
The studies presented in this chapter were undertaken to examine the effect of cooling
on the contractile response to ET-1 in resistance arteries obtained from rat mesenteries
and from human subcutaneous fat samples taken at surgery. In order to investigate the
role of ET-1 in the pathogenesis of Raynaud's disease, concentration-response curves
to ET-1 were also generated in resistance arteries taken from gluteal fat biopsies
obtained from control subjects and patients with Raynaud's disease. In addition, the
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modulatory role of the vascular endothelium on the response to ET-1 was examined, at
both 37°C and at 24°C.
The effects of cooling on the contractions induced by the a i-adrenoceptor agonist,
phenylephrine (PE), or by KC1 were also examined in rat vessels. The contribution of
the endothelium to any cold-induced effect was assessed initially by de-
endothelialisation, and, where appropriate, the subsequent use of bosentan, a non¬
selective ETa/b receptor antagonist, and the NO-synthase and cyclooxygenase
inhibitors, N°-nitro-L-arginine methyl ester (L-NAME) and indomethacin
respectively.
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4.2. Small vessel arteriograph (perfusion myograph)
4.2.1 The effect of cooling on the response to endothelin-1
4.2.1.1. Rat mesenteric resistance arteries
Mean resting lumen diameter, % contraction to PE and % relaxation to ACh did not
differ significantly between the group at 37°C and the group at 24°C (Table 4.1).
TABLE 4.1. Baseline data for vessels studied at 37°C and 24°C
37°C 24°C
LD (pm)
% Contraction to PE







LD, resting lumen diameter; PE, phenylephrine (10'5M); ACh, acetylcholine (10~6M).
Values are mean ± SEMfor n = 12 vessels at each temperature (total n = 24/18).
At 37°C, arteries with endothelium removed had a more than 2-fold greater sensitivity
to ET-1 than arteries with an intact endothelium (EC50 = 2.4 ± 0.4 x 10~9M intact vs.
1.0 ± 0.2 x 10"9M denuded; P<0.05) (Table 4.2) (Figure 4.1a). Similarly, at 24°C,
removal of the endothelium resulted in a 2-fold increase in sensitivity to ET-1
compared to the intact vessel (EC50 = 1.4 ± 0.2 x 10"9M intact vs. 6.3 ± 1.3 x 10"10M
denuded; P<0.01) (Table 4.2) (Figure 4.1b). There was a significant increase in the
Emax for ET-1 after de-endothelialisation, at both 37°C (from 101 ± 2 to 108 ± 1;
P<0.01) and 24°C (from 101 ± 2 to 108 ± 1; P<0.05) (Table 4.3).
When the effect of temperature on arteries was examined, it was seen that cooling to
24°C caused a 1.7-fold increase in sensitivity to ET-1 (EC50 = 2.4 ± 0.4 x 10"9M at
37°C vs. 1.4 ± 0.2 x 10-9M at 24°C; P<0.05) (Table 4.2) (Figure 4.2a). After
denudation, this leftward shift of the concentration-response curve to ET-1 was still
apparent, but it was only significant at higher concentrations (10~9 and 3xl0~9M;
P<0.05 and P<0.001 respectively), and not for EC50 values (EC50 = 1.0 ± 0.2 x
10"9M at 37°C vs. 6.3 ± 1.3 x 10-10M at 24°C; P=0.09) (Table 4.2) (Figure 4.2b).
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2.4 ± 0.4 x 10-9M
1.4 ±0.2 x 10"9M t
1.0 ± 0.2 x 10"9M *
6.3 ± 1.3 x 10"10M **
Values are mean ± SEM for n = 6 vessels in each group. *P < 0.05 ; **P < 0.01
compared to intact vessel. fP < 0.05 compared to 37°C (unpaired t-test).









Values are mean + SEM for n = 6 vessels in each group. *P < 0.05 ; **P < 0.01






FIGURE 4.1. The effect of endothelial removal on the contractile response to ET-l
in rat mesenteric resistance arteries: concentration-response curves to ET-l (expressed
as % response to PE, 10'5M) at 37°C (Figure 4.1a), intact (•; n=6) and denuded
(O; n=6) and at 24°C (Figure 4.1b), intact (■; n-6) and denuded (□; n-6). All
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FIGURE 4.2. The effect of cooling on the contractile response to ET-l in rat
mesenteric resistance arteries: concentration-response curves to ET-l (expressed as %
response to PE, 10'^M) in intact vessels (Figure 4.2a), at 37°C (0; n=6) and at
24°C (0; n=6) and in denuded vessels (Figure 4.2b), at 37°C (O; n=6) and at 24°C
(O; n=6). All values are mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001
(unpaired t-test).
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In order to further investigate the nature of the endothelium-dependent part of the cold-
induced potentiation of the contractile response to ET-1, the effects of the NO synthase
inhibitor, NG-nitro-L-arginine methyl ester (L-NAME), and the cyclooxygenase
inhibitor, indomethacin, were examined. From Table 4.4, it can be seen that there was
no significant difference between mean resting lumen diameter, % contraction to PE,
and % relaxation to ACh, for the groups at 37°C and those at 24°C. After a 30 min
incubation period, neither L-NAME (10_4M) or indomethacin (10"5M) significantly
changed the resting lumen diameter of the vessels studied (Table 4.4).
TABLE 4.4. Baseline data for vessels studied at 37°C and 24°C, and the effects of
L-NAME or indomethacin on vessel diameter
37°C 24°C
LD 303 ±8 29818
% Contraction to PE 73 + 1 7310
% Relaxation to ACh 96 ± 1 9810
LD before L-NAME 314+16 3081 15
LD after L-NAME 315 ± 17 285 1 17
LD before indomethacin 297 1 22 302 1 17
LD after indomethacin 300 ± 24 3061 18
Resting lumen diameter, LD (flm); phenylephrine, PE (10'^M); acetylcholine, ACh
(10'6M); NG-nitro-L-arginine methyl ester, L-NAME (10'4M); indomethacin (10~5M).
Values are mean + SEMfor n = 11-12 vessels at each temperature (total n = 23/16).
The % relaxation to ACh was reduced by L-NAME at both 37°C (P<0.05) and 24°C
(PcO.OOl), but was not significantly altered by indomethacin at either temperature
(P = 0.51 and P = 0.36, at 37°C and 24°C respectively) (Table 4.5). Interestingly,
L-NAME tended to oroduce a greater degree of reduction of the relaxant response to
ACh during cooling, compared to that at 37°C, although this difference was not
statistically significant (P = 0.13, unpaired r-test; P = 0.26, Wilcoxon rank sum test)
(Table 4.5).
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TABLE 4.5. The effects of L-NAME or indomethacin on relaxant response to ACh
% Relaxation to ACh: 37°C 24° C
before L-NAME 94 ±2 99 ± 1
after L-NAME 37 ± 13 * J J _|_ Q * * *
before indomethacin 95 + 3 97 ± 1
after indomethacin 97 ± 1 96 ± 1
Acetylcholine, ACh (10'6M); NG-nitro-L-arginine methyl ester, L-NAME (10~4M);
indomethacin (10'5M\ Values are mean ±SEMfor n = 5-6 vessels at each temperature
(total n— 23/16). *P < 0.05; ***P < 0.001 (paired t-test).
When combining the control data from this further study (n = 5) with that from the
initial study of the effects of cooling on the contractile response to ET-1 (n = 6), it was
found that the additional experiments did not increase the significance of the cold-
induced leftward shift of the concentration-response curve to ET-1; a 1.8-fold increase
in sensitivity was found with n = 11 (EC50 = 2.0 ± 0.3 x 10~9M at 37°C vs. 1.1 ± 0.2
x 10~9M at 24°C; P<0.05) (Table 4.6), compared to 1.7-fold with n = 6 (see above)
(Figure 4.3a).
L-NAME (10"4M) abolished the cold-induced increase in sensitivity to ET-1 (EC50 =
1.3 ± 0.3 x 10"9M at 37°C vs. 1.3 ± 0.3 x 10"9M at 24°C; P=0.95) (Table 4.6)
(Figure 4.3b). The reason for this can be seen when comparing the response to ET-1
in the presence of L-NAME against the control curve at each temperature (Figures 4.4a
and 4.4b). Whilst L-NAME induced a leftward-shift of the concentration-response
curve to ET-1 at 37°C, no such shift was found at 24°C, thus making the curves
superimposible when put together (Figure 4.3b).
In a similar way to endothelial removal in the initial study (Figure 4.2b), the addition
of indomethacin prevented a cold-induced shift of the concentration-response curve to
ET-1 at lower concentrations, whilst allowing an enhanced sensitivity at higher
concentrations, and indeed, an increased maximal response (Emax = 103 + 1 at 37°C
vs. 111 ± 2 at 24°C; P < 0.01) (Table 4.7).(Figure 4.3c).
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2.0 + 0.3 x 10"9M
1.3 ± 0.3 x 10-9M
2.8 ± 1.0 x 10-9M
1.1 ±0.2 x 10"9M
1.3 ± 0.3 x 10-9M
8.9 + 0.8 x 10"10M
NG-nitro-L-arginine methyl ester, L-NAME (10~4M); indomethacin (10~5M). Values are
mean ± SEMfor n = 5-6 vessels at each temperature (total n = 23/16).
Table 4.7. Emax values for ET-1 concentration-response curves in rat mesenteric
resistance arteries
37°C 24°C
Intact 100+1 102 ± 1
L-NAME 107 + 3 107 ±2
Indomethacin 103 + 1 111+2 **
NG-nitro-L-arginine methyl ester, L-NAME (10~4M); indomethacin (1(L5M). Values are





FIGURE 4.3. The effect of cooling on the contractile response to ET-l in rat
mesenteric resistance arteries: concentration-response curves to ET-l (expressed as %
response to PE, 10'5M) in: intact vessels (Figure 4.3a), at 37°C (0; n=5) and at
24°C (M; n=5); in vessels with L-NAME (10~4M) (Figure 4.3b), at 37°C (O; n=5)
and at 24°C (O; n-6); and in vessels with indomethacin (10'5M) (Figure 4.3c), at
37°C (A; n=6), and at 24°C (A; n=6). All values are mean ± SEM. *P < 0.05;
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FIGURE 4.4. The effect of cooling, L-NAME and indomethacin on the contractile
response to ET-lin rat mesenteric resistance arteries: concentration-response curves to
ET-1 (expressed as °7c response to PE, 10'5M) in vessels: at 37°C (Figure 4.4a),
intact (•; n=5), intact with L-NAME (O; n=5), and intact with indomethacin (A; n=6);
and at 24°C (Figure 4.4b), intact (M; n=5), intact with L-NAME (O; n=6), and
intact with indomethacin (A; n=6). All values are mean ±SEM (for clarity, statistical
significance is not shown - see text).
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4.2.1.2.Human subcutaneous resistance arteries obtained during surgery
Mean resting lumen diameter, % contraction to KC1 and % relaxation to ACh at 37°C
did not differ significantly between each group (Table 4.8), and the age and sex ratio
of the patients in each group were not significantly different (see Table2.1, Chapter 2).
TABLE 4.8. Baseline data for vessels studied at 37°C and 24°C
37°C 24°C
LD
% Contraction to KCl







Resting lumen diameter, LD (pm); potassium chloride, KCl (60mM); acetylcholine,
ACh (10'6M). Values are mean ±SEMfor n = 8 at 37°C and n = 7 at 24°C.
ET-1 produced a concentration-dependent constriction in all vessels. Cooling to 24°C
caused a decrease in sensitivity to ET-1 as seen by a rightward-shift of the
concentration-response curve (Figure 4.5) and an 8-fold increase in the EC50 (6.6 ±
2.5 x 10"10M at 37°C vs. 5.5 ± 2.5 x 10"9M at 24°C; P < 0.05) (Table 4.9). There
was a tendency for the maximal contraction to be higher during cooling, but the
difference was not statistically significant (114 ± 9 at 37°C vs. 138 ± 14 at 24°C;
P = 0.18) (Table 4.9).
1(T12 10 11 10"10 10"9 10"7 10"6
FIGURE 4.5. The effect of cooling on the contractile response to ET-1 in human
subcutaneous resistance arteries: concentration-response curves to ET-1 (expressed as
% response to KCl, 60mM) at 37°C (O; n=8) and 24°C (•; n=7). All values are mean
± SEM. *P < 0.05 (unpaired t-test; ANOVA).
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Table 4.9. EC50 and Emax values for ET-1 concentration-response curves in human




6.6 ±2.5 x 10-10M
114 ±9
5.5 + 2.5 x 10-9M *
138 ± 14
Values are mean ±SEMfor n = 8 at 37°C and n = 7 at 24°C. *P < 0.05 compared to
37°C (unpaired t-test).







Mean arterial pressure (mmHg) 85 - 100 92 + 2 94 ±2
Haemoglobin (g/1) 120- 180 128 ±3 131+3
ESR (mm/hr) 1-9 5+ 1 5+ 1
Urea (mmol/1) 3.3 - 6.6 4.3 ± 0.3 4.2 ± 0.3
Sodium (mmol/1) 135 - 145 140 ± 1 140 ±0
Potassium (mmo/1) 3.5 - 5.0 4.7 ± 0.1 4.7 ± 0.1
Glucose (mmol/1) 3.9 - 5.0 4.6 ± 0.2 4.3 + 0.2
Creatinine (jamoU) 70-110 75 ±4 71 ±2
ESR = erythrocyte sedimentation rate. Values are shown as mean ± sem.
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4.2.1.3. Human subcutaneous resistance arteries from gluteal biopsies
The mean arterial pressure of control subjects and patients with Raynaud's disease
were not significantly different (P=0.48) (Table 4.10). Normal haemoglobin,
erythrocyte sedimentation rate, urea, electrolytes, glucose and creatinine were
confirmed in all volunteers (Table 4.10). The results from the immunological
screening showed antinuclear antibodies (ANA) were present in one control subject
and four Raynaud's patients.
Mean resting lumen diameter, % contraction to KC1 and % relaxation to ACh (for
intact artery studies) did not differ significantly between the control subject group, at
37°C and 24°C, and the Raynaud's patient group, at 37°C and 24°C (Table 4.11).
TABLE 4.11. Baseline data for vessels studied at 37°C and 24°C
Control subjects Raynaud's patients
37°C 24°C 37°C 24°C
LD
% Contraction to KCl













Resting lumen diameter, LD (/am); potassium chloride, KCl (60mM); acetylcholine,
ACh (10'6M). Values are mean +SEMfor n = 12-13 for LD and % contraction to KCl
(total n = 49/34), and n- 6-7for % relaxation to ACh (total = 26/24).
From Figure 4.6a it can be seen that cooling increased the sensitivity to ET-1 in intact
arteries from control subjects (EC50 = 3.7 ± 0.7 x 10"10M at 37°C vs. 1.8 ± 0.3 x
10-10m at 24°C; P<0.05) (Table 4.12). After removal of the endothelium, the
sensitivity to ET-1 was reduced at 24°C compared to 37°C (EC50 = 1.7 ± 0.3 x
10"10M at 37°C vs. 6.0 ± 1.8 x 10-10M at 24°C; P<0.05) (Table 4.12) (Figure 4.6b).
When comparing the effects of endothelial removal at individual temperatures in
control arteries, it was found that denudation enhanced contraction to ET-1 at 37°C
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(EC50 = 3.7 ± 0.7 x 10_10M in intact arteries vs. 1.7 ± 0.3 x 10"10M in denuded
arteries; P<0.05) (Table 4.12) (Figure 4.7a), whilst at 24°C it caused a rightward-shift
of the concentration-response curve to ET-1 (EC50 =1.8 ± 0.3 x 10"10M in intact
arteries vs. 6.0 ± 1.8 x 10"10M; P<0.05) (Table 4.12) (Figure 4.7b). There were no
significant changes in maximal contraction to ET-1 after cooling or denudation of
vessels from control subjects (Table 4.13).
Cooling did not significantly affect the response to ET-1 in either intact (Figure 4.8a)
or denuded vessels obtained from Raynaud's patients (Figure 4.8b) (EC50 = 1.9 ± 0.3
x 10~'°M at 37°C vs. 3.0 ± 0.6 x 10~10M at 24°C in intact arteries; P=0.16; and EC50
= 4.6 ± 1.2 x 10~10M at 37°C vs. 4.3 + 1.0 x 10~10M at 24°C in denuded arteries;
P=0.82) (Table 4.14). Cooling had no effect on the maximum contraction to ET-1 in
arteries from Raynaud's patients (Table 4.15).
Figure 4.9a shows that removal of the endothelium tended to reduce the sensitivity to
ET-1 at 37°C in arteries from patients with Raynaud's disease, although this did not
quite reach significance (EC50 = 1.9 ± 0.3 x 10~10M in intact arteries vs. 4.6 ± 1.2 x
10" 10m in denuded arteries; P=0.05) (Table 4.14). At 24°C there was no significant
difference between intact and denuded arteries (EC50 = 3.0 ± 0.6 x 10"10M in intact
arteries vs. 4.3 ± 1.0 x 10~l°M in denuded arteries; P=0.30) (Table 4.14)
(Figure 4.9b). The maximum contraction to ET-1 did not change significantly after
endothelial removal in vessels from Raynaud's patients (Table 4.15).
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TABLE 4.12. EC50 values for ET-1 concentration-response curves in resistance




3.7 ±0.7 x 10~10M
1.8 + 0.3 x 10"10M t
1.7 ± 0.3 x 10_10M *
6.0+ 1.8 x 10-10M *|
Values are mean ± SEM for n = 6 vessels in each group. *P < 0.05 compared to intact
vessel. fP < 0.05 compared to 37°C (unpaired t-test).
TABLE 4.13. Emax values for ET-1 concentration-response curves in resistance








Values are mean ± SEMfor n = 6 vessels in each group.
TABLE 4.14. EC50 values for ET-1 concentration-response curves in resistance




1.9 ±0.3 x 10"10M
3.0 ± 0.6 x 10"10M
4.6 ± 1.2 x 10-10M
4.3 ± 1.0 x 10-10M
Values are mean ± SEMfor n = 6 vessels in each group.
TABLE 4.15. Emax values for ET-1 concentration-response curves in resistance

















FIGURE 4.6. The effect of cooling on the contractile response to ET-1 in human
subcutaneous resistance arteries from control subjects: concentration-response curves
to ET-1 (expressed as % response to KCl, 60mM) in intact vessels (Figure 4.6a)
and in denuded vessels (Figure 4.6b), at 37°C (O; n-6) and at 24°C (•; n=6). All
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FIGURE 4.7. The effect ofde-endothelialisation on the contractile response to ET-1
in human subcutaneous resistance arteries from control subjects: concentration-
response curves to ET-1 (expressed as % response to KCl, 60mM) in vessels at 37°C
(Figure 4.7a) and at 24°C (Figure 4.7b), in intact vessels (O; n=6) and in





FIGURE 4.8. The effect of cooling on the contractile response to ET-l in human
subcutaneous resistance arteries from Raynaud's patients: concentration-response
curves to ET-l (expressed as % response to KCl, 60mM) in intact vessels (Figure
4.8a) and in denuded vessels (Figure 4.8b), at 37°C (O; n=6) and at 24°C (0;
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FIGURE 4.9. The effect of de-endothelialisation on the contractile response to ET-1
in human subcutaneous resistance arteries from Raynaud's patients: concentration-
response curves to ET-1 (expressed as % response to KCl, 60mM) in vessels at 37°C
(Figure 4.9a) and at 24°C (Figure 4.9b), in intact vessels (O; n=6) and in
denuded vessels (•; n-6). All values are mean +SEM.
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At 37°C, intact vessels from Raynaud's patients had a higher sensitivity to ET-1
compared to those from control subjects (EC50 = 3.7 ± 0.7 x 10"10M for control group
vs. 1.9 ± 0.3 x 10"10M for Raynaud's group; P<0.05) (Table 4.16) (Figure 4.10a) .
At 24°C there was no significant difference between arteries from Raynaud's patients
and controls (EC50 = 1.8 ± 0.3 x 10~10M for control group vs. 3.0 ± 0.6 x 10~10M for
Raynaud's group; P=0.11) (Table 4.16) (Figure 4.10b). The maximal contraction to
ET-1 did not differ significantly between each group at either temperature (At 37°C
Emax = 117 ± 10 for controls vs. 122 ± 4 for Raynaud's (P=0.64); and at 24°C Emax
= 122 ± 5 for controls vs. 124 ± 4 for Raynaud's (P=0.75)) (Table 4.17) .
Denuded vessels from Raynaud's patients had a significantly lower sensitivity to ET-1
compared to those from controls at 37°C (EC50 = 1.7 ± 0.3 x 10"10M for control
group vs. 4.6 ± 1.2 x 10~10M for Raynaud's group; P<0.05) (Table 4.18) (Figure
4.1 la). There was no significant difference between the groups at 24°C (EC50 = 6.0 ±
1.8 x 10"10M for control group vs. 4.3 ± 1.0 x 10~10M for Raynaud's group; P=0.44)
(Table 4.18) (Figure 4.11b). At neither temperature was there any significant
difference in maximal contraction between the two groups (At 37°C Emax = 124 ± 7
for controls vs. 117 ± 9 for Raynaud's; P=0.55; at 24°C Emax = 114 ± 3 for controls
vs. 120 ± 4 for Raynaud's; P=0.27) (Table 4.19) .
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TABLE 4.16. EC50 values for ET-1 concentration-response curves in intact




3.7 ± 0.7 x 10"10M
1.8 ±0.3 x 10"10M
1.9 ± 0.3 x 10~10M *
3.0 ± 0.6 x 10~10M
Values are mean + SEM for n = 6 vessels in each group. *P < 0.05 compared to
control vessel (unpaired t-test).
TABLE 4.17. Emax values for ET-1 concentration-response curves in intact








Values are mean ± SEMfor n = 6 vessels in each group.
TABLE 4.18. EC50 values for ET -1 concentration-response curves in denuded




1.7 ±0.3 x 10-10M
6.0 ± 1.8 x 10"10M
4.6 ± 1.2 x 10"10M *
4.3 ± 1.0 x 10"10M
Values are mean ± SEMfor n = 6 vessels in each group. *P < 0.05 compared to intact
vessel (unpaired t-test).
TABLE 4.19. Emax values for ET-1 concentration-response curves in denuded
resistance arteries from control subjects vs. Raynaud's patients
Control Raynaud's
37°C 124 ±7 117 ± 9
24°C 114 ±3 120 ±4
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FIGURE 4.10. A comparison of the contractile response to ET-1 in subcutaneous
resistance arteries isolated from control subjects and Raynaud's patients:
concentration-response curves to ET-1 (expressed as % response to KCl, 60mM) at
37°C (Figure 4.10a) and at 24°C (Figure 4.10b), in intact vessels from control
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FIGURE 4.11. A comparison of the contractile response to ET-1 in de-
endothelialised resistance arteries from control subjects and Raynaud's patients:
concentration-response curves to ET-1 (expressed as % response to KCl, 60mM) at
37°C (Figure 4.11a) and at 24°C (Figure 4.11b), in denuded vessels from control
subjects (O; n=6) and Raynaud's patients (0; n=6). All values are mean +SEM.
132
4.2.2. The effect of cooling and antagonism of ET receptors on the
response to phenylephrine
4.2.2.1. Rat mesenteric resistance arteries
Mean resting lumen diameter, % contraction to PE and % relaxation to ACh did not
differ significantly between the group at 37°C and the group at 24°C (Table 4.20). The
presence of bosentan (10"6M) had no significant affect on resting lumen diameter
(Table 4.20).
TABLE 4.20. Baseline data for vessels studied at 37°C and 24°C, and the effects of
bosentan on vessel diameter
37°C 24°C
LD (|im) 308 ±8 310 ± 10
% Contraction to PE 73 ± 1 73+ 1
% Relaxation to ACh 94 ±2 95 ±2
LD before bosentan 323 ± 13 323 ± 24
LD after bosentan 323 ± 13 323 ± 24
Resting lumen diameter, LD; phenylephrine, PE (10~5M); acetylcholine, ACh (10~6M).
Values are mean ± SEM for n = 18/18 at 37 C, n= 17/17 at 24°C, and n = 6 for
vessels with bosentan (10'6M) at 37°C and 24°C (total = 12/7).
Figure 4.12 shows the effect of the mixed ETa/b-receptor antagonist, bosentan
(10"6M), against ET-1. There was a rightward-shift of the concentration-response
curve to ET-1, confirming that the same dose used in the PE experiments was
sufficient to antagonise the effects of ET (EC50 values were not calculated because
maximal contraction to ET-1 was not obtained in the presence of bosentan).
In arteries with an intact endothelium, cooling to 24°C caused a 4-fold increase in
sensitivity to PE (EC50 = 5.9 ± 1.0 10"7M at 37°C vs. 1.4 ± 0.2 x 10"7M at 24°C;
P<0.01) (Table 4.21) (Figure 4.13a). After denudation, this leftward-shift of the
concentration-response curve to PE was still apparent (EC50 = 5.7 ±1.0 10~7M at
37°C vs. 2.9 ± 5.0 x 10"7M at 24°C; P=0.05) (Table 4.21) (Figure 4.13b), but was
significantly reduced compared to the intact arteries at 24°C (P<0.05). Similarly, the
presence of bosentan (10"6M) reduced the cold-induced increase in sensitivity such
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FIGURE 4.12. The antagonist action of bosentan on the contractile response to ET-
1 in rat mesenteric resistance arteries: concentration-response curves to ET-1
(expressed as % response to PE, 10'^M) in control vessels (O; n=3) and in vessels













FIGURE 4.13. The effect of cooling on the contractile response to PE in rat
mesenteric resistance arteries: concentration-response curves to PE (expressed as %
response to 'wake-up' PE, 10'^M) in: intact vessels (Figure 4.13a), at 37°C (0;
n=6) and at 24"C (0; n=6); in denuded vessels (Figure 4.13b), at 37°C (O; n=6)
and at 24°C (O; n=6); and in intact vessels with bosentan present (Figure 4.13c), at
37°C (A; n-6) and at 24°C (A; n=6). All values are mean ± SEM. *P<0.05;
**P<0.01; ***P<0.001.
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that the leftward-shift of the concentration-response curve to PE no longer reached
significance (EC50 = 7.6 ± 1.6 10"7M at 37°C vs. 4.9 ± 1.2 x 10"7M at 24°C; P=0.34)
(Table 4.21) (Figure 4.13c).
When combining the above results for each temperature, it was seen that at 37°C
endothelial removal or bosentan (10~6M) had no significant effect on the sensitivity of
arteries to PE, compared to intact control vessels (EC50 = 5.9 ± 1.0 x 10~7M intact vs.
5.7 + 1.0 x 10"7M denuded (P=0.88), and vs. 7.6 ± 1.6 x 10~7M with bosentan
(P=0.39)) (Table 4.21) (Figure 4.14a). However, at 24°C, removal of the
endothelium or addition of bosentan resulted in a 2- (EC50 = 1.4 ± 0.2 x 10~7M intact
vs.2.9 + 5.0 x 10"7M denuded; P<0.05) and 3-(EC5o = 1.4 ± 0.2 x 10"7M intact vs.
4.9 ± 1.2 x 10"7M with bosentan; P<0.05) fold decrease in sensitivity to PE,
respectively, compared to the intact control vessel (Table 4.21) (Figure 4.14b). There
was no significant difference in the Emax for PE between any of the groups studied
(Table 4.22).
TABLE 4.21. EC50 values for PE concentration-response curves in rat mesenteric





5.9 ± 1.0 x 10"7M
5.7+ 1.0 x 10"7M
7.6 ± 1.6 x 10"7M
1.4 ± 0.2 x 10"7M **
2.9 ± 5.0 x 10"7M
4.9+ 1.2 x 10-7M
Bosentan, mixed ETa/ETb receptor antagonist (10'6M). Values are mean ± SEM.
n = number of vessels. **P < 0.01 compared to 37°C (unpaired t-test).
TABLE 4.22. Emax valuesfor PE concentration-response curves in rat mesenteric
resistance arteries at 37°C and 24 °C
37°C 24° C
Intact (n=6-7) 103 ± 1 103 ± 1
Denuded (n=5-6) 106 ±2 107 ±3
Bosentan (n=6) 104 ± 1 101 ±3
Bosentan, mixed ETa/ETb receptor antagonist (10~6M). Values are mean ± SEM.
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FIGURE 4.14. The effect of cooling, removal of the endothelium, and bosentan on
the contractile response to PE in rat mesenteric resistance arteries: concentration-
response curves to PE (expressed as % response to 'wake-up' PE, 10~^M) in vessels:
at 37°C (Figure 4.14a), intact (0; n-6), denuded (O; n-6), and intact with
bosentan (A; n=6); and at 24°C (Figure 4.14b), intact (0; n=6), denuded (O; n=6),
and intact with bosentan present (A; n=6). All values are mean ± SEM (for clarity,
statistical significance is not shown - see text).
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4.2.3. The effect of cooling on the response to potassium chloride
4.2.3.1. Rat mesenteric resistance arteries
Mean resting lumen diameter, % contraction to PE and % relaxation to ACh did not
differ significantly between the group at 37°C and the group at 24°C (Table 4.23). The
presence of combined L-NAME (10"4M) and indomethacin (10~5M) did not cause a
significant change in resting lumen diamete (Table 4.23). The % relaxation to ACh
was not significantly attenuated after the addition of L-NAME and indomethacin (Table
4.24).
TABLE 4.23. Baseline data for vessels studied at 37°C and 24°C, and the effects of
L-NAME/indomethacin on vessel diameter
37°C 24°C
LD 298 ±4 309 ±6
% Contraction to PE 73+ 1 73 ±0
% Relaxation to ACh 98 ± 1 95 ± 1
LD before L-NAME/indo 290 ± 12 310 ± 8
LD after L-NAME/indo 292 ± 12 310 + 8
Resting lumen diameter, LD (flm); phenylephrine, PE (10~5M); acetylcholine, ACh
(10'6M); NG-nitro-L-arginine methyl ester, L-NAME (10~4M); indomethacin, indo
(10~5M). Values are mean ±SEM for n = 18 at 37°C, n = 21 at 24 °C (total n = 39/24)
and n = 6for vessels with L-NAME/indomethacin (total = 12/10).
TABLE 4.24. The effects of L-NAME/indomethacin on relaxant response to ACh







Acetylcholine, ACh (10~6M); NG-nitro-L-arginine methyl ester, L-NAME (10'4M);
indomethacin, indo (10~5M). Values are mean ± SEM for n = 6 vessels at each
temperature (total n = 12/10).
In arteries with an intact endothelium, cooling to 24°C decreased the maximal
contraction to KC1 (Table 4.26), but did not significantly affect the sensitivity (EC50 =
26 ± 2 mM at 37°C vs. 21+2 mM at 24°C; P=0.06) (Table 4.25) (Figure 4.15a).
After denudation, there was no longer a depression of the maximum response to KC1
at 24°C (Table 4.26), and cooling in fact caused a marked leftward-shift of the
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FIGURE 4.15. The effect of cooling on the contractile response to KCl in rat
mesenteric resistance arteries: concentration-response curves to KCl (expressed as %
response to PE, 10'^M) in: intact vessels (Figure 4.15a), at 37°C (•; n=6) and at
24°C (M; n-10); in denuded vessels (Figure 4.15b), at 37°C (O; n=6) and at 24°C
(□; n=5); and in intact vessels with L-NAME (10'4M) and indomethacin (10~5M)
present (Figure 4.15c), at 37°C (A; n=6) and at 24°C (A; n=6). All values are
mean ± SEM. *P<0.05; **P<0.01; ***P<0.001.
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concentration-response curve to KC1 (EC50 = 27+1 mM at 37°C vs. 20 ± 1 mM at
24°C; P<0.01) (Table 4.25) (Figure 4.15b). Similarly, the combination of L-NAME
and indomethacin restored the maximum contractile response to KC1 during cooling
(Table 4.26), and caused a slight leftward-shift of the concentration-response curve,
but only at low concentrations of KC1 (Figure 4.15c). In the presence of L-NAME and
indomethacin there was no significant change to EC50 values during cooling (EC50 =
24 ± 1 mM at 37°C vs. 24 ±1 mM at 24°C; P=0.93) (Table 4.25).
When combining the above results for each temperature, it was seen that at 37°C
removal of the endothelium had no significant effect on the sensitivity of arteries to
KC1, in comparison with intact control vessels (EC50 = 26 ± 2 mM intact vs. 27 ± 1
mM denuded; P=0.50) (Table 4.25) (Figure 4.16a). The concentration-response curve
to KC1 in the presence of L-NAME and indomethacin lay to the left of that for intact
arteries, but the leftward-shift failed to reach significance (EC50 = 26 ± 2 mM intact
vs. 24+1 mM with L-NAME/indomethacin; P=0.45) (Table 4.25). The maximum
contractile response to KC1 was not significantly affected by endothelial removal at
37°C, but L-NAME and indomethacin significantly enhanced the response (Table
4.26). At 24°C, the sensitivity to KC1 was unaffected by removal of the endothelium
(EC50 = 21+2 mM intact vs. 20 + 1 mM denuded; P=0.46) (Table 4.25) or by the
addition of L-NAME and indomethacin (EC50 = 22 ± 2 mM intact vs. 24+1 mM with
L-NAME/indomethacin; P=0.31) (Table 4.25) (Figure 4.16b). Maximal contraction to
KC1 was significantly increased with endothelial removal or addition of L-NAME and
indomethacin (Table 4.26).
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TABLE 4.25. EC50 values for KCl concentration-response curves in rat mesenteric
resistance arteries at 37°C and 24°C
37°C 24°C
Intact (n=6-10) 26 + 2 mM 21 ±2mM
Denuded (n=5-6) 27 ± 1 mM 20 ± 1 mM **
L-NAME/indo (n=6) 24 ± 1 mM 24 ± 1 mM
L-NAME (10'4M) / indomethacin (10'5M). Values are mean + SEM. n = number of
vessels. **P<0.01 compared to 37°C (unpaired t-test).
TABLE 4.26. Emax values for KCl concentration-response curves in rat mesenteric
resistance arteries at 37°C and24°C
37°C 24°C
Intact (n=6-10) 101 ±2 83 ±6 *
Denuded (n=5-6) 104 + 2 107 ± 2 t
L-NAME/indo (n=6) 115 ± 3 ft 114 ± 3 t t
L-NAME (10~4M) / indomethacin (10'^M). Values are mean + SEM. n = number of
vessels. fP<0.05; ffP<0.01 compared to intact vessel for individual temperature
group. *P<0.05 between groups at 37°C and 24°C (unpaired t-test).
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FIGURE 4.16. The effect of cooling, removal of the endothelium, and
L-NAME/indomethacin on the contractile response to KCl in rat mesenteric resistance
arteries: concentration-response curves to KCl (expressed as % response to PE, 10'
5M) in vessels: at 37°C (Figure 4.16a), intact (0; n=6), denuded (O; n=6), and
intact with L-NAME/indomethacin (A; n=6); and at 24°C (Figure 4.16b), intact (0;
n=10), denuded (O; n=5), and intact with L-NAME/indomethacin present (A; n=6).
All values are mean +SEM (for clarity, statistical significance is not shown - see text).
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The results from these studies show that the sensitivity of rat mesenteric resistance
arteries to ET-1 is increased during cooling. This is in part due to altered availability
and/or actions of endothelium-derived relaxing and contracting factors. Enhanced
sensitivity of the vascular smooth muscle to ET-1 also contributes, but this only
occurs at high concentrations of ET-1 (nanomolar range) - with regard to normal
circulating levels of ET, which in healthy humans are in the low picomolar range
(Davenport et al., 1990) this may not appear physiologically relevant, but the
concentrations at the endothelial-smooth muscle interface are likely to be much
higher than those found in the plasma. Further studies using the cyclooxygenase
inhibitor indomethacin revealed that constrictor prostanoids, such as TXA2,
probably account for the endothelium-dependent cold-induced leftward shift of the
concentration response curve to ET-1.
The experiments carried out in de-endothelialised vessels demonstrate that
endothelium-derived dilator substances oppose vasoconstriction to ET-1 at both
37°C and 24°C, as seen by enhanced sensitivity and contraction to ET-1 after
denudation. Depending on the extent to which NO contributes to vasodilator
function in these vessels, one may expect to find a similar increase in the response
to ET-1 if NO synthesis is blocked, as indeed was found at 37°C in the presence of
the NO synthase inhibitor, L-NAME. Interestingly however, L-NAME had no
effect on the response to ET-1 at 24°C, implying that NO is not released during
cooling. Although this could account for the enhanced sensitivity to ET-1 at 24°C in
intact arteries, it is inconsistent with the results found in denuded vessels which
show that endothelium-derived dilator substances oppose ET-1-induced
vasoconstriction. A possible explanation for this finding is that denudation removes
a factor(s) in addition to NO, such as endothelium-derived hyperpolarising factor
(EDHF). Nagao & Vanhoutte (1993) propose that EDHF accounts for a greater
proportion of endothelium-dependent dilatation than NO in small arteries, and
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clearly, in the present study L-NAME was unable to completely block the relaxant
response to acetylcholine (ACh). PGI2 is unlikely to be involved since
indomethacin failed to attenuate the dilator response to ACh. Larger vessels have
been shown to produce more PGI2 than the microvasculature (Maclntyre et al.,
1978), thus PGI2 may have a lesser role in vasodilator function than NO or EDHF
in resistance arteries.
Cooling was found to decrease the sensitivity to ET-1 in intact human resistance
arteries isolated from subcutaneous fat biopsies obtained during surgery. In a similar
study using the rabbit ear artery, Monge et al. (1991) examined the effect of the NO
synthase inhibitor, L-NAME, and also de-endothelialisation, on responses to ET-1 at
37°C and 24°C. Their findings suggest that the decrease in ET-1 sensitivity during
cooling is caused either by an increased availability of NO, which could be due to
increased generation or reduced clearance, or, alternatively, due to increased sensitivity
to NO. An alternative explanation for these results is a decrease in vascular smooth
muscle sensitivity or responsiveness to ET-1 at 24°C.
In the studies using arteries obtained from gluteal fat biopsies, cooling was found to
increase the sensitivity to ET-1 in control subjects. After endothelial removal, the
sensitivity to ET-1 was reduced during cooling, implying that vasoconstrictor factors
are released from the endothelium, which enhances the contraction to ET-1 at 24°C.
This is confirmed when the responses to ET-1 are compared between intact and
denuded vessels at each temperature. At 37°C, removal of the endothelium increased
sensitivity to ET-1, \ hilst at 24°C it decreased the sensitivity. It would appear,
therefore, that the vascular endothelium can modulate the response to ET-1 in different
ways in a temperature-dependent manner; namely by releasing dilator substances
which oppose vasoconstriction at 37°C, and by releasing constrictor substances which
augment vasoconstriction at 24°C. Vasoconstriction in response to moderate cooling is
a physiological phenomenon (Vanhoutte, 1980) and the present results are in accord
143
with this. There are several reasons why the results from the surgical samples are not
in agreement with those from the gluteal biopsy studies. Most importantly is probably
the fact that the sex ratio and the mean age of the patients are different between the two
studies: the majority of surgical patients were male, whilst the biopsy patients were
predominantly female and significantly younger. Sex hormones are known to
influence vascular reactivity (Williams et al. 1988; Yue et al., 1995). When comparing
the results from the two studies in light of the difference in the sex ratios, one may
propose that in men cooling decreases ET-1-mediated contraction, whilst in women,
cooling enhances the response to ET-1. Although very speculative, this suggestion is
certainly compatible with the fact that Raynaud's disease affects predominantly
females. Another reason for the observed difference in the results between the two
studies is that one group comprises patients undergoing gastrointestinal (GI) surgery,
whilst the other comprises healthy volunteers. Although not cardiovascular in origin,
the conditions requiring surgery, and indeed the medication received, may well affect
vascular function in these individuals. In addition, as mentioned in a previous section,
volatile anaesthetics can inhibit endothelium-dependent dilatation (Muldoon et al.,
1988; Stone & Johns, 1989V Different types of anaesthetic (general for GI surgery
versus local for gluteal biopsy) were used in the two samples, and the amount present
in the surgical biopsies would not have been as uniform as that present in the gluteal
biopsies, a factor that may have influenced the results. Furthermore, in the surgical
samples, the time at which the biopsy was taken during the operation may have
affected the results. A recent paper shows that plasma ET levels increase gradually
during surgery, and this phenomenon is dependent on the surgical procedure carried
out (Shirakami et al., 1995). Desensitisation following raised levels of ET-1 may have
contributed to the depressed response to exogenous ET-1 during cooling, since the
time of biopsy was not taken into account in the present study. However, it is unlikely
that only the biopsies studied at 24°C, and not those at 37°C, were taken at the end of
surgery when levels of ET were high.
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In arteries from Raynaud's patients, cooling had no significant effect on responses to
ET-1, either in intact or de-endothelialised vessels. These results indicate that, unlike
control vessels, cooling modulates neither endothelial function or smooth muscle
sensitivity to ET-1 in response to exogenous ET-1 in arteries from Raynaud's patients.
At 37°C, there was a tendency for intact arteries from Raynaud's patients to have a
higher sensitivity to ET-1 compared to denuded vessels, suggesting endothelium-
derived constrictor factors are released. The presence of the endothelium did not
appear to affect the response to ET-1 at 24°C. These results suggest that in Raynaud's
patients the endothelium has a greater modulatory role at 37°C compared to 24°C.
Perhaps then cooling causes the endothelium to malfunction, whereby it can no longer
release constrictor substances. Alternatively, the generation of endothelium-derived
dilator substances may be increased during cooling in arteries from Raynaud's
patients, which would counteract the enhanced constriction (see Chapter 6).
When comparing responses in intact vessels obtained from patients with Raynaud's
disease with those from healthy subjects, it was found that the sensitivity to ET-1 was
higher in Raynaud's patients at 37°C. This difference probably arose from the
combination of the release of endothelium-derived constrictors in arteries from
Raynaud's patients, and dilator release in arteries from control subjects, as discussed
above. Interestingly, at 24°C, no significant difference in responsiveness to ET-1 was
found between Raynaud's patients and controls, in either intact or denuded arteries. If
ET is implicated in the pathogenesis of Raynaud's disease, one would expect to find
either an enhanced response to exogenous ET-1 compared to controls, due to
increased smooth muscle sensitivity, or a depressed response, due to smooth muscle
desensitisation through receptor down-regulation if endogenous ET levels are
increased during cooling in Raynaud's patients. The fact that no significant difference
was found would imply that ET is not a primary candidate in the pathogenesis of
Raynaud's disease.
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From the plasma samples taken from the volunteers, antinuclear antibodies (ANA)
were found to be present in one control subject and four Raynaud's patients. The
presence of such antibodies are associated with the development of connective tissue
disease, and can be present many years before clinical symptoms arise. Only one of
the volunteers presented with a connective tissue disease (Sjogren's syndrome), and
was thus classified as having secondary Raynaud's phenomenon, but primary
Raynaud's disease can precede the onset of rheumatological diseases by many years
(Wollersheim et al., 1989). It is therefore impossible to accurately classify subjects as
either primary or secondary Raynaud's patients. No correlation was found between
the presence of ANA and the response to ET-1 in the vessels obtained from patients
with ANA compared to those without.
The sensitivity to the ai-adrenoceptor agonist, phenylephrine (PE), was increased
during cooling in rat mesenteric resistance arteries with an intact endothelium. On
initial inspection, these findings are in contrast to studies carried out in large arteries
and veins, where cooling augments contractile responses to 0C2- but not a 1-adrenergic
agonists (Flavahan et al., 1985). This may reflect differences between large vessels
and resistance arteries, or differences in the type of blood vessel under study; acute
cooling has been shown to decrease contraction to PE in the canine femoral vein
(Flavahan & Vanhoutte, 1986), whilst having no significant effect on the response in
canine saphenous veins (Flavahan et al., 1985). However, Flavahan & Vanhoutte
(1986) have shown a differential effect of cooling on the response to PE which is
dependent on the length of time for which the vessels are cooled. Prolonged cooling -
for 30 min - was found to potentiate the contractile response to PE in canine saphenous
veins (Flavahan & Vanhoutte, 1986). Since the cooling time in the studies carried out
in this thesis exceeded 30 min, the present results are in agreement with those of
Flavahan & Vanhoutte (1986). The cold-induced increase in sensitivity to PE appeared
to be partly mediated by an endothelium-derived vasoconstrictor in the present study,
probably ET, since denudation or addition of the ETa/b-receptor antagonist, bosentan,
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reduced the increase. In agreement with these findings, Prasad et al. (1991) have
shown that ai-adrenoceptors, but not a2-adrenoceptors, are responsible for mediating
catecholamine-induced release of ET-1 from endothelial cells in culture. In addition,
rapid release of ET-1 from cultured endothelial cells has been demonstrated, perhaps
through de novo synthesis (Kurihara et al., 1989b) or release from secretory stores
(Milner et al., 1990), on a time scale which would fit with the above proposal of
ai-adrenoceptor-mediated stimulation of ET-1 activity. The present results, therefore,
suggest that ET might contribute to the cold-induced potentiation of a-adrenoceptor-
mediated contraction.
The fact that denudation or the presence of bosentan had no effect on the response to
PE at 37°C suggests that PE was not stimulating the release of endothelium-derived
factors at this temperature. It would thus appear that simultaneous cooling and
a i-adrenoceptor activation is required to induce the release of ET in rat mesenteric
resistance arteries. At 24°C, bosentan caused a further rightward shift of the
concentration-response curve to PE than removal of the endothelium. The most likely
reason for this is that in the presence of the ETa/b receptor antagonist, endothelium-
derived dilator substances were still able to oppose vasoconstriction, whereas
denudation removed both constrictor and dilator substances.
Other evidence for the endothelium modulating the response to contractile agents
during cooling comes from the studies using potassium chloride (KC1). In intact rat
mesenteric arteries the contractile response was depressed at 24°C compared to that at
37°C. The depressant effect of cooling on the contractile response of KC1 has been
attributed to a decrease in calcium ion permeability of the vascular smooth muscle cell
membrane (Vanhoutte, 1980). The present results, however, would suggest that this
effect is at least partly mediated by the release of endothelium-derived dilator
substances, probably NO and PGI2, since removal of the endothelium or the presence
of L-NAME/indomethacin abolished the reduction in maximal contraction during
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cooling. The results from the experiments using L-NAME/indomethacin imply that
EDHF is not involved in modulating the response to KC1 during cooling.
In a similar study, cooling to 24°C was found to attenuate the response to KC1 (50mM)
in both rabbit ear and femoral arteries (Monge et al., 1993). However, removal of the
endothelium only augmented the contraction to KC1 during cooling in ear arteries, and
not in femoral arteries. This led Monge and colleagues (1993) to conclude that cooling
possibly facilitates the release of endothelium-derived dilators only in the cutaneous
vasculature. Clearly, the results from the present study do not agree with this finding.
There is a possibility that mesenteric arteries, in some species at least, behave more like
cutaneous vessels than deep, non-cutaneous vessels such as the femoral artery used in
the study by Monge et al. (1993). Cooling has been shown to augment contraction
induced by electrical field stimulation in canine cutaneous veins (Vanhoutte &
Shepherd, 1970), and in mesenteric vessels (Rogers et al., 1965; Vanhoutte & Lorenz,
1970), whilst depressing those responses in the femoral vein (Vanhoutte & Lorenz,
1970). Similar cooling-induced enhancement of sympathetic stimulation has been
demonstrated in rat mesenteric arteries (Malik, 1969). Vanhoutte (1980) suggested that
the mesenteric vasculature may resemble cutaneous vessels because it is exposed to
local variations in temperature during food and water consumption.
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CHAPTER 5:




At present, the physiological mechanisms underlying cold-induced vasoconstriction
are poorly understood. Although there is some evidence for involvement of
adrenoceptors, particularly a2-adrenoceptors, and of nitric oxide (NO), the majority of
studies investigating the effects of temperature on vascular tone have been carried out
using isolated blood vessels, and there has been little work in studies in vivo. There
has been no work, as yet, exploring the role of endothelin (ET) in cold-induced
vasoconstriction using specific receptor antagonists, even though there is evidence to
suggest that ET-1 may play an important role in vasospasm. In the studies presented in
this chapter, potential mediators of cold-induced vasoconstriction were examined in
the autoperfused rat hindlimb model, using a-adrenoceptor antagonists and ET-
receptor antagonists.
5.2. Autoperfused hindlimb of the anaesthetised rat
5.2.1. The role of a-adrenoceptors in mediating cold-induced
vasoconstriction
The effects of the a-adrenoceptor antagonists on the cold-induced rise in hindlimb
perfusion pressure (HLPP) are shown in Figures 5.1 - 5.4. Basal HLPP (mmHg) and
slopes of the temperature-HLPP curves before and after administration of the a-
adrenoceptor antagonists are shown in Table 5.1.
From Figure 5.1 and Table 5.1 it can be seen that the non-selective ai/a2
-adrenoceptor antagonist, phentolamine, significantly attenuated the rise in HLPP
induced by cooling (P < 0.05). The presence of either the ai-adrenoceptor antagonist
prazosin (Figure 5.2, Table 5.1), or the a2-adrenoceptor antagonist yohimbine
(Figure 5.3, Table 5.1) alone, failed to produce such an attenuation (P = 0.84 and
0.54, for prazosin and yohimbine repectively). The combination of prazosin and
yohimbine was unable to mimic the effect of phentolamine (P = 0.30), but was more
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effective in reducing the slope of the temperature-HLPP curve than either antagonist
given alone (Figure 5.4, Table 5.1).
From Table 5.1, it can be seen that prazosin and yohimbine significantly reduced the
basal HLPP (P < 0.01 and 0.01, for prazosin and yohimbine repectively).
5.2.2. The role of endothelin in mediating cold-induced
vasoconstriction
The effects of ET-receptor antagonists on the cold-induced rise in hindlimb perfusion
pressure (HLPP) are shown in Figures 5.5 and 5.6. Basal HLPP (mmHg) and slopes
of the temperature-HLPP curves before and after administration of the ET-receptor
antagonists are shown in Table 5.2.
From Figure 5.5 and Table 5.2 it can be seen that the non-selective ETa/B-receptor
antagonist, bosentan, had no effect on the rise in HLPP induced by cooling (P =
0.29). The presence of the selective ETA-receptor antagonist BQ-123 attenuated the
rise, but this failed to reach significance (P = 0.09) (Figure 5.6, Table 5.2).
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Drug Basal HLPP Slope
Control 92 + 2 16.72 ± 1.67
Phentolamine 83 ±8 10.07 ±1.22 *
Control 120 ±6 17.14 ± 1.48
Prazosin 103 ±5 ** 17.38 + 1.22
Control 110 ± 2 16.63 ± 1.26
Yohimbine 93 ±4 ** 15.89 ± 0.30
Control 119 ± 10 17.76 ± 2.25
Prazosin & Yohimbine 98 + 7 14.65 + 0.97
Table 5.1. Basal HLPP (mmHg) at 37°C and slope of temperature-HLPP curves
before (control) and after antagonist: phentolamine, lOpg/kg; prazosin, lOOpg/kg;
yohimbine, 300pg/kg. All values are mean ± SEM. n=4-6 animals in each group.
*P<0.05, **P<0.01 with respect to control; paired t-test.
Drug Basal HLPP Slope
Control 136 ± 10 18.32 ± 2.75
Bosentan 130 ± 12 21.50 ± 3.39
Control 114 ±9 18.51 ± 1.66
BQ-123 111 +7 13.41 ± 3.48
Table 5.2. Basal HLPP (mmHg) at 37°C and slope of temperature-HLPP curves
before (control) and after antagonist: bosentan, lOOOpg/kg; BQ-123, lOOOpg/kg. All
values are mean ± SEM. n=5 and 6 animals for bosentan and BQ-123 group
respectively.
151
0.02 0.03 0.04 0.05
1/T
Figure 5.1. The effect of phentolamine on the cold-induced rise in hindlimb
perfusion pressure (HLPP): temperature (T)-HLPP curves from 37°C to 21 °C; control
(O) and in the presence ofphentolamine (10/j.gAg) (0). n=5 animals.
Figure 5.2. The effect of prazosin on the cold-induced rise in hindlimb perfusion
pressure (HLPP): temperature (T)-HLPP curves from 37°C to 21 °C; control (O) and
in the presence ofprazosin (lOOpg/kg) (0). n-6 animals.
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Figure 5.3. The effect of yohimbine on the cold-induced rise in hindlimb perfusion
pressure (HLPP): temperature (T)-HLPP curves from 37°C to 21 "C; control (O) and
in the presence ofyohimbine (300/J.gAg) (0). n-6 animals.
Figure 5.4. The effect of combined prazosin and yohimbine on the cold-induced rise
in hindlimb perfusion pressure (HLPP): temperature (T)-HLPP curves from 37°C to
21 °C; control (O) and in the presence of prazosin (lOOpgAg) and yohimbine
(300/J.gAg) (0). n=4 animals.
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Figure 5.5. The effect of bosentan on the cold-induced rise in hindlimb perfusion
pressure (HLPP): temperature (T)-HLPP curves from 37°C to 21 °C; control (O) and
in the presence ofbosentan (1000jlg/kg) (0). n=5 animals.
Figure 5.6. The effect of BQ-123 on the cold-induced rise in hindlimb perfusion
pressure (HLPP): temperature (T)-HLPP curves from 37°C to 21 °C; control (O) and
in the presence ofBQ-123 (lOOOpg/kg) (0). n=6 animals.
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5.3. Discussion
The effect of phentolamine suggested a role for a-adrenoceptors in mediating the cold-
induced vasoconstriction in the rat hindlimb. However, the selective aj-antagonist,
prazosin, and the selective ot2-antagonist, yohimbine, failed to attenuate the cold-
induced vasoconstriction. From the literature, a2-adrenoceptor-mediated
vasoconstriction has been shown to be augmented by cooling (Flavahan et al., 1985;
Ekenvall et al., 1988). One may therefore expect a2-adrenoceptors to be partly
responsible for the cold-induced vasoconstriction in the present hindlimb model.
Perhaps the lack of effect of yohimbine was due to an enhanced ai-adrenoceptor-
mediated constriction, resulting from the blockade of 0C2-adrenoceptors located
prejunctionally on nerve terminals (Illes & Norenberg, 1987) and on endothelial cells
(Angus et al., 1986), which inhibit noradrenaline release and mediate the release of
endothelium-derived dilator substances, respectively. Thus, to eliminate the possibility
that a simultaneous blockade of both a-adrenoceptors is required to mimic the effect of
phentolamine, the effect of combining prazosin and yohimbine was studied. This
combination was, however, unable to reproduce the effect of phentolamine, indicating
that the action of phentolamine may not involve a-adrenoceptors. Phentolamine has
also been reported to block ATP-sensitive K+-channels (McPherson & Angus, 1989;
Schwietert et al., 1992), but this action would seem unlikely in the present study,
since closure of such channels would favour increased vasoconstriction, which is the
opposite of the effect it produced in the hindlimb. Another reported action of
phentolamine is antagonism at 5-hydroxytrptamine (5-HT) receptors (Carroll et al.,
1977; Limberger et al., 1989). Since 5-HT has been implicated in cold-induced
vasoconstriction (Seibold, 1985) it is possible that the present results using
phentolamine were due to blockade of 5-HT2 receptors. This could be investigated by
performing similar experiments in the presence of the 5-HT2 receptor antagonist
ketanserin.
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It is perhaps worth noting that the basal HLPP was significantly reduced in the
presence of prasozin and yohimbine, and had a tendency to be reduced when prasozin
and yohimbine were given in combination. To eliminate the possibility that the level of
basal vascular tone had influenced the effectiveness of the selective a\- and
(^-adrenoceptor antagonists, the studies could be repeated in the presence of a
vasoconstrictor which does not act on adrenoceptors, such as the thromboxane A2
mimetic U46619, which would counteract any fall in HLPP induced by prazosin or
yohimbine.
There would appear to be a role for endothelin (ET) in mediating cold-induced
vasoconstriction, perhaps through the ETa receptor, because there was a tendency for
the selective ETa receptor antagonist, BQ-123, to reduce the rise in hindlimb perfusion
pressure during cooling, although this did not quite achieve statistical significance
CP=0.09). Bolus administration of ET-1 has been shown to produce a marked increase
in hindquarters blood flow in the rat (Gardiner et al., 1989; Wright & Fozard, 1988).
During the pressor phase, or during intravenous infusion where there was no initial
fall in blood pressure, no change in hindquarters blood flow occurred, although there
were marked decreases in blood flow to other vascular beds. Thus, ET may be more
effective in activating vasodilator mechanisms in the hindquarter bed, perhaps due to a
higher density of dilator ETg receptors present on endothelial cells or a reduced
number of constrictor vascular smooth muscle ETa/b receptors, compared to other
vascular beds. This may explain why the effect of BQ-123 failed to reach significance
in the present study; the hindlimb might not be a sensitive model for investigating ETa
receptors. Also, studies using the endothelin-converting enzyme (ECE) inhibitor,
phosphoramidon, led Gardiner et al. (1991) to suggest that ECE activity may be lower
in the rat hindquarters compared to other vascular beds. Hence, any cold-induced
stimulation of ET production may not be as apparent in the present model as it might
be in other vascular beds. An additional confounding factor is the presence of heparin
in the circulating blood, which is administered in the hindlimb model to prevent
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coagulation. Heparin has been shown to inhibit ET-1 generation in cultured endothelial
cells, probably through the action of nitric oxide (NO) (Yokokawa et al., 1993). For
this reason, the experiments using BQ-123 could be repeated in the absence of
heparin.
Bosentan, the non-selective ETA/B-receptor antagonist, had no effect on cold-induced
vasoconstriction. This probably reflects the additive effect of blocking smooth muscle
ETa receptors, which would favour a decrease in cold-induced vasoconstriction as
seen with BQ-123, and blocking endothelial ETg receptors, which would favour an
increase in cold-induced vasoconstriction.
Further studies, using selective inhibitors of the nitric oxide and prostacyclin
pathways, could be performed in order to investigate the role of endothelium-derived
vasodilators in cold-induced vasoconstriction in vivo-, if dilator function is increased
during cooling, one would expect to find an enhanced vasoconstriction induced by
cooling in the presence of such inhibitors.
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CHAPTER 6:




Several studies involving the use of blood vessels from animals have revealed that
cooling can potentiate the release and/or response to nitric oxide (NO). In experiments
using rat aortic strips, Karaki & Nagase (1987) demonstrated that lowering the bath
temperature from 37°C to 33°C increased relaxation to the endothelium-dependent and
-independent vasodilators, carbachol and sodium nitroprusside (SNP), respectively.
Since the response to both dilators was similarly enhanced, it appears that the vascular
smooth muscle sensitivity to NO is augmented during cooling. Monge et al. (1991)
examined the effect of NG-nitro-L-arginine methyl ester (L-NAME), an inhibitor of
NO synthase, and also de-endothelialisation on the responses to endothelin-1 (ET-1) at
37°C and 24°C. Their findings suggest that the decrease in sensitivity to ET-1 found
during cooling is caused either by an increased availability of NO, which could be due
to increased generation or reduced clearance or, alternatively, by increased sensitivity
to NO.
If this increase in NO-mediated responses during cooling is absent in the vascular
endothelium of patients with Raynaud's disease, possibly through injury to the
endothelial cells, increased production and enhanced constriction to ET-1 could cause
vasospasm. Evidence that the endothelium may be injured in Raynaud's disease comes
from studies showing that factor VIII and von Willebrand factor antigen levels are
raised in Raynaud's patients (Kahaleh et al., 1981), and higher levels are associated
with greater severity of the disease (Lau et al., 1991).
The studies presented in this chapter examined the relaxant responses to the
endothelium-dependent vasodilator, acetylcholine (ACh), and the endothelium-
independent vasodilator, SNP, in resistance arteries obtained from (i) rat mesentery
and (ii) gluteal fat biopsies taken from control subjects and patients with Raynaud's
disease. It has been shown that the response to exogenous nitrovasodilators is
potentiated when endogenous endothelium-dependent dilatation is depressed, possibly
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due to hypersensitivity of the soluble guanylate cyclase enzyme in smooth muscle cells
(Shirasaki & Su, 1985; Moncada et al., 1991). In order to prevent such a modulating
effect of the endothelium in the present study, vessels were de-endothelialised prior to
generating concentration-relaxation curves to SNP. Any effect of temperature on the
response to SNP would therefore be the result of a change in smooth muscle
sensitivity to NO. In addition, the effect of cooling on the vasorelaxation to the
endothelium-dependent and -independent vasodilators was investigated. This is an
important factor which, until now, has not been addressed in patients with Raynaud's
disease.
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6.2. Small vessel arteriograph (perfusion myograph)
6.2.1. The effect of cooling on the relaxation to acetylcholine
6.2.1.1. Rat mesenteric resistance arteries
Mean resting lumen diameter, % contraction to phenylephrine (PE) and % relaxation to
ACh did not differ significantly between the group at 37°C and the group at 24°C (see
Table 6.1).
TABLE 6.1. Baseline data for vessels studied at 37°C and 24°C
37°C 24°C
LD (pm)
% Contraction to PE







LD, resting lumen diameter; PE, phenylephrine (10'5M); ACh, acetylcholine (10'6M).
Values are mean ±SEMfor n = 6 vessels at each temperature (total n = 12/12).
Cooling to 24°C caused a small rightward shift of the concentration-relaxation curve to
ACh (Figure 6.1), but this failed to reach statistical significance (EC50 = 1.2 ± 0.3 x
10"7M at 37°C vs. 1.8 ± 0.6 x 10"7M at 24°C; P=0.36). The Emax for ACh at 24°C




Figure 6.1. The effect of cooling on the relaxant response to ACh in rat mesenteric
resistance arteries preconstricted with PE (10~5M): concentration-relaxation curves to
ACh (expressed as % relaxation towards resting lumen diameter (LD)) at 37°C (O;
n=6) and at 24°C (•; n=6). All values are mean ±SEM. *P < 0.05 (unpaired t-test).
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6.2.1.2. Human resistance arteries from gluteal biopsies
Mean resting lumen diameter, % contraction to KC1 and % relaxation to ACh did not
differ significantly between the control subject group, at 37°C and 24°C, and the
Raynaud's patient group at 37°C and 24°C (see Table 4.11, Chapter 4).
In arteries obtained from control subjects, there was no significant effect of cooling on
the concentration-relaxation curve to ACh, although there was a trend of a rightward-
shift and a decrease in the maximal relaxation (Figure 6.2a), (EC50 = 7.8 ± 2.8 x
10-8M at 37°C vs. 1.4 ± 0.4 x 10"7M at 24°C; P=0.29. Emax = 88 ± 4 at 37°C and
74 + 9 at 24°C; P=0.21). (Tables 6.2 & 6.3). Figure 6.2b shows the effect of cooling
on the relaxant response to ACh in vessels from Raynaud's patients. There was no
significant change in sensitivity to ACh during cooling (EC50 = 8.4 ± 5.6 x 10"8M at
37°C vs. 1.7 ± 0.9 x 10~7M at 24°C; P=0.42) (Table 6.2), but there was a marked
enhancement in the maximal relaxation attainable at 24°C (Emax = 44 ± 14 at 37°C and
86 ± 3 at 24°C; P=0.01) (Table 6.3).
When comparing the relaxant responses to ACh between arteries from control subjects
and those from Raynaud's patients, the maximal relaxation was found to be
significantly depressed in Raynaud's patients at 37°C (Emax = 88 ± 4 for controls vs.
44 ± 14 for Raynaud's patients; P<0.01) (Table 6.3) (Figure 6.3a). There was no
significant difference in sensitivity to ACh between the groups (EC50 = 7.8 ± 2.8 x
10"8M for controls vs. 8.4 ± 5.6 x 10"8M for Raynaud's patients; P=0.93) (Table
6.2), although there was a rightward-shift of the concentration-relaxation curve in the
Raynaud's group (Figure 6.3a). Interestingly, at 24°C the sensitivity and maximal
relaxation to ACh were not significantly different between controls and Raynaud's
patients; indeed, there was a tendency for the relaxation in vessels from Raynaud's
patients to be greater than that found in vessels from control subjects (EC50 = 1.4 ±
0.4 x 10"7M for controls vs. 1.7 ± 0.9 x 10"7M for Raynaud's patients; P=0.73. Emax
= 74 ± 9 for controls vs. 86 ± 3 for Raynaud's patients; P=0.24) (Tables 6.2 & 6.3)
(Figure 6.3b).
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TABLE 6.2. EC50 values for ACh concentration-relaxation curves in human
resistance arteries obtainedfrom gluteal biopsies
Control Raynaud's
37°C 7.8 ±2.8 x 10-8M 8.4 ± 5.6 x 10"8M
24°C 1.4 +0.4 x 10"7M 1.7 ±0.9 x 10"7M
Values are mean ± SEMfor n = 6 vessels in each group.
TABLE 6.3. Emax values for ACh concentration-relaxation curves in human
resistance arteries obtainedfrom gluteal biopsies
Control Raynaud's
37°C 88 ±4 44 ± 14 11
24°C 74 ± 9 86 ±3 *
Values are mean ±SEMfor n = 6 vessels in each group. *P < 0.05 compared to 37°C;











Figure 6.2. The effect of cooling on the relaxant response to ACh in human
subcutaneous resistance arteries preconstricted with NA (10'5M): concentration-
relaxation curves to ACh (expressed as % relaxation towards resting lumen diameter
(LD)) in vessels from control subjects (Figure 6.2a) and Raynaud's patients
(Figure 6.2b) at 37°C (O; n=6) and at 24°C (•; n=6). All values are mean ± SEM.
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Figure 6.3. A comparison between the relaxant response to ACh in subcutaneous
resistance arteries isolatedfrom Raynaud's patients and control subjects preconstricted
with NA (10'5M): concentration-relaxation curves to ACh (expressed as % relaxation
towards resting lumen diameter (LD)) at 37°C (Figure 6.3a) and at 24°C (Figure
6.3b) in vessels from control subjects (O; n=6) and Raynaud's patients (0; n=6). All
values are mean +SEM. *P<0.05 (unpaired t-test; ANOVA).
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6.2.2.The effect of cooling on relaxation induced by sodium nitroprusside
6.2.2.1. Rat mesenteric resistance arteries
Mean resting lumen diameter and % contraction to PE did not differ significantly
between the group at 37°C and the group at 24°C, but there was a significant
difference in % relaxation to ACh between the groups (Table 6.4).
TABLE 6.4. Baseline data for vessels studied at 37°C and 24°C
37°C 24°C
LD (pm)
% Contraction to PE






93 + 2 *
LD, resting lumen diameter; PE, phenylephrine (10~5M); ACh, acetylcholine (10~6M).
Values are mean ± SEM for n = 6 vessels at each temperature (total n = 12/12).
*P < 0.05 (unpaired t-test).
Cooling to 24°C tended to cause a small rightward shift of the concentration-relaxation
curve to SNP (Figure 6.4), but this did not reach statistical significance (EC50 = 6.2 ±
3.9 x 10"8M at 37°C vs. 6.2 ±1.4 x 10"8M at 24°C; P=0.99). The Emax for SNP at





Figure 6.4. The effect of cooling on the relaxant response to SNP in rat mesenteric
resistance arteries preconstricted with PE (10~5M): concentration-response curves to
SNP (expressed as % relaxation towards resting lumen diameter (LD)) at 37°C (O;
n=6) and at 24 °C (•; n=6). All values are mean ± SEM. *P < 0.05 (unpaired t-test).
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6.2.2.2. Human subcutaneous resistance arteries from gluteal biopsies
Mean resting lumen diameter, % contraction to KC1 and % relaxation to ACh did not
differ significantly between the control subject group, at 37°C and 24°C, and the
Raynaud's patient group, at 37°C and 24°C (see Table 4.11, Chapter 4).
In vessels from control subjects, cooling decreased the sensitivity to SNP, as seen by
a rightward shift of the concentration-relaxation curve (EC50 = 1.8 ± 0.5 x 10"7M at
37°C vs. 2.1 ± 0.7 x 10"6M at 24°C; P=0.01) (Table 6.5) (Figure 6.5a). The
difference in maximal relaxation was not statistically significant (Emax = 92 ± 15 at
37°C vs. 80 ± 5 at 24°C; P=0.45) (Table 6.6). Cooling did not significantly reduce
sensitivity or maximal relaxation to SNP in arteries obtained from Raynaud's patients,
but there was a tendency for both to be reduced at 24°C (EC50 = 3.0 ± 1.8 x 10~6M at
37°C vs. 1.6 ± 1.1 x 10"5M at 24°C; P=0.29. Emax = 73 ± 9 at 37°C vs. 67 ± 9 at
24°C; P=0.65) (Tables 6.5 & 6.6) (Figure 6.5b).
Although there were no significant differences in the relaxation to SNP between
arteries from Raynaud's patients and those from controls, at 37°C the concentration-
relaxation curve generated in Raynaud's vessels lay to the right of the curve from
control subjects (EC50 = 1.8 ± 0.5 x 10"7M for controls vs. 3.0 ± 1.8 x 10~6M for
Raynaud's patients; P=0.14) (Table 6.5) (Figure 6.6a). Also, there was a tendency for
the maximal relaxation to SNP to be reduced in vessels from Raynaud's patients
compared to that in controls (Emax = 92 ± 15 for controls vs. 73 ± 9 for Raynaud's
patients; P=0.30 at 37°C.Emax = 80 ± 5 for controls vs. 67 ± 9 for Raynaud's
patients; P=0 °8 at 24°C) (Table 6.6) (Figures 6.6a and 6.6b).
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TABLE 6.5. EC50 values for SNP concentration-relaxation curves in human
resistance arteries obtainedfrom gluteal biopsies
Control Raynaud's
37°C 1.8 ±0.5 x 10"7M 3.0 ± 1.8 x 10"6M
24°C 2.1 ±0.7X 10"6M * 1.6+ 1.1 x 10"5M
Values are mean ± SEMfor n = 6 vessels in each group. *P < 0.05 compared to 37°C
(unpaired t-test).
TABLE 6.6. Emax values for SNP concentration-relaxation curves in human
resistance arteries obtainedfrom gluteal biopsies
Control Raynaud's
37°C 92 ± 15 73 + 9
24°C 80 ±5 67 ±9





Figure 6.5. The effect of cooling on the relaxant response to SNP in human
subcutaneous resistance arteries preconstricted with NA (10'5M): concentration-
relaxation curves to SNP (expressed as % relaxation towards resting lumen diameter
(LD)) in vessels from control subjects (Figure 6.5a) and Raynaud's patients
(Figure 6.5b) at 37°C (O; n=6) and at 24°C (•; n=6). All values are mean ± SEM.























Figure 6.6. A comparison between the relaxant response to SNP in subcutaneous
resistance arteries isolatedfrom Raynaud's patients and control subjects preconstricted
with NA (10~5M): concentration-relaxation curves to SNP (expressed as % relaxation
towards resting lumen diameter (LD)) at 37°C (Figure 6.6a) and at 24°C (Figure
6.6b) in vessels from control subjects (O; n-6) and Raynaud's patients (•; n=6). All
values are mean ± SEM.
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6.1.4. Discussion
The results from the studies in rat mesenteric resistance arteries showed there was no
significant effect of cooling on the dilator response to the endothelium-dependent
vasodilator, acetylcholine (ACh). However, a more marked effect was seen using
subcutaneous vessels taken from control subjects, in which cooling appeared to
depress the activity of endothelium-derived dilator substances. Perhaps the difference
between the human and rat data reflect species differences or differences between
cutaneous arteries and deep arteries; because of the constant changes in their
physiological environment, cutaneous vessels may adapt in order to function optimally
during changes in temperature. Responses to temperature changes may therefore be
more pronounced in cutaneous vessels than in deep vessels. Evidence to support such
an adaptation in the cutaneous vasculature comes from a study where the potentiating
effect of cooling on the responsiveness of rabbit ear arteries was shown to be more
pronounced in animals which were housed at 5°C, than those kept at 20°C
(McClelland etal., 1969).
The fact that cooling tended to attenuate the relaxant response to ACh in control
subjects implies that there may be inhibition at some point in the production and/or
release of nitric oxide (NO), prostacyclin (PGI2) and/or endothelium-derived
hyperpolarising factor (EDHF) at 24°C. Studies using fetal cotyledons from sheep
have shown that prostaglandin H synthase (PGHS) activity is maximal near the
normal body temperature of sheep - 39°C - and cooling markedly reduces enzyme
activity (Wimsatt et al., 1995). Since prostaglandin H2 (PGH2) is the common
precursor of the prostanoids, these findings provide support for a cold-induced
reduction in PGI2 production. There is, to date, no information available regarding the
effect of temperature on NO synthase (NOS) activity.
The fact that the relaxant response to SNP in arteries from control subjects was
attenuated during cooling suggests that the responsiveness of the vascular smooth
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muscle to NO may itself be reduced. Possible mechanisms for a cold-induced decrease
in smooth muscle sensitivity to NO are: (1) a reduction in activity of soluble guanylate
cyclase (sGC); (2) a decrease in cGMP levels via an enhanced activity of cGMP
phosphodiesterase; or (3) a reduced sensitivity of the cGMP-dependent mechanisms
responsible for relaxation. However, a recent study demonstrated that plasma levels of
cGMP increased during cold exposure in healthy female controls but not in women
with Raynaud's disease (Leppert et al., 1995), implying that sGC activity is not
depressed during cooling in control subjects. The second possibility would appear
unlikely because cyclic nucleotide phosphodiesterases have been found to be
insensitive to temperature (Amer & Kreighbaum, 1975). To further investigate the
third possibility, studies could be carried out using 8-bromo cGMP, a membrane-
permeable cGMP derivative, to activate cGMP-dependent protein kinases directly. A
confounding factor in the observation that cooling depresses the response to SNP in
control arteries is the ability of SNP to generate NO varies depending on the
experimental conditions; cooling has been shown to decrease the amount of NO
released from SNP (Feelisch & Noack, 1987). It is therefore difficult to determine
whether the depressed response to SNP at 24°C was due to a change in smooth
muscle sensitivity to NO or to a reduction in the release of NO.
The relaxant response to SNP in rat mesenteric resistance arteries was not significantly
attenuated at 24°C compared to 37°C, but there was a trend for reduced dilatation
during cooling. Perhaps statistical significance was unable to be achieved because the
number of vessels studied was too low. Also, the group at 24°C displayed less
relaxation to ACh before endothelial removal; this may have given rise to a potentiation
of endothelium-independent dilatation (Moncada et al., 1991), which would oppose
any rightward-shift of the concentration-relaxation curve induced by cooling. In
addition, as mentioned earlier, the difference between the rat and human results may
reflect an adaptation to cooling in the cutaneous vasculature, although species
differences cannot be excluded.
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In arteries obtained from Raynaud's patients, ACh-induced vasodilatation was found
to be significantly enhanced at 24°C compared to the response at 37°C. The fact that
the relaxation to SNP was similar at both temperatures suggests that smooth muscle
sensitivity to NO is not temperature-dependent in Raynaud's patients. This implies that
the production and/or release of endothelium-dependent dilator substances are
enhanced in arteries from Raynaud's patients at 24°C, or alternatively, that they are
depressed at 37°C.
When comparing the relaxant responses between arteries from control subjects and
Raynaud's patients it was found that endothelium-dependent relaxation was impaired
at 37°C in Raynaud's vessels, implying that there is a dysfunction of the endothelium
in Raynaud's disease. Unexpectedly however, no such impairment was found during
cooling; the response to ACh at 24°C was similar to that found in vessels from control
subjects. This suggests, therefore, that endothelium-dependent dilator activity is
depressed at 37°C, but is normal at 24°C. Possible mechanisms for a decrease in
dilator release include: (1) reduced activities of NO synthase (NOS) and/or PGI2
synthase; (2) increased levels of endogenous NOS inhibitors, such as asymmetric
dimethyl-L-arginine (ADMA) and NG-monomethyl-L-arginine (L-NMMA); (3)
reduced diffusibility of NO through altered permeability of cell membranes; (4) and
augmented breakdown of NO by increased levels of superoxide anions. Each of these
possibilities could be investigated as follows: (1) using radioimmunoassays to
measure the enzymatic conversion of radiolabeled substrates in cultured endothelial
cells; (2) measuring plasma levels of ADMA and L-NMMA by radioimmunoassay; (3)
by exposing one side of a chamber divided by a lipid bilayer to NO and measuring the
concentration of gas that has diffused through the membrane to the other side; and (4)
carrying out experiments in the presence of the superoxide anion scavenger,
superoxide dismutase (SOD). Perhaps during cooling there is a temperature-dependent
improvement in the above mechanisms because no impairment of the response to ACh
was found at 24°C. In the context of cold-induced vasospasm, however, this would
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not appear to make sense. In the present findings it should be remembered that it was
the agonist-stimulated generation of endothelium-dependent vasodilators that was
examined, which need not necessarily reflect basal production in vivo. It is possible
that during cooling production of endogenous NO is reduced to such a degree that
there is up-regulation of the stimulated NO pathway. Because the responses to SNP
were not similarly potentiated, it would appear that the up-regulation occurs at a site
proximal to smooth muscle. NO has been shown to inhibit its own synthesis through a
negative feedback mechanism on NOS (Assreuy et al., 1993). It is possible, therefore,
that during cooling a reduction in NO generation, through decreased NOS activity for
example, would reduce negative feedback. A recent study showed that plasma cGMP
levels did not rise in Raynaud's patients after cold-exposure, whilst those in control
subjects were found to increase markedly (Leppert et al., 1995), supporting the theory
of a decreased production of endogenous NO during cooling. NOS activity may be
decreased by a cold-induced conformational change or a reduction in calcium ion
(Ca2+) mobilisation from intracellular stores. The initial cold-induced decrease in NOS
activity would be compensated for by an enhanced stimulation through ACh-
muscarinic receptor binding. There is evidence to suggest that cooling increases the
affinity of a wide range of agonists for their receptors. This may reflect changes in the
fluidity of the cell membrane which reveal binding sites more easily on the receptor
surface (Vanhoutte, 1980). In addition, increased formation of high affinity receptor-
G-protein complexes, which are sensitive to temperature, have been shown to occur
for a number of receptor types, including muscarinic (Aronstam & Narayanan, 1988),
0t2-adrenergic (Gantzos & Neubig, 1988), and calcitonin gene-related peptide (CGRP)
receptors (van Rossum et al., 1993). Studies using canine saphenous arteries and
veins support such an increase in the affinity of muscarinic receptors during cooling,
since both the constrictor (Vanhoutte & Shepherd, 1970) and dilator response (Soares
de Moura & Vanhoutte, 1988) to ACh was found to be augmented by cooling.
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Similarly at 37°C, but not at 24°C, endothelium-independent relaxation had a tendency
to be reduced in arteries from Raynaud's patients compared to those from healthy
controls. One might have expected to find an augmented response to SNP at 37°C in
Raynaud's vessels if, as the ACh data would suggest, NO production is impaired
owing to hypersensitivity of the vasular smooth muscle to exogenous NO (Shirasaki
& Su, 1985; Moncada et al., 1991). Perhaps then the response to ACh is not
indicative of NO production, but instead reflects the generation of additional
vasodilators, such as PGI2 and EDHF, which have been shown to account for a
greater proportion of relaxation than NO in the microvasculature (Nagao & Vanhoutte,
1993).
The results obtained using arteries from Raynaud's patients at 37°C are similar to
those which have been reported in other conditions associated with vasospasm.
Impaired relaxation to endothelium-dependent and -independent dilator substances was
found in canine cerebral arteries following subarachnoid haemorrhage, despite a
normal release of NO (Kim et al., 1988; 1989). These arteries were subsequently
shown to have a reduced activity of sGC (Kim et al., 1992). This may also account
for the depressed relaxation found in vessels from Raynaud's patients.
Since work began on this thesis, three clinical studies have examined dilator function
in Raynaud's disease. The first of these compared the responsiveness of dorsal hand-
veins to the endothelium-dependent vasodilator, bradykinin, and the endothelium-
independent vasodilator, SNP, between Raynaud's patients and control subjects
(Bedarida et al., 1993). The results showed that endothelium-dependent venodilatation
was impaired in patients with Raynaud's disease, whilst smooth muscle
responsiveness to NO was similar in both groups. In a similar study, this time
examining digital artery responses to acetylcholine (ACh), an endothelium-dependent
vasodilator, and glyceryl trinitrate (GTN), an endothelium-independent vasodilator,
Raynaud's patients were found to have a depressed dilator response to ACh compared
173
to controls (Singh et al., 1995), again implying impaired vasodilatation exists in
Raynaud's disease. In addition, dilatation to GTN was enhanced in subjects with
Raynaud's, compared to controls. This finding supports the hypothesis of diminished
NO-activity in Raynaud's disease, because, as mentioned earlier, it has been reported
that the response to exogenous nitrovasodilators is potentiated after removal of NO-
mediated vasodilator tone (Shirasaki & Su, 1985; Moncada et al., 1991). The third
study measured fingertip and forearm blood flow responses to brachial artery
infusions of SNP and the endothelium-dependent vasodilator, methacholine (MCh)
(Khan & Coffman, 1994). Interestingly, an enhanced response to MCh was found in
Raynaud's patients compared to control subjects. No difference in the responses to
SNP was shown. The authors were unable to suggest a mechanism responsible for
these findings.
None of the above studies examined the relaxant response of the vasodilators during
cooling. The results from the studies by Bedarida et al. (1993) and Singh et al. (1995)
concerning endothelium-dependent dilatation are in agreement with the present data
(Table 6.7), in that the cutaneous resistance arteries of patients with Raynaud's disease
show impaired responsiveness to ACh at 37°C. Although the response to SNP was
attenuated in vessels from Raynaud's patients compared to controls, the results were
not statistically significant, and are comparable to those reported by Bedarida et al.
(1993), who also found a non-significant decrease in the maximal dilatation. Singh
and colleagues (1995) examined the relaxant response to a single dose of glyceryl
trinitrate (GTN), so it is difficult to compare the present results with that study, but a
diminished response to agonist-stimulated vasodilatation may reflect a diminished
generation of dilator substances other than NO, in which case one would not expect to
find a difference in smooth muscle responsiveness to NO.
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TABLE 6.7. A comparison of the in vitro results presented in this thesis with
published in vivo studies examining vasodilator responses in Raynaud's disease
Endothelium - dependent Endothelium - independent
Agonist used RD vs. control Agonist used RD vs. control
Bedarida et al., 1993 BK i SNP -
Khan & Coffman,
1994
MCh T SNP -
Singh et al., 1995 ACh I GTN T
Smith - Chapter 6 ACh i SNP -
Bradykinin, BK; methacholine, MCh; acetylcholine, ACh; sodium nitroprusside,
SNP; glyceryl trinitrate, GTN. J, / T represent impaired/enhanced responses in
Raynaud's patients compared to control subjects; - represents no significant difference
of the responses between the two groups.
Although conflicting, the results from the study by Khan & Coffman (1994) can
perhaps be explained by the endothelium-dependent dilator used. Chowienczyk and
colleagues (1993) have shown that the vasodilator response to MCh is unaffected by
inhibitors of NOS, implying that MCh elicits dilatation through an NO-independent
mechanism, which may account; for the results from the study by Khan & Coffman
(1994). In addition, a variability in the temperature of the subjects' vasculature may be
responsible. It is unlikely that the blood vessels of the arm experience a temperature of
37°C; Bazett et al. (1948) demonstrated temperatures as low as 21.5°C for the radial
and 31.1°C for the brachial artery in subjects who had thermocouples inserted into
vessels in their arm. Therefore, the increased responsiveness to MCh may reflect an
enhanced response to muscarinic receptor stimulation at temperatures below 37°C,
possibly through increased receptor affinity which, as discussed earlier, has been
shown to occur during cooling (Aronstam & Narayanan, 1988). When studying
vascular responses in vivo, it is important to take into account possible temperature
differences in the vasculature between subjects. Despite maintaining a constant room
temperature, skin temperatures can vary significantly; Walmsley and Goodfield (1990)
found that the Raynaud's patients in their study had a lower skin temperature
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compared to controls. Perhaps the vessels under study in the patients used in the study
by Khan & Coffman (1994) were at a lower temperature than those from the other two
studies. This discussion raises some questions as to whether 37°C is an appropriate
temperature to use in isolated vessel studies (see Chapter 7).
In the study by Bedarida et al. (1993) it was found that the Raynaud's patients who
had antinuclear antibodies (ANA) present in their plasma, were among the lowest
responders to bradykinin, although the sample size was insufficient to test statistical
significance. There was a similar trend in the present study with respect to the
responsiveness to ACh in vessels from Raynaud's patients, but again the sample size
was too small to draw any firm conclusions.
The fact that a disorder of the vascular endothelium was observed in dorsal hand-veins
of patients with Raynaud's disease (Bedarida et al., 1993) provides further support for
the use of arteries isolated from the gluteal region in this thesis. The study by Bedarida
and co-workers demonstrates that endothelial dysfunction can be observed at sites







The results from the perfusion myograph studies of isolated rat mesenteric resistance
arteries showed that the endothelium is an important modulator of the cold-induced
effects associated with several vasoconstrictor agents, either by enhancing contraction
through the release of vasoconstrictors such as endothelin-1 (ET) or thromboxane A2
(TXA2), or by depressing contraction through the release of dilators, such as nitric
oxide (NO) or prostacyclin (PGI2). Thus, the endothelium does not exert a uniform
influence on the responsiveness of an artery to an agonist, but instead its modulatory
effect is dependent on the individual agonist used.
The results from the studies of resistance arteries dissected from gluteal fat biopsies
taken from control subjects and from patients with Raynaud's disease revealed that at
37°C arteries from Raynaud's patients showed an enhanced sensitivity to ET-1 in
comparison with those from controls. A possible explanation for this could be
increased release of endothelium-derived constrictors, as suggested by a reduction in
sensitivity after endothelial removal, and/or a reduced dilator function in Raynaud's
patients, as suggested by the responses to the endothelium-dependent dilator
acetylcholine (ACh) and the endothelium-independent dilator sodium nitroprusside
(SNP), which were both attenuated in vessels from patients with Raynaud's disease in
comparison with controls. This implied that there was a decrease in smooth muscle
sensitivity to NO, and possibly NO-synthase (NOS) activity, at 37°C. Interestingly, at
24°C, the responses to ET-1, ACh and SNP were similar in control arteries and in
those from patients with Raynaud's disease. It would appear from the ACh data that
NOS activity was enhanced in vessels from Raynaud's disease patients during
cooling, with the increase in NO production opposing the contraction to ET-1.
Nevertheless, this might only apply to agonist-stimulated NO production, which may
be potentiated as a result of depressed basal production. The results obtained at 37°C
support the hypothesis that vascular endothelial function is abnormal in Raynaud's
disease. It is possible that cooling to 24°C does not represent the actual temperature
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that the digital vasculature is subjected to, or at least not upon initial exposure to cold,
and therefore the primary pathophysiological mechanism involved would be stimulated
at a temperature above 24°C. The question then arises - what temperature is most
relevant to the situation that occurs in digital arteries in vivo? It is unlikely that
temperatures as high as 37°C are experienced according to Bazett and colleagues
(1948), who reported that blood in vessels such as the radial artery may have a
temperature between 20°C and 25°C. If universally true, this finding leads to re-
interpretation of published in vitro data obtained from vessels at 37°C. The
temperatures of 37°C and 24°C were chosen in the studies presented in this thesis
because they are directly comparable with many published reports, and represent body
temperature and moderate cooling. Ideally, one would measure accurately the
temperature of the digital vasculature, under normal and cold conditions, and repeat
the present studies at these temperatures in order to gain a closer insight into the
mechanisms involved in cold-induced vasospasm. Ofcourse, the ultimate way of
achieving physiological temperatures is to carry out in vivo studies in humans, but this
has the disadvantage that not all drugs can be administered to human subjects.
The autoperfused hindlimb of the rat was set up as a model for studying mediators of
cold-induced vasoconstriction, which may in turn reveal potential factors involved in
the pathogenesis of Raynaud's disease. The use of a non-selective a-adrenoceptor
antagonist supported a role for a-adrenoceptors in mediating cold-induced
vasoconstriction, but it remains unclear whether this finding was indeed due to
antagonism of a-adrenoceptors, since selective antagonists for aj- and a2-
adrenoceptors were unable to attenuate the vasoconstriction induced by cooling in this
model. There would appear to be a role for ET in mediating cold-induced
vasoconstriction, perhaps through the ETA-receptor, because there was a tendency for
a selective ETA-receptor antagonist to decrease the rise in hindlimb perfusion pressure
during cooling - increasing the number of experiments may help to determine this role.
Further studies, using inhibitors of the nitric oxide and prostacyclin pathways, could
179
be performed in order to examine the role of endothelium-derived vasodilators in cold-
induced vasoconstriction in vivo.
Results obtained using the hindlimb preparation need careful interpretation,
particularly in comparison with those from isolated blood vessels used in previous
studies, with regard to the role of a-adrenoceptors in cold-induced vasoconstriction.
However, there are advantages in using a functional preparation such as the
autoperfused hindlimb, including: the innervation of the vascular bed is intact, a wide
range of vessels are being studied, and blood-borne factors, including hormones, are
present. A disadvantage of the model is the fact that the temperature-dependent
changes in hindlimb perfusion pressure are the result of changes in blood flow to
skeletal muscle rather than the cutaneous circulation; this may account for the apparent
insensitivity to antagonist drugs. Perhaps a better preparation in which to investigate
the effects of temperature on vascular reactivity would be the rat tail, which serves as
an important thermoregulatory organ in this animal (Rand et al., 1965). A recent study
by Redfern and colleagues (1995) demonstrated the role of postjunctional 0C2-
adrenoceptors in controlling blood flow, and hence heat loss, from the tail of the rat.
This study highlights the similarities between the rat tail and the human digit, the
arteries of which have been shown to possess postjunctional ot2-adrenoceptors
(Stevens & Moulds, 1986).
An important finding in this thesis is that the effects of temperature on the
responsiveness of blood vessels cannot be predicted according to the type of vessel
under study. As a general rule it has been said that cooling constricts cutaneous
vessels and dilates other vascular beds (Vanhoutte, 1980). However, this does not
necessarily imply that cooling potentiates the responses to contractile agents in
cutaneous vessels, whilst inhibiting those non-cutaneous vessels. Many studies have
found this not to be the case, including those in this thesis: contractile responses to
ET-1 and phenylephrine were augmented in rat mesenteric resistance arteries in vitro,
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and cooling was found to increase vascular resistance in the rat autoperfused hindlimb
in vivo, a preparation which appears to reflect blood flow to the skeletal vascular bed.
In his review of the effects of temperature on blood vessel function, Vanhoutte (1980)
points out the difficulties in comparing data from different studies, even when using
the same type of vessel. Many factors can influence the results, including time course,
magnitude of temperature alterations, and acclimitisation, age or hormonal status of
animal/subject preceeding the study.
7.2. Implications of present studies
When examining the results drawn from the present study, together with evidence
from the literature, one can speculate on the mechanisms involved in the
pathophysiology of Raynaud's disease. It appears likely that there is a dysfunction of
the vascular endothelium in patients with Raynaud's disease, which causes a reduction
in NO, PGI2 and/or endothelium-derived hyperpolarising factor (EDHF) activity
(Chapter 6; Bedarida et al., 1993; Singh et al., 1995). This primary dilator
dysfunction will reduce negative feedback signals on ET-1 production, resulting in
enhanced levels of circulating ET-1, as reported by Zamora and colleagues (1990).
During cold exposure, or emotional stress, adrenaline is released from the adrenal
medulla, and noradrenaline release (and co-release of neuropeptide Y and ATP) from
adrenergic nerve terminals is increased through enhanced sympathetic nerve activity
(Vanhoutte, 1980). Noradrenaline and adrenaline then act on aj- and 0C2-
adrenoceptors to cause vasoconstriction. The present studies show that sub-pressor
amounts of endogenous ET can potentiate the response to a 1-adrenoceptor agonists
(Chapter 4), confirming similar studies by Yang et al. (1990) in which exogenous
ET-1 potentiated the response to noradrenaline and 5-hydroxytryptamine (5-HT). In
the isolated rat tail, it has been demonstrated that the contractile response to 0C2-
adrenoceptor agonists is dependent on the level of vascular tone present, whereby the
contractile response is potentiated following the induction of tone (Templeton et al.,
1989; MacLean & McGrath, 1990). By extending this to the vasculature of Raynaud's
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patients in vivo, the augmented contraction to a i-adrenoceptor stimulation may
unmask ot2-adrenoceptors present. In addition, many studies have shown that cooling
potentiates contractile responses mediated by a2-adrenoceptors (e.g. Flavahan et al.,
1985). Vasospasm during cooling could therefore arise as a result of an increase in
0C2-adrenoceptor number and affinity, and oci-adrenoceptor-mediated release of ET.
Because the endothelium in control subjects is functioning normally, ET production is
constantly kept in check by opposing endothelium-derived vasodilators. Cold
exposure or emotional stress will still increase sympathetic nerve activity, and augment
vasoconstriction mediated by a2-adrenoceptors, but at the same time the affinity of
ct2-adrenoceptors present on endothelial cells will be increased. This will stimulate
endothelium-derived dilator substances to be released and hence counteract the
vasoconstriction. In control subjects, the overall balance favours vasoconstriction as a
physiological response to cold or emotional stimuli. Vasospasm is prevented because
NO, PGI2 and EDHF are inhibiting ET-1 generation. In Raynaud's patients, however,
the unopposed generation of ET is ultimately responsible for the observed prolonged
vasospasm. The results from the dilator studies presented in Chapter 6 indicate that
NOS activity, or indeed PGI2 synthase, is markedly enhanced at 24°C. It makes sense
that the arteries of Raynaud's patients have an increased NOS activity and/or PGI2
synthase at 24°C; this temperature may represent a critical degree of cooling which
activates mechanisms responsible for reversing the vasospasm in order to prevent
damage to the digits and other affected extremities. A possible mechanism for inducing
dilator function may be the loss of shear stress during a vasospastic attack. It is known
that flow-induced shear stress regulates the production of PGI2 (Frangos et al., 1985)
and NO (Rubanyi et al., 1986). Perhaps then flow-induced PGI2 and NO production
is depressed during cold-induced vasospasm, causing the up-regulation of enzymes
involved in the generation and/or action of the dilators. Stimulation of endothelial (X2-
adrenoceptors by increased levels of noradrenaline would result in an enhanced release
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of vasodilator substances which would overcome the spasm, thus allowing the blood
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Figure 7.1. Schematic outlining the hypothesised pathway which may account for the
vasospasm found in patients with Raynaud's disease. ET-1 = endothelin-1; VSM =
vascular smooth muscle; EC = endothelial cells; I = decrease; and t = increase. Parts
refering to Raynaud's patients are underlined in red.
The hypothesis outlined above unites the theories of Maurice Raynaud and Sir Thomas
Lewis, whereby overactivity of the sympathetic nervous system is attributed to




The most important results to come out of this thesis with regard to the pathogenesis
of Raynaud's disease, are the studies in the isolated resistance arteries obtained from
Raynaud's patients and control subjects. The observed differences between the rat and
human data highlight the importance of studying vessels obtained from human
subjects. Despite the difficulties in obtaining gluteal fat biopsies, the results from these
studies are of greater potential significance to our understanding of cold-induced
vasoconstriction and the pathophysiology of Raynaud's disease than vessels obtained
from animal tissue. It is therefore vital to increase the numbers of biopsy studies in
order to clarify, with statistical certainty, the pathogenetic role of the vascular
endothelium in Raynaud's disease. Although the present results implicate a
dysfunction of the endothelial-dependent dilator system, the involvement of ET is less
clear. Hopefully, by increasing the number of vessels studied, the role of ET and NO
in Raynaud's will be determined.
The involvement of the vascular endothelium in the pathogenesis of Raynaud's disease
gives rise to new areas for drug development. Clinical trials have already shown
beneficial effects of L-Arginine therapy, the substrate for NOS, in patients with
secondary Raynaud's phenomenon (Agostoni et al., 1991). If, in the light of further
biopsy studies, ET does appear to have a role in the development of vasospasm, albeit
due to a primary dysfunction of the endothelium-dependent dilator system, ET
receptor antagonists should be examined as a potential treatment of Raynaud's disease.
Orally active ET receptor antagonists, which have been shown to be effective in animal
studies (Clozel et al., 1993), are currently being developed for use in humans. It
would be of interest to investigate the effectiveness of such drugs in preventing
vasospastic attacks in Raynaud's patients. Appropriate studies could be carried out to
determine if a selective ETa receptor antagonist would be preferable to a non-selective
ETa/b receptor antagonist, such as bosentan, in Raynaud's disease. Vasospasm in
Raynaud's disease is thought to occur primarily in the smaller arteries, so a non-
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selective ETa/b receptor antagonist may be advantageous because ETb receptors have
been shown to contribute to vasconstriction in human resistance arteries in vitro (Deng
et al., 1995) and in vivo (Haynes et al., 1995). Blockade of these constrictor ETg
receptors may outweigh the deleterious effects of blocking ETs-mediated endothelium-
dependent dilatation, which, as the results presented in Chapter 6 indicate, is impaired
in any case in Raynaud's patients.
Preliminary macroautoradiographic studies which I have carried out in subcutaneous
resistance arteries from control subjects reveal the presence of ETa and ETb receptors.
Further quantitative autoradiographic studies could be carried out in vessels from
patients with Raynaud's disease and healthy controls in order to determine whether
there is a difference in the density and distribution of ET receptors. Perhaps
Raynaud's patients have a reduced number of ETg receptors present on endothelial
cells, or an enhanced number of ETa and ETb receptors on vascular smooth muscle
cells, which would promote vasoconstriction.
The studies presented in this thesis suggest that endothelium-dependent dilator
substances are affected by cooling. It remains unclear whether endogenous generation
of these substances is diminished in Raynaud's patients, because agonist stimulated
production may not reflect the situation in vivo. In order to investigate further the
effect of cooling on the generation of NO, studies could be performed in cultured
endothelial cells from Raynaud's patients and control subjects, in which NOS activity
could be measured at 37°C versus 24°C, for example by a spectrophotometric assay,
of the conversion of oxy- to methaemoglobin (Feelisch & Noack, 1987), or by a
citrulline assay, of the conversion of [3H]-L-arginine to [3H]-L-citrulline (Salter et al.,
1991). The results from such studies would help to elucidate the mechanisms involved
in the depressed endothelium-derived dilator function in control subjects, and the
enhanced function in Raynaud's patients, during cooling.
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The results from the hindlimb model are inconclusive regarding a role for ET in cold-
induced vasoconstriction. Clearly further experiments need to be performed using ET
receptor antagonists in an attempt to affirm the role of ET with confidence. However,
as discussed in Section 7.1, a better model in which to study cold-induced
vasoconstriction would be the rat tail, since this is a physiological thermoregulatory
organ, and is perhaps more similar to the human digit. In addition, the role of
endothelium-derived vasodilator substances could be explored by using inhibitors of
the NO and PGE pathways.
Since endothelial dysfunction has been implicated in the pathogenesis of Raynaud's
disease and there are clear gender differences in the occurence of this disorder, it
would appear likely that there is an interaction between endothelium-derived factors
and sex hormones. It is well established that sex hormones alter the vascular
responsiveness to various vasoactive factors, including a-adrenoceptor agonists
(Vanhoutte et al., 1981); less clear is their effect on the vascular endothelium. Recent
evidence does support an interaction between female sex hormones and the
endothelium (see Chapter 1, Section D.1.8). Progesterone (Williams et al., 1988) and
oestrogen (Gilligan et al, 1994) have been shown to enhance endothelium-dependent
dilatation . Future work, at the molecular level, could investigate the influence of sex
hormones on the ET and NO pathways, for example on the activities of endothelin-
converting enzyme (ECE) and NOS, or on the expression of ET receptors. Although
serum levels of female sex hormones do not differ significantly between Raynaud's
patients and controls (Bartelink et al., 1994), it is feasible that women with Raynaud's
disease are less responsive to progesterone and oestrogen, thus making them more
prone to vasospasm.
7.4. Conclusions
The results presented in this thesis demonstrate that the vascular endothelium is an
important modulator of cold-induced effects on the response to several vasoconstrictor
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agents, either by enhancing contraction through the release of vasoconstrictors such as
ET or TXA2, or by depressing contraction through the release of dilators, such as NO
or PGI2.
At the outset of this thesis it was hypothesised that vasoconstriction to ET is opposed
by increased NO production in healthy controls during cold-exposure, the balance
favouring vasoconstriction (but not of sufficient severity or duration to cause
vasospasm), and that patients with Raynaud's disease have a dysfunctional
endothelium, perhaps resulting from an increased production of ET and/or reduced
production of NO, favouring prolonged vasospasm. The results from the gluteal
biopsy studies would largely support this hypothesis, in that vessels from Raynaud's
patients displayed an enhanced sensitivity to ET-1 at 37°C, which was dependent on
changes in dilator function, namely a depressed action of endothelium-derived
vasodilators and smooth muscle sensitivity to NO. Although an increase in the
response to ET-1 was not found at 24°C, the results obtained at 37°C would support
the hypothesis that the release and/or actions of NO is reduced in Raynaud's disease,
allowing enhanced constriction to ET. These results suggest, therefore, that the
vascular endothelium is involved in the pathophysiology of Raynaud's disease. As
indicated in Figure 7.1, a-adrenoceptors are also likely to play an important role in the
development of cold-induced vasoconstriction and vasospasm.
These findings, together with the proposals for future work, indicate directions for the
development of specific and effective treatment for Raynaud's disease, for which there
is currently no generally effective therapy. In addition, since Raynaud's disease
appears to be part of a more generalised vasospastic disorder, which includes variant
angina and migraine, the present results may lead to a clearer understanding of the
mechanisms underlying these other vasospastic conditions, and again point to new
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